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Abbreviations 
AE  adverse events 
ALT  alanine transaminase 
6-AMMP  2-amino-‘6-methylmercaptopurine  
5-ASA   5-aminosalicylic acid 
AST  aspartate transaminase  
AUC  area under the curve 
AZA  azathioprine 
CAI  Colitis activity index 
CD  Crohn’s disease 
CDAI  Crohn’s disease activity index 
CI95%  95% confidence interval 
CRP  C-reactive protein 
Css  steady state concentration 
DPK  diphosphate kinase 
DTT  dithiothreitol 
ESR  erythrocyte sedimentation rate 
F  female 
GMPS  guanosine monophosphate synthetase 
GTPase guanidine triphosphatase 
Hb  haemoglobin 
HPLC  high-performance liquid chromatography 
HPRT  hypoxanthine phosphoribosyl transferase  
Hr  hour 
IBD  inflammatory bowel disease 
IMPD  inosine monophosphate dehydrogenase 
ITPase  inosine triphosphate pyrophosphohydrolase 
kg  kilogram 
6-MP  6-mercaptopurine 
M  male 
6-MMP  6-methylmercaptopurine 
6-MMPR 6-methylmercaptopurine ribonucleotides 
MPK  monophosphate kinase  
MRI  magnetic resonance imaging 
6-MTGN 6-methylthioguanine nucleotides 
MTX  methotrexate 
Mw   molecular weight 
N  number of patients 
ND  not determined 
NNT  number needed to treat 
NRH  nodular regenerative hyperplasia 
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 OR  Odds ratio 
ORF   open reading frame  
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
pmol  picomoles 
Pt  patient 
RBC  red blood cells (erythrocytes) 
ROC curve  receiver operating characteristic curve  
SNPs   single nucleotide polymorphisms  
t  time point 
TDM  therapeutic drug monitoring 
6-TG  6-thioguanine 
6-TGN  6-thioguanine nucleotides 
6-TGTP 6-thioguanine triphosphate 
6-TIMP  6-thioinosine monophosphate  
TPMT  thiopurine S-methyltransferase 
6-TUA  6-thiouric acid  
TWDAI  Truelove-Witts disease activity index 
6-TXMP 6-thioxanthosine monophosphate 
UC  ulcerative colitis 
VAS  visual analog scale 
VNTR   variable number tandem repeat  
VOD  veno-occlusive disease  
XO  xanthine oxidase 
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Introduction 
Inflammatory bowel diseases (IBD) include Crohn’s disease (CD), ulcerative 
colitis (UC) and indetermined colitis. These diseases are relatively new and 
their incidence is still increasing. The first report, most probably describing a 
case of Crohn’s disease, originates from 1769 and was written by Morgagni1. 
Until the 20th century however, these diseases were very rarely described in 
medical literature. Only in 1932, Burril B. Crohn introduced the term ‘regional 
ileitis’ as an entity2. Later, his name was given to this disease.  
Until now, it is still not clear why a patient gets IBD. Due to an unknown agent 
or process, a pro-inflammatory cascade is set up, leading to bowel 
inflammation differing from mild local mucositis to deep penetrating or even 
perforating ulceration. Crohn’s disease can be found from mouth to anus, while 
ulcerative colitis is limited to the colon. Several extra-intestinal organs can be 
involved: eyes, liver, joints and skin. These great inter-individual differences in 
disease phenotype make IBD difficult to study in clinical research, but also 
fascinating. During the last 60 years, IBD have become one of the major 
problems in gastroenterology. 
Nowadays, many contributing factors in IBD have been revealed: genetic, 
environmental, nutritional, smoking and medication3. Because of the lack of 
aetio-pathogenetic clues, it has been very difficult to develop a targeting 
treatment for IBD. Only recently, the wind seems to turn positively due to the 
development of the so called ‘biologicals’: antibodies against specific cytokines, 
such as infliximab, in the inflammatory cascade (although these medications do 
not treat the still unknown cause of IBD!). These biologicals, such as infliximab, 
adalimumab and certolizumab show good short term efficacy and safety4,5. 
However, they are expensive and their longterm safety profiles are not known 
yet. Therefore older medications like mesalamines, corticosteroids and 
thiopurines (azathioprine and 6-mercaptopurine) are still very important in daily 
practice. In thiopurine therapy new strategies were developed in recent years 
to improve efficacy and safety. One of these strategies is therapeutic drug 
monitoring (TDM), which means measurement of thiopurine metabolite levels 
with the purpose of improving safety and efficacy of thiopurine therapy6,7. 
Thiopurines are widely used in the treatment of inflammatory bowel disease 
(IBD). However, in clinical practice, azathioprine (AZA) or 6-mercaptopurine 
(6-MP) are not effective in one-third of patients and up to one-fifth of patients 
discontinues thiopurine therapy due to adverse events. Major advances in 
mechanistic and biochemical fields contributed to develop new strategies to 
improve pharmacotherapy. This review of literature focuses on thiopurine 
pharmacology, pharmacogenetics, interactions and new strategies for 
optimization of pharmacotherapy. Thiopurine efficacy and toxicity are described 
15 
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in less detail because it is respectively well established and generally 
understood. 
Efficacy 
Thiopurines have proven efficacy in IBD8-10. In clinical practice, in 68% of IBD-
patients the initial therapeutic goal (i.e. mucosal healing, elimination of steroids, 
healing of internal fistulas or abscesses, pain relief, etc) is achieved and after 
initial response efficacy is reasonably well sustained with remission rates of 
95%, 69% and 55% after 1, 3 and 5 years respectively11,12. 
Both AZA and 6-MP have proven efficacy in induction of remission in active 
Crohn’s disease (CD) with odds ratios (OR) up to 3.1 compared to placebo9-13. 
The OR of response increases after 17 weeks, suggesting there is a minimum 
length of time for trial of thiopurine therapy13. Thereby, the thiopurines have a 
considerable steroid-sparing effect and the combination of AZA with 
prednisolone is superior to treatment with prednisolone alone9,14. 
AZA and 6-MP seem to be effective in maintaining remission of quiescent CD 
patients that are steroid dependent or –refractory or in CD-patients finished 
with surgical treatment with a number needed to treat (NNT) of 7 9,15-18, though 
not everybody is convinced19. Also, in the prevention of exacerbations, the 
addition of 6-MP to a regimen of steroids significantly lessens the need for 
prednisone20,21. There is debate for how long thiopurines should be given to 
CD-patients in prolonged remission. Some question the use of potential toxic 
immunosuppressant for longer than four years22, whereas others demonstrate 
that their efficacy is reasonably well sustained over a period of five years13. 
AZA and 6-MP in combination with other immunosuppressants like 
cyclosporine, tacrolimus, methotrexate, thalidomide or infliximab have proven 
efficacy in CD perianal fistulas with prolonged fistula closure in 30-40% of 
cases23-26. Also, both thiopurines help to prevent the recurrence of CD after 
surgery, especially in high risk patients, with a NNT of 4 in two years to prevent 
one clinical relaps27-30. 
Although less pronounced than in CD populations, both AZA and 6-MP are 
effective in inducing remission in ulcerative colitis (UC) with remission rates up 
to 70%8,31,32. However, scarce but conflicting data have been published, 
demonstrating AZA had no effect at all in achieving remission33. 
The role of thiopurines in maintaining remission of UC is less controversial8. 
AZA maintenance treatment in UC is beneficial for at least two years after an 
initial response and significantly lowers the proportion of relapses33,34. 
Moreover, combination therapy is more effective than treatment with 
steroids8,21,35 or 5-aminosalicylic acids (5-ASA) alone36. Also the combination of 
thiopurines and oral cyclosporine has proven to be safe and effective for 
16 
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maintenance of intravenous cyclosporine-induced remission of severe steroid-
refractory UC37,38, though monotherapy with a thiopurine may be sufficient39. 
Toxicity 
In IBD-patients treated with thiopurines, up to 20% has to discontinue drug 
therapy due to the occurrence of adverse events40-42. The adverse events of 
thiopurines can be divided into dose-dependent, pharmacologically explainable 
events (type A) on one hand and dose-independent, hypersensitivity reactions 
(type B) on the other. Type A adverse events, which often reveal themselves in 
a subsequent stage, are largely associated with the formation of potentially 
toxic metabolites and include general malaise and nausea (11%), infectious 
complications (7.4%), hepatitis (0.3-1.3%) and myelosuppression (1.4-5%)9.41-
43. The reported frequency of leukopenia even varies up to 11%, depending on 
the definition of leukopenia and the dose prescribed44. At present, frequent 
blood tests are advocated after start of thiopurine therapy to prevent 
myelotoxicity. The manufacturers of AZA and 6-MP recommend full blood 
counts weekly up to eight weeks after start of therapy followed by blood tests at 
least three-monthly. However, there is no evidence that this is effective as 
severe leukopenia can develop swiftly within two blood tests. Less frequent 
monitoring (within four weeks of starting therapy and every six-twelve weeks 
thereafter) may be sufficient45. 
Type B reactions (2%) often occur within three to four weeks after start of 
treatment and result in immune-mediated symptoms like fever, rash and 
arthralgia46,47. Also, pancreatitis (1.4-3.3%) is thought to be an idiosyncratic 
reaction13,41. 
Although increased frequencies of malignancies are reported in other patient 
populations on thiopurines, this seems not to be the case in IBD patients48. 
Moreover, in a decision analysis it was concluded that the benefits of 
thiopurines outweigh the potential risk of lymphoma49. Recently however, 
Kandiel and colleagues reported an approximate four-fold increased risk of 
lymphoma in IBD patients treated with thiopurines. The authors stated that the 
increased risk of lymphoma could be a result of the medications, the severity of 
the underlying disease, or a combination of the two50. 
The use of thiopurines before or during pregnancy appears to be safe as there 
is no statistical difference in abortions, congenital malformations or neoplasia 
among IBD patients on thiopurines compared with healthy controls51. 
17 
Chapter 1 
Pharmacology 
Pharmacokinetics 
Neither AZA nor 6-MP has intrinsic activity, hence have to undergo extensive 
metabolic transformations. AZA is a pro-drug, that is rapidly and almost 
completely (88%) converted to 6-MP and methylnitroimidazole (Figure 1.1, 
cleavage site 1) by a non-enzymatic reaction in the liver. The latter causes 
intolerance in a considerable group of patients of whom 75% successfully 
switches to 6-MP52, but may have immunosuppressive properties of its own53. 
The remaining 12% of AZA yields hypoxanthine and methylnitrothioimidazole 
(Figure 1.1, cleavage site 2)54. These non-enzymatic conversions are aided by 
glutathione or other endogenous sulphydryl-containing proteins55,56. Smoking 
and higher age lower glutathione levels57 and may cause larger variability in the 
amount of 6-MP originating from AZA58. 
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Figure 1.1 Chemical structures of the thiopurines.  
 For azathioprine, cleavage sites of the non-enzymatic reaction in the liver are 
depicted. Cleavage site 1 yields 6-mercaptopurine and methylnitroimidazole while 
cleavage site 2 yields hypoxanthine and methylnitrothioimidazole. 
 
 
The absorption of AZA is incomplete and variable resulting in a bioavailability of 
16-72%55. The bioavailability of 6-MP originating from AZA is approximately 
60% compared to only 5-37% when 6-MP is administered as such, mainly as a 
result of extensive catabolic conversion of the latter to 6-thiouric acid (6-TUA) 
in the bowel and liver by xanthine oxidase (XO)59. The molecular weight of 
6-MP (Mw = 152.18 g/mol) is 55% of the molecular weight of AZA (Mw = 277.27 
g/mol), resulting in a conversion factor of 2.08 (1/0.55 x 1/0.88) when 
converting 6-MP to an equivalent pharmaceutical dose of AZA assuming 100% 
bioavailability60. The plasma half-life of 6-MP is very short, at the most two 
hours.  
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Figure 1.2 Proposed thiopurine metabolism.  
 AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MMPR, 6-methylmercaptopurine; 
6-TUA, 6-thiouric acid; 6-MTIMP, 6-methylthioinosine monophosphate; 6-MTIDP, 
6-methylthioinosine diphosphate; 6-MTITP, 6-methylthioinosine triphosphate; 6-TIMP, 
6-thioinosine monophosphate; 6-TIDP, 6-thioinosine diphosphate; 6-TITP, 
6-thioinosine triphosphate; 6-TXMP, 6-thioxanthosine monophosphate; 6-TGMP, 
6-thioguanine monophosphate; 6-TGDP, 6-thioguanine diphosphate; 6-TGTP, 
6-thioguanine triphosphate; 6-MTGMP, 6-methylthioguanine monophosphate; 6-TG, 
6-thioguanine; 6-MTG, 6-methylthioguanine; XO, xanthine oxidase; TPMT, thiopurine 
S-methyltransferase; HPRT, hypoxanthine phosphoribosyl transferase; IMPD, inosine 
monophosphate dehydrogenase; GMPS, guanosine monophosphate synthetase; 
MPK, monophosphate kinase; DPK, diphosphate kinase; ITPA, inosine triphosphate 
pyrophosphatese (ITPase). 
 6-MTIMP, 6-MTIDP and 6MTITP together form the 6-methylmercaptopurine 
ribonucleotides (6-MMPR). 6-TGMP, 6-TGDP and 6-TGTP together form the 
6-thioguanine nucleotides (6-TGN). In therapeutic drug monitoring, a 6-MMPR level 
consists of the sum of 6-MMP, 6-MTIMP, 6-MTIDP and 6-MTITP levels, while a 6-TGN 
level consists of the sum of 6-TGMP, 6-TGDP, 6-TGTP (if AZA or 6-MP is 
administered) and 6-TG levels (if 6-TG is administered as such). 
 
Following intracellular uptake, 6-MP is then further metabolised by three 
enzymes (Figure 1.2); two of which are catabolic, XO and thiopurine 
S-methyltransferase (TPMT), and one is anabolic, hypoxanthine 
phosphoribosyl transferase (HPRT)54. XO metabolises 6-MP to 6-TUA, 
whereas TPMT methylates 6-MP to 6-methylmercaptopurine (6-MMP). HPRT 
carries out the first anabolic step to produce 6-thioinosine monophosphate 
(6-TIMP), which by inosine monophosphate dehydrogenase (IMPD) is further 
transformed  by a rate-limiting step into 6-thioxanthosine monophosphate 
(6-TXMP), which is ultimately metabolised to 6-thioguanine monophosphate 
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(6-TGTP), -diphosphate (6-TGDP) and -triphosphate (6-TGTP), together the 
so-called 6-thioguanine nucleotides (6-TGN). The 6-TGN have a half-life of 
approximately 5 days with a large variability of 3-13 days55,61. 6-TIMP can 
alternatively be methylated by TPMT, yielding 6-methylthioinosine 
monophosphate (6-MTIMP), -diphosphate (6-MTIDP) and –triphosphate 
(6-MTITP), the so-called 6-methylmercaptopurine ribonucleotides (6-MMPR). 
Finally, it is hypothesized that 6-TIMP successively is converted into 
6-thioinosine diphosphate (6-TIDP) and -triphosphate (6-TITP) to form 6-TIMP 
once again by the enzyme inosine triphosphate pyrophosphatase (ITPA or 
ITPase).  
In contrast to AZA and 6-MP, pharmacokinetics (metabolism in particular) of 
6-thioguanine (6-TG) is much less complicated. The absorption of oral 6-TG is 
incomplete and variable, resulting in a bioavailability of 14-46%59. Plasma 6-TG 
concentrations may range up to thirty-fold62 and become undetectable after six 
hours as it is rapidly transported into the cell63,64. HPRT directly converts 6-TG 
to the 6-TGN, whereas the competing TPMT and XO yield 6-methylthioguanine 
(6-MTG) and 6-TU respectively65. 
Pharmacodynamics 
In recent years, the molecular mechanisms of action of the thiopurines have 
been elucidated at least in part. The 6-TGN (Figure 1.3), as a result of their 
structural similarity to the endogenous purine-base guanine, are incorporated 
into DNA (Figure 1.4) of leucocytes as fraudulent bases, resulting in strand 
breakage and subsequently immunosuppression54,66. Also, one of the 6-TGN in 
particular, 6-TGTP, is considered to contribute to the immunosuppressive 
effects due to inhibition of Rac1 upon CD28 co-stimulation, inducing T-cell 
apoptosis67. Rac1 is a small GTPase and plays a role in inhibiting T-cell 
apoptosis. 6-TGTP binds to Rac1 instead of GTP, thereby suppressing the 
activation of Rac1 target genes like mitogen-activated protein kinase, NF-κB, 
and bcl-xL. 
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Figure 1.3 Chemical structures of the 6-thioguanine nucleotides (6-TGN). 6-TGMP, 6-thioguanine 
monophosphate; 6-TGDP, 6-thioguanine diphosphate; 6-TGTP, 6-thioguanine 
triphosphate. 
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Figure 1.4 Chemical structure of DNA. The 6-thioguanine nucleotides strongly exhibit structural 
similarity to the endogenous purine-base guanine. They possess a thiole-group 
instead of an oxygen-atom, resulting in strand breakage when they are incorporated 
into DNA as fraudulent bases. 
 
Also, the 6-MMPR contribute to the anti-proliferative properties of the 
thiopurines, probably through inhibition of de novo purine synthesis68. 
Furthermore, as mentioned before, AZA has an immunosuppressive effect 
additional to that attributable to 6-MP alone and it is proposed that this is 
associated with an action of the nitromethylimidazol substituent by a so far 
unsolved mechanism53. In addition to this, other mechanisms may contribute to 
the immunosuppressive effects of the thiopurines, such as interference with 
function of similar endogenous molecules like ATP and GTP, which play an 
important role as carriers of energy and cellular second messengers69.  
It is obvious, that the immunosuppressive properties of the thiopurines are not 
attributable to one unique mechanism, but are based on multiple and complex 
mechanisms. To date however, it is unclear to what extent these mechanisms 
contribute to the overall effect of the thiopurines. 
Pharmacogenetics 
The observed interindividual differences in therapeutic response or toxicity are 
partly explained by the variable formation of active metabolites due to genetic 
polymorphisms of the genes encoding crucial enzymes in thiopurine 
metabolism. These enzymes include TPMT, XO, HPRT and ITPase. 
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TPMT 
One of the most intensively studied genetic polymorphisms is that of TPMT, 
though neither its biological function nor the endogenous substrates are 
known70. In thiopurine treated patients, TPMT determines the delicate balance 
between the 6-MMPR and the 6-TGN. The gene encoding TPMT is located 
upon chromosome 6 (6p22.3) and contains ten exons. To date, two wild type 
alleles (TPMT*1 and *1S) and 20 mutant alleles (TPMT*2, *3A, *3B, *3C, *3D, 
*4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18) responsible for 
TPMT deficiency have been described (Figure 1.5)71,72. These alleles are 
characterised by one or more single nucleotide polymorphisms (SNPs) in the 
open reading frame (ORF) sequences of the TPMT gene. Besides, several 
intronic mutations and mutations outside the ORF exist. Recently, a variable 
number tandem repeat (VNTR) within the TPMT promoter region of the TPMT-
gene has also been reported to modulate levels of TPMT activity73,74. 
Enhanced degradation of TPMT proteins encoded by certain mutant alleles has 
been proposed as mechanisms for lower TPMT protein and catalytic activity: 
whereas the degradation half-life of TPMT*1 is 18 hours, TPMT*2 and 
TPMT*3A have a strongly decreased half-life of 15 minutes75. The distribution 
of TPMT mutant alleles differs significantly among ethnic populations. 
TPMT*3A (3.2-5.7%) is the most occurring mutant allele in Caucasian 
populations, followed by TPMT*2 (0.2-0.5%) and TPMT*3C (0.2-0.8%) 
accounting for the vast majority (>95%) of mutant alleles69-71,76-82. In Asians and 
African populations however, TPMT*3C is the most frequent mutant allele83-85. 
There is high correlation between TPMT geno- and phenotype43,72. The 
resulting frequency distribution of TPMT activity in Caucasian populations is 
trimodal: approximately 89% of the population are homozygous for the wild-
type allele (homozygous TPMTH) and consequently have high enzyme activity 
(13.50 ± 1.86 U/ml RBC), 11% inherit one wild type allele and one mutant allele 
(heterozygous TPMTH/TPMTL) and have intermediate levels of enzyme activity 
(7.20 ± 1.08 U/ml RBC), while one in 300 subjects has two mutant alleles 
(homozygous TPMTL) and low or no detectable enzyme activity at all69,86. 
TPMT activity is high in children compared to adults, among adults higher in 
men than in women and higher in smokers than in non-smokers72,87,88. Also, 
TPMT activity significantly increases during thiopurine treatment as a result of 
enzyme induction54. 
XO 
Xanthine oxidase is a cytoplasmic enzyme that oxidises endogenous 
substrates such as hypoxanthine and xanthine, but also the exogenous 6-MP. 
Its activity is particularly high in the intestinal mucosa and liver89, resulting in a 
substantial reduction of 6-MP bioavailability. On the other hand, oxidised 
thiopurine metabolites may inhibit TPMT, resulting in higher levels of the active 
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6-TGN90. There exists four-fold interindividual variation in hepatic XO activity 
and the presence of a subgroup of patients with low activity is suspected. XO 
activity is approximately 20% higher in men than in women91. The molecular 
basis of these differences remains unclear54. 
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Figure 1.5a Thiopurine S-methyltransferase (TPMT) genotypes (1). The black and white boxes 
represent translated and untranslated exons respectively. The grey boxes represent 
translated exons on mutant alleles containing a single nucleotide polymorphism 
(SNP); the SNP is captioned below the relevant exon. 
23 
Chapter 1 
 
C(-178)T
A356A
G430C
G395A
C374T
A83T
A1G
GA
G488A
C124G
G211A
TPMT mutant alleles (2)
TPMT*9
TPMT*10
TPMT*11
TPMT*12
TPMT*13
TPMT*14
TPMT*15
TPMT*16
TPMT*17
TPMT*18
Intronic- and outside ORF mutations
G98T C58T
T114A
A(-101)T
T35C
T(-30)A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5b Thiopurine S-methyltransferase (TPMT) genotypes (2). The black and white boxes 
represent translated and untranslated exons respectively. The grey boxes represent 
translated exons on mutant alleles containing a single nucleotide polymorphism 
(SNP); the SNP is captioned below the relevant exon. ORF, open reading frame. 
HPRT 
Only limited information exists on the range of HPRT activity. What is known 
however, is that HPRT is completely deficient in subjects with the very rare 
(1:100,000) Lesch-Nyhan syndrome characterized by self-mutilating 
behaviours such as lip biting and head banging54. Thiopurines are not cytotoxic 
in Lesch-Nyhan patients and SNPs in the HPRT-gene appear to be the 
molecular basis of this syndrome92. Moreover, HPRT activity increases during 
long-term thiopurine treatment54. 
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ITPase or ITPA  
Inosine triphosphate pyrophosphatase (ITPase) catalyzes the 
pyrophosphohydrolysis of inosine triphosphate (ITP) to inosine monophosphate 
(IMP) and deficiency leads to abnormal accumulation of ITP, which is not 
known to be associated with any defined pathology93. In ITPase deficient 
patients treated with AZA or 6-MP, accumulation of 6-TITP is suggested94. The 
gene encoding ITPase is located on chromosome 20 and five SNPs have been 
identified so far, of which three (G138A, G561A, G708A) are silent and two 
(C94A, IVS2 + A21C) are associated with decreased ITPase activity (Figure 
1.6)94. C94A is the most frequently occurring SNP. Homozygotes for the C94A 
missense mutation have no enzyme activity at all and IVS2+A21C 
homozygotes have approximately 60% of normal ITPase activity, but the 
incidence is unknown. It is estimated that approximately 6% of the population 
are C94A heterozygotes and they possess 22.5% of normal enzyme activity95. 
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Figure 1.6 Location of the five single nucleotide polymorphisms (SNPs) on the inosine 
triphosphate pyrophosphatase (ITPase) gene. The black and white boxes represent 
translated and untranslated exons respectively. G138A, G561A and G708A are silent 
SNPs, while C94A and IVS2+A21C are missense mutations associated with 
decreased ITPase activity.  
Interactions 
A number of co-administered drugs may potentially influence thiopurine 
metabolism and consequently has to be taken into account. In vitro studies 
have demonstrated 5-aminosalicylic acid (5-ASA) compounds (i.e. balsalazide, 
olsalazine and sulphasalazine) to be potent TPMT inhibitors96-98. In vivo, 6-TGN 
concentrations are significantly higher when thiopurines are combined with 
5-ASA. The observed higher 6-TGN levels can not solely be explained by 
TPMT inhibition and other yet unknown interaction mechanisms may exist99. 
Consequently, a higher frequency of leukopenia is observed in patients using 
this combination96,100. Other frequently prescribed TPMT inhibitors include 
acetylsalicylic acid101 and furosemide102. 
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Allopurinol potently inhibits XO and a dose-reduction to 25-33% of standard 
daily dosages of AZA or 6-MP is recommended when combined to prevent 
serious myelotoxicity59,103. Mycophenolate inhibits IMPD, theoretically reducing 
the conversion of 6-TIMP to 6-TXMP and 6-TGN consequently43. 
New strategies 
In the past 10-20 years, knowledge of both thiopurine pharmacology and 
-pharmacogenetics has been extended dramatically and used to develop new 
strategies to improve efficacy and reduce toxicity. These strategies include 
therapeutic drug monitoring (TDM) of thiopurine metabolites, geno- or 
phenotyping crucial enzymes in thiopurine metabolism like TPMT and ITPA 
and the use of 6-TG as such. All strategies and their potential are discussed. 
Therapeutic drug monitoring 
The active metabolites of the thiopurines, 6-TGN and 6-MMPR, can be 
quantified in the human red blood cell (RBC) by a reversed-phase high-
performance liquid chromatographic (HPLC) assay with UV-detection 
developed by Lennard and colleagues104,105. In brief, for measurement of 
intracellular thionucleotides the free base is obtained by acid hydrolysis of the 
nucleotide back to the purine. The resulting purines are extracted from the 
biological matrix by forming a phenylmercury adduct into toluene. During back-
extraction with hydrochloric acid the adduct is splitted and the free thiopurine is 
liberated into the acid layer once again. RBC are a good surrogate matrix 
because they are easily obtained, exist in sufficient numbers and contain 
concentrations of 6-TGN that reflect concentrations of 6-TGN in the less 
accessible putative target tissues, the leucocytes6. Various other 
chromatographic methods for the same purpose have been developed ever 
since, but considerable differences in 6-TGN concentrations are observed 
when comparing these methods, probably attributable to the extent of 
nucleotide hydrolysis, extraction procedure, chromatographic conditions and 
method of detection106,107. Direct comparison of several methods with the 
Lennard-method showed that metabolite concentrations are 2.6-fold higher in 
the Dervieux-method108, 1.4-fold higher when both slightly modified109 and 
1.6-fold lower when determined by the Erdmann-method110. The Lennard-
method has found the greatest application in clinical studies yet and has served 
as the basis for the establishment of treatment-related therapeutic ranges for 
thiopurine therapy107. 
In one of the first clinical studies in which thiopurine metabolites were assayed, 
a correlation was found between 6-TGN levels and therapeutic efficacy on one 
hand and between 6-MMPR levels and toxicity on the other6. In another study 
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with a paediatric population specific metabolite target levels were proposed: the 
frequency of therapeutic response increased at 6-TGN levels above 235 
pmol/8x108 RBC (OR: 5.0) and hepatotoxicity correlated with 6-MMPR levels 
above 5700 pmol/8x108 RBC, the risk increasing three-fold7. In a subpopulation 
with leukopenia a mean 6-TGN level of 490 pmol/8x108 RBC was measured7. 
Since then, in large cohorts of both paediatric and adult populations, conflicting 
data have been published. A comparable correlation between metabolite 
concentrations and efficacy and toxicity was demonstrated by several studies. 
In a study with 82 adult IBD patients 6-TGN concentrations above 
250 pmol/8x108 RBC correlated with treatment efficacy111. In another study with 
60 adult IBD patients, 6-TGN levels also were associated with clinical response 
and though there was a fair amount of overlap, the maximal differentiation 
between responders and non-responders was seen at 6-TGN levels above 260 
pmol/8x108 RBC112. In yet another study with 131 adult IBD patients with 
evaluable 6-TGN levels over a two year period, patients who remained in 
remission had significantly higher mean 6-TGN levels than those patients who 
developed active disease. 6-MMPR levels did neither correlate with drug 
efficacy nor toxicity58. Similar results were found in a study with 55 IBD 
patients: 6-TGN level but not drug dose was related to disease activity113. 
Finally, an inverse relationship between 6-MMPR/6-TGN ratio and therapeutic 
efficacy has been described and a ratio of 11 has been suggested as a cut-off 
point above which the frequency of response is diminished114,115. Other 
immunosuppressive therapy should be considered in this case. 
These results are contradicted by the findings of other studies that showed no 
or weak correlation between metabolite concentrations and efficacy or toxicity. 
In 28 patients with CD, there was a broad overlap in 6-TGN concentrations 
between patients in remission or not and responders to AZA/6-MP therapy or 
not116. Also, 6-TGN concentrations did not correlate with disease activity in a 
cohort of 170 IBD patients117. In another study with 101 pediatric IBD patients, 
58% of the patients in remission had 6-TGN levels less than the 235 
pmol/8x108 RBC proposed by Dubinsky and colleagues118. Furthermore, poor 
correlation between metabolite levels and efficacy or toxicity was found in a 
study with 74 eligible IBD patients: 38% of patients with active disease had a 
6-TGN level above 235 pmol/8x108 RBC and no hepatotoxicity was observed 
despite 6-MMPR levels above 5700 pmol/8x108 RBC in 12.2% of patients119. 
Currently, it is much debated whether assessment of metabolite concentrations 
is clinically useful in predicting both drug efficacy and toxicity120,121. These 
controversies, at least in part, result from the lack of proper pharmacokinetic 
data in IBD patients. In the near future, these data need to be collected in 
prospective pharmacokinetic trials to elucidate this matter. Unquestioned 
however, is the fact that therapeutic drug monitoring (TDM) is the only way to 
reveal non-compliance122,123. 
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If TDM is used for optimizing thiopurine pharmacotherapy in IBD patients, the 
explanations for measured steady state thiopurine metabolite concentrations 
summarized in Table 1.1 can be used.  
In conclusion, TDM seems to be an attractive approach for optimizing 
thiopurine therapy in IBD patients, but there is an unmet need for prospective 
studies. 
 
 
Table 1.1 Possible utilization of metabolite measurement in inflammatory bowel disease patients 
treated with azathioprine or 6-mercaptopurine 
Explanation 6-TGN level 
(pmol/8x108 RBC)
6-MMPR level 
(pmol/8x108 RBC) 
6-MMPR/6-TGN ratio 
therapeutic target achieved 250-500 <5700 5-25 
non-compliance <<250 <<5700 5-25 
under-dosing   <250   <5700 5-25 
potential myelotoxicity 
(absent TPMT activity) 
>>500 <<5700 0 
possible myelotoxicity 
(low TPMT activity) 
  >500 <5700 0 
possible hepatotoxicity 
(high TPMT activity) 
<250-500 >5700 30-100 
potential myelotoxicity 
(very high TPMT activity) 
<<250 >>5700 >>100 
6-TGN, 6-thioguanine nucleotides; 6-MMPR, 6-methylmercaptopurine ribonucleotides; pmol, 
picomoles; RBC, red blood cells; TPMT, thiopurine S-methyltransferase. 
Geno- and phenotyping 
Another strategy that may contribute to a better pharmacotherapy of IBD with 
thiopurines is genotyping genes encoding key enzymes in their metabolism, 
such as TPMT. Reliable polymerase chain reaction (PCR)-based methods 
have been developed for detecting the major inactivating mutations at the 
human TPMT locus70,78,124. In brief, leukocyte DNA is amplified by PCR 
techniques and digested by specific restriction enzymes. The resulting DNA-
fragments are analyzed by gel electrophoresis. Finally, the identified SNPs 
yield a specific TPMT genotype (Figure 1.5).  
Alternatively, TPMT phenotype can be determined by measuring TPMT activity 
based on the in vitro conversion of 6-MP to 6-MMP125. Phenotyping may be 
more relevant in some cases, as there is a large variation in TPMT activity 
among individuals with the same genotype and thus will give more information. 
Also, as mentioned before, phenotype can alter due to thiopurine therapy and 
the use of concomitant medication whereas genotype can not. On the other 
side, sometimes phenotyping may lead to misclassification of a patient’s TPMT 
status, for example after a blood transfusion126. 
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Lately, the use of determining TPMT status, the exact moment when to perform 
geno- or phenotyping and the clinical implications are subject to 
discussion69,127. Patients with one or two mutant alleles have less TPMT 
activity, consequently grossly elevated 6-TGN concentrations, leading to an 
increased risk for the development of bone marrow suppression69. Conversely, 
some wild type patients with very high TPMT activity, so called ultra-
methylators, develop suboptimal 6-TGN concentrations by shunting 6-MP away 
to 6-MMPR resulting in treatment failure114. 
In a retrospective study with 106 IBD patients, TPMT genotype predicted 
phenotype which correlated to drug efficacy and toxicity: intermediate TPMT 
activity was associated with an increased risk of AZA toxicity (OR: 5.4), while 
high activity (>14 U/ml RBC) predicted treatment failure (OR: 0.21)80. In a 
prospective study with 67 patients with rheumatic disease, six patients were 
heterozygous for mutant TPMT alleles, of which five discontinued therapy 
within the first month of AZA treatment due to reduced total leukocyte 
counts128. In another study with 262 IBD patients, TPMT genotype predicted 
leukopenia with an OR of 6.32 for patients with mutant TPMT alleles compared 
to wild type patients129. In yet another study with 113 IBD patients, it was 
demonstrated that during the initial four months, lower TPMT activities 
correlated with low neutrophil counts. Also, patients with lower TPMT activity 
could be safely managed on a low (<2.0 mg/kg) AZA dose130. Similar results 
were reported in a cohort of 71 patients with CD: patients with normal TPMT 
status received AZA in an initial dose of 2-2.5 mg/kg/day compared to 1-1.5 
mg/kg/day for patients with intermediate enzyme activity and neither developed 
acute leukopenia131. In general, a 50% starting dose, that is 1-1.5 mg/kg/day 
AZA or 0.75 mg/kg/day 6-MP, is advocated in patients with heterozygous 
TPMT alleles132. Some recommend an even safer initial dose reduction to 33% 
of the standard dose in heterozygotes133. It is generally recommended that 
homozygous mutants should not receive thiopurines at all for their IBD132,133. 
Recently however, three case-reports demonstrated that TPMT deficiency does 
not preclude thiopurine therapy and hence offers a further option for 
homozygous mutants; these patients were safely treated with 0.16-0.29 mg/kg 
AZA daily which is approximately 10% of standard dose134. 
In several other studies no or very poor correlation was found between TPMT 
status and thiopurine toxicity. In a study with 41 leukopenic patients with 
Crohn’s disease (CD) treated with AZA, only 27% of the patients had one or 
two mutant TPMT alleles135. Myelosuppression was more often caused by 
other factors, such as viral infections, drugs interfering with AZA metabolism 
(allopurinol and 5-aminosalicylates) or causing bone marrow suppression by 
their own (trimethoprim-sulfamethoxazole, captopril and metronidazole). In the 
majority of cases however, no obvious cause of the developed 
myelosuppression was apparent. The lag time to the first appearance of 
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myelosuppression was longer in patients with wild type alleles though. Similar 
results were found in another study with 56 IBD patients: a slight trend for more 
frequent TPMT mutations in patients with adverse reactions on AZA or 6-MP 
was reported, though not statistically significant136. Therefore, it was concluded 
that TPMT genotype does not predict adverse reactions due to thiopurines in 
this population. 
Another enzyme of interest in thiopurine metabolism is ITPase. The 
identification of SNPs in the ITPase-gene is done in a similar way as TPMT 
genotyping with other primers and restriction enzymes of course95. ITPase-
activity can be determined by measuring the in vitro conversion of ITP to IMP 
by a HPLC method137. 
Recently, in a study with 62 IBD patients, the association between 
polymorphism in the ITPase gene and adverse drug reactions to AZA therapy 
was investigated: the C94A ITPase deficiency-associated allele significantly 
correlated with adverse events (OR 4.2), such as flu-like symptoms, rash and 
pancreatitis94. Besides, in the same study, no correlation was found between 
these adverse events and TPMT genotype. However, these results were 
contradicted by two other studies with 73 and 41 IBD patients 
respectively133,138. 
In a study by Zelinkova and colleagues it was demonstrated that the C94A 
allele predicted leukopenia with an OR of 3.50 for patients with mutant ITPase 
alleles compared to wild type patients129. 
In conclusion, whereas TPMT genotyping seems to play a role in the prediction 
of early drug toxicity in patients who have not been previously exposed to AZA 
or 6-MP, the predictive value for drug toxicity in patients established on 
thiopurines may be limited69. Studies with larger number of patients are needed 
to confirm this hypothesis. If TPMT genotyping is available, it is appropriate to 
genotype an IBD-patient before start of thiopurine treatment. Homozygous 
mutants should receive 10% of standard starting dose or no thiopurine at all, 
heterozygous mutants 50% of standard starting dose and wild-type patients 
can be safely given standard starting dose. 
There is little experience in ITPase genotyping in IBD populations and its 
predictive value, but the first results are promising. More and larger studies are 
needed to confirm and clarify these provisional data. 
6-Thioguanine 
Yet another strategy to avoid AZA or 6-MP related toxicity or to enhance 
efficacy is the administration of 6-TG, an agent more directly leading to the 
formation of the active 6-TGN and until recently used only in patients suffering 
from leukaemia. In a small pilot-study, 6-TG was given as such to ten ultra-
methylators, that is IBD patients with a preferential overproduction of 6-MMPR 
when given AZA or 6-MP65. These therapy-resistant patients continued to have 
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suboptimal 6-TGN levels despite dose escalation of their AZA or 6-MP and 
70% experienced dose related toxicity. On 6-TG treatment, seven out of ten 
patients responded or were in remission after one to four months. Though 
6-TGN levels were nine-fold higher on 6-TG than on 6-MP, no patient 
experienced a recurrence of previous hepatic or haematologic toxicity. 
6-MMPR concentrations were undetectable at all times. The authors concluded 
that 6-TG is a safer and more efficacious thiopurine in this subgroup of IBD 
patients resistant to 6-MP therapy.  
Theoretically, the administration of 6-TG also seems an attractive approach in 
patients with AZA or 6-MP intolerance because the number of possibly toxic 
metabolites is strongly reduced139. Accordingly, several clinical studies have 
been performed in this patient population140-145. In a short-term safety 
assessment with 32 AZA or 6-MP intolerant IBD patients it was shown that 
81% of patients were able to tolerate 6-TG in the first 8 weeks of treatment140. 
Comparable results were found in another study with 21 IBD patients with 
rechallenged allergic reactions on AZA or 6-MP: 82% were able to tolerate 
6-TG141. In a study with 49 AZA or 6-MP intolerant or resistant IBD patients, 
only 10% was forced to discontinue 6-TG due to the occurrence of adverse 
events142. 6-TGN concentrations were considerably higher on 6-TG compared 
to the concentrations measured on AZA or 6-MP therapy in all studies. Despite 
higher 6-TGN levels no haematological toxicity occurred. 
6-TG efficacy was demonstrated in a 24-week prospective study with 37 
patients with active CD: 35% achieved remission (CDAI <150) and 57% 
achieved a response (decrease of >70 points in CDAI)143. In a follow-up study, 
remission was maintained for one year in 88% of responders to 6-TG144. 
Initial enthusiasm tempered when nodular regenerative hyperplasia (NRH) of 
the liver was reported in a substantial number of 6-TG treated IBD patients144-
147. NRH is a serious complication also associated with AZA and 6-MP and a 
frequent cause of portal hypertension148,149. Currently, the use of 6-TG in IBD 
therapy is strongly discouraged until more definite results on toxicity are 
available. 
In conclusion, important issues like 6-TG short- and long term safety, efficacy 
in IBD, pharmacokinetics and the significance of higher 6-TGN levels during a 
longer period of time merit further exploration before 6-TG can be 
recommended in routine practice or be banned. 
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Conclusions 
TPMT genotyping and TDM are useful instruments for individualizing thiopurine 
pharmacotherapy of IBD. TPMT genotyping before initiation of treatment 
prevents early and severe myelosuppression by identifying homozygous 
mutants. Furthermore, in case of TPMT heterozygosity, safety measures such 
as precautionary dose reductions can be taken. Subsequently, TDM can guide 
thiopurine dosing to optimal metabolite levels herewith reducing the risk of drug 
related toxicity and increasing the chance on drug efficacy. Furthermore, TDM 
is useful whenever non-compliance is suspected. ITPase genotyping may be 
helpful in case of inexplicable myelotoxicity. At present, it is clear however that 
neither TDM nor TPMT or ITPase genotyping will replace or exclude frequent 
blood monitoring in the screening for possible myelotoxicity. 
In case of AZA- or 6-MP-intolerance, 6-TG seems a promising alternative. 
However, in the near future more knowledge needs to be gathered about its 
potential hepatotoxicity before it can be advocated or banned. 
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Outline of the thesis 
After the publications about therapeutic drug monitoring (TDM) of thiopurine 
therapy in IBD by Cuffari and Dubinsky, we became interested in thiopurine 
metabolism and the clinical use of metabolite levels measurement in our own 
thiopurine treated IBD patients6,7. This was the start of a fruitful collaboration 
between the Departments of Gastroenterology and Clinical Pharmacy in the 
Maasland Hospital, Sittard, Netherlands.  
With increasing knowledge about thiopurine metabolism and recognition of 
large inter-individual differences in metabolism, we decided to perform TDM in 
an organised way with study protocols approved by the local Medical Ethical 
Committee. Subsequently, gastroenterologists from other Dutch hospitals 
(Laurentius Hospital Roermond, University Medical Centre St.Radboud 
Nijmegen, Rijnstate Hospital Arnhem, VU Medical Centre Amsterdam, 
Academic Medical Centre Amsterdam, Isala Hospital Zwolle, University 
Hospital Maastricht and Catharina Hospital Eindhoven) participated in these 
studies. 
The aim of this clinical research was to improve efficacy and safety of 
thiopurine therapy in individual patients by TDM, but also to demonstrate the 
usefulness of TDM in thiopurine treated IBD patients on a larger scale. 
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Outline of thesis: 
Chapter 2: At first, this chapter describes the methods of metabolite 
measurements and TPMT genotyping, which are the 
pharmacological fundaments of this manuscript. Secondly, 
therapeutic drug monitoring is described prospectively in a 
6-mercaptopurine (6-MP) treated IBD cohort of thirty patients. 
Chapter 3: Some cases are reported, showing the clinical usefulness of 
therapeutic drug monitoring in individual IBD patients treated 
with azathioprine (AZA) or 6-MP. 
Chapter 4: Non-compliance to therapy is a well known problem in chronic 
diseases, such as diabetes and hypertension. Theoretically, 
measuring metabolite levels can reveal non-compliance. This 
chapter describes compliance, measured by therapeutic drug 
monitoring, in a cohort of AZA treated patients with IBD in 
remission. 
Chapter 5: The proposed therapeutic and toxic thresholds of 6-TGN and 
6-MMPR metabolites are based on retrospective studies in 
mostly paediatric IBD cohorts. Chapter 5 describes a 
prospective study on thiopurine treated adult IBD patients 
comparing metabolite levels between patients with active 
disease and patients with IBD in remission. A therapeutic 
6-TGN threshold is calculated and compared with previously 
proposed metabolite threshold levels. 
Chapter 6: In vitro studies showed evidence for TPMT inhibition by 
mesalazine. Only two in vivo studies have been performed. 
This chapter describes an in vivo interaction study of oral 
mesalazine and 6-MP in IBD patients. 6-MP metabolite levels 
and TPMT activity are measured during steady state 
combination therapy with mesalazine, after interruption of 
mesalazine, and after reintroduction. 
Chapter 7: 6-Thioguanine (6-TG) is a thiopurine that has been used in 
haemato-oncology for more than thirty years. This thiopurine is 
closer to the effective 6-thioguanine nucleotides (6-TGN), 
leading to fewer toxic metabolites, such as 6-methyl-
mercaptopurine ribonucleotides (6-MMPR). Due to the 
increasing knowledge about thiopurine metabolism, 6-TG was 
introduced as an alternative for AZA- and 6-MP-intolerant IBD 
patients in 2001. This chapter describes the pharmacokinetics 
of this thiopurine. 
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Chapter 8: Short term effects and safety of 6-TG in AZA- or 6-MP- 
intolerant IBD patients are described in this part of the thesis. 
Chapter 9: This chapter describes the one-year efficacy and safety of 
6-TG therapy in a Dutch IBD cohort. 
Chapter 10: In 2004, nodular regenerative hyperplasia of the liver was 
reported in 6-TG treated IBD patients. This chapter describes 
the results of 6-TG metabolite measurements, liver histology 
and MRI of the liver after intravenous gadolinium and 
ferrumoxide in long term 6-TG treated IBD patients. 
Chapter 11: The results described in this thesis are discussed in relation to 
relevant literature on TDM in thiopurine treatment. 
Chapter 12: A clinical advice is formulated, based on the findings of this 
thesis. 
Chapter 13:  Summary  
Chapter 14:  Samenvatting (Summary in Dutch) 
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Abstract  
Background & aims 
Proper prospective pharmacokinetic studies of 6-mercaptopurine (6-MP) in inflammatory bowel 
disease (IBD) patients are lacking, which have resulted in conflicting recommendations for 
metabolite monitoring in routine practice. The authors have evaluated 6-MP pharmacokinetics in 
IBD patients, including the genetic background for thiopurine methyltransferase (TPMT). 
 
Methods 
Red blood cell (RBC) 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine 
ribonucleotides (6-MMPR) concentrations were measured in thirty IBD-patients at t=1, 2, 4 and 
8 weeks after starting 6-MP, 50 mg once daily. Outcome measures included mean 6-TGN and 
6-MMPR concentrations (±95% confidence interval (CI95%)), and their associations with TPMT 
genotype, 6-MP dose, hematologic-, hepatic-, pancreatic- and efficacy parameters during the eight 
week period. 
 
Results 
Steady state concentrations were reached after four weeks, indicating a half life of approximately 
five days for both 6-TGN and 6-MMPR, and were 368 (CI95%: 284-452) and 2837 (CI95%: 2101-
3573) pmol/8x108 RBCs respectively. Large inter-patient variability occurred at all time-points. 
TPMT genotype correlated with 6-TGN concentrations (0.576, p<0.01) and patients with mutant 
alleles had a relative risk (RR) of 12.0 (CI95%: 1.7-92.3) of developing leukopenia. A 6-MMPR/ 
6-TGN ratio <11 was associated with therapeutic efficacy. 
 
Conclusions 
Based on this pharmacokinetic analysis, therapeutic drug monitoring is essential for rational 6-MP 
dosing. 
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Introduction 
6-Mercaptopurine (6-MP) is widely used in treatment of inflammatory bowel 
disease (IBD) and has proven to be effective for both inducing and maintaining 
long-term remission of Crohn’s disease (CD) and ulcerative colitis (UC)1-3. 
6-MP is more frequently used in the United States, whereas its precursor 
azathioprine (AZA) is the thiopurine of choice in Europe. 6-MP is transformed 
along competing enzymatic pathways4 and individual differences probably 
account for variations in metabolite concentrations4. Thiopurine metabolism, as 
depicted in Figure 2.1, ends with the formation of 6-thioguanine nucleotides 
(6-TGN), which are incorporated into DNA inducing cytotoxicity and 
immunosuppression4,5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Thiopurine metabolism. 
AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MMPR, 6-methylmercaptopurine 
ribonucleotides; 6-TU, 6-thiouric acid; 6-MeTIMP, 6-methylmercaptopurine 
ribonucleotide; 6-TIMP, 6-thioinosine monophosphate; 6-TXMP, 6-thioxanthosine 
monophosphate; 6-TGMP+6-TGDP+6-TGTP, 6-thioguanine nucleotides; 6-MeTGMP, 
6-methylthioguanine nucleotide; XO, xanthine oxidase; TPMT, thiopurine 
S-methyltransferase; HPRT, hypoxanthine phosphoribosyl transferase; IMPD, inosine 
monophosphate dehydrogenase; GMPS, guanosine monophosphate synthetase; 
MPK, monophosphate kinase; DPK, diphosphate kinase 
 
Currently, it is much debated whether assessment of metabolite concentrations 
is clinically useful in predicting both drug efficacy and toxicity and conflicting 
results have been published: a correlation between 6-TGN concentrations and 
clinical efficacy was shown in paediatric patients6, but not in a large cohort of 
adult patients7,8. In addition, thiopurine dosing did not correlate with clinical 
efficacy6,7. It is also uncertain which 6-MP metabolites are responsible for 
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specific side effects. It has been suggested that high 6-TGN concentrations are 
associated with leukopenia, whereas elevated 6-methylmercaptopurine 
ribonucleotides (6-MMPR) concentrations correlate with hepatotoxicity6. 
However, the precise role of 6-MMPR remains unclear, since this metabolite 
also has anti-proliferative properties that may result in clinical efficacy9. 
These controversies in part result from a lack of prospective pharmacokinetic 
data in IBD patients. Besides, the clinical implications of genetic differences in 
6-MP metabolism such as the much reported thiopurine S-methyltransferase 
(TPMT) polymorphism remain uncertain, leading to various recommendations 
on the use of metabolite measurements10,11. 
The aim of this study was to collect pharmacokinetic data of thiopurines in IBD 
patients in a prospective study.   
Materials and methods 
Patient selection 
IBD patients in which 6-MP was indicated, aged between 18 and 75 years and 
attending the out-patient clinics of Maasland Hospital Sittard or St Laurentius 
Hospital Roermond, were eligible for the study. Considered as indications for 
6-MP treatment were steroid-dependency, steroid-resistancy and AZA-
intolerance. Exclusion criteria were: pregnancy or expected pregnancy within 
six months, inadequate contraception in women, lactation, presence of active 
infection, history of tuberculosis, HIV, hepatitis B or C, severe pancreatitis 
(necrotizing pancreatitis or pancreatitis leading to multi organ failure), 
malignancy, ongoing treatment with other immunosuppressive drugs like 
cyclosporine, methotrexate, thalidomide or infliximab, impaired renal function 
(serum creatinin >2 times normal upper limit), elevated liver function tests (>2 
times normal upper limit) and bone marrow suppression.  
Study design 
The trial design was a prospective open-label multicentre study. At entry 
patient demographics and clinical history were collected as well as medication-
use during the past year. Subsequently, 6-MP (Puri-NetholTM, tablet 50 mg, 
Glaxo Wellcome, Zeist, the Netherlands) was prescribed as a single oral 50 mg 
evening dose. Concomitant medication was continued. Laboratory parameters 
and disease activity scores (Crohn’s Disease Activity Index (CDAI) for CD and 
Truelove-Witts Disease Activity Index (TWDAI) for UC) were obtained at 0 
(baseline), 1, 2, 4 and 8 weeks after start of medication. Blood was drawn at 
each visit for measurement of 6-TGN and 6-MMPR concentrations, alanine 
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transaminase (ALT), aspartate transaminase (AST), bilirubin, amylase, lipase, 
leukocytes (plus differentiation), platelets and haemoglobin (Hb).  
Ethical considerations 
The protocol was approved by the local medical ethics committee and in 
accordance with the Helsinki Declaration. Informed written consent was 
obtained before enrolment. 
Outcome measures 
Outcome measures were mean 6-TGN and 6-MMPR concentrations ± CI95%, 
correlation between either steady state 6-TGN or 6-MMPR concentrations with 
several other parameters including dose per kg bodyweight, TPMT genotype 
(TPMT*1/TPMT*2/TPMT*3A/TPMT*3B/TPMT*3C), leukocyte counts, platelet 
counts, Hb, the occurrence of myelotoxicity (leukocyte count <4.0x109/l, platelet 
count <100x109/l), alanine transaminase (ALT), aspartate transaminase (AST), 
amylase, lipase, bilirubins, the occurrence of hepatic toxicity (ALT >80 U/l, AST 
>80 U/l, bilirubins >40 µmol/l), pancreatic toxicity (amylase >220 U/l, lipase 
>120 U/l (elevations >2 times normal upper limit)), CDAI (CD) or TWDAI (UC) 
during the 8 week period.  
Analytical procedures 
TPMT genotype 
TPMT-genotyping of leukocyte DNA was carried out by the laboratory of the 
Department of Gastroenterology and Hepatology, Academic Medical Centre, 
Amsterdam, based on a previously reported assay12. TPMT-genotyping of 
leukocyte DNA was carried out by polymerase chain reaction (PCR) 
amplification in a thermocycler Gene AMP® PCR System 9700 (Perkin Elmer, 
Norwalk, CT, USA) followed by digestion with specific restriction enzymes. The 
products were separated by 2% agarose gel containing 1x TAE with 0,5 µg/ml 
ethidium bromide and read using the GeneGenius (Syngene, Cambridge, UK). 
The TPMT*2 allele contains a single G238C transversion mutation. The 
TPMT*3A allele contains two nucleotide transition mutations, being G460A and 
A719G. The TPMT*3B allele contains only the G460A mutation, whereas the 
TPMT*3C allele only has a single A719G mutation. 
G238C detection: The detection of the G238C mutation was carried out using a 
mutant primer P2M (5’-GTATGATTTTATGCAGGTTTG-3’) or a wild primer 
P2W (5’-GTATGATTTTATGCAGGTTTC-3’) and a reverse primer P2C 
(5’-TAAATAGGAACCATCGGACAC-3’). 100 µl PCR-mix was prepared using 
49 µl H2O, 49 µl ReddymixTM PCR Mastermix [2,5 mM MgCl2] (Abgene, 
Surney, UK), 1 µl P2M or P2W and 1 µl P2C. 1 µl of worksolution (one part of 
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above mentioned DNA by ten parts TE) was used as template in 10 µl PCR-
mix. The PCR reaction was carried out using the following cycles: an initial 
cycle of five minutes at 94°C followed by 30 cycles of 30 seconds at 94°C, one 
minute at 54°C, one minute at 72°C, and a single final  extension cycle at 72°C 
for five minutes. The PCR-products were analyzed by electrophoresis under 
the conditions as mentioned above. A DNA fragment was amplified with P2M 
and P2C primers when the G238C allele was present and with P2W and P2C 
primers when the wild-type allele was present. 
G460A detection: The detection of the G460A mutation was done using 
restriction fragment length polymorphism (rplf) analysis. The primers used for 
amplification by PCR were G460Afor (5’-ATAACAGAGTGGGAGGCTGC-3’) 
and G460Arev (5’-CTAGAACCCAGAAAAAGTATAG). 100 µl PCR- mix was 
prepared using 49 µl H2O, 49 µl ReddymixTM PCR Mastermix, 1 µl G460Afor 
and 1µl G460Arev. One µl of worksolution (one part of above mentioned DNA 
by 10 parts TE) was used as template in 10 µl PCR-mix. The PCR reaction was 
carried out in the same way as with the G238C detection. The PCR-products 
were digested by the endonuclease MwoI (New England Biolabs) for three 
hours at 60°C. Ten µl digestion-mix consisting of 0.1 µl MwoI [5 u/µl] 2 µl MwoI-
buffer and 7.9 µl H2O was used per 10 µl PCR-products. Digested products 
were analyzed by electrophoresis under the conditions as mentioned above. 
MwoI digestion of wild-type DNA yields fragments of 267 and 98 base pairs, 
whereas DNA containing the G460A mutation is not digested and yields an 
uncleaved fragment of 365 base pairs. 
A719G detection: This detection was also carried out by rflp analysis. The 
primers used for this amplification by PCR were p719f (5’-GJGKJGKJHGJHG-
3’) and the p719r (5’-GJHFGFHJGFJH-3’). A 100 µl PCR- mix was prepared 
using 49 µl H2O, 49 µl ReddymixTM PCR Mastermix, 1 µl p719f and 1 µl p719r. 
1 µl of worksolution (one part of above mentioned DNA by ten parts TE) was 
used as template in 10 µl PCR-mix. The PCR reaction was carried out using 
the following cycles: an initial cycle of five minutes at 94°C followed by 30 
cycles of 30 seconds at 94°C, 40 seconds at 55°C, one minute at 72°C, and a 
single final extension cycle at 72°C for five minutes. The PCR-products were 
digested by the endonuclease AccI (New England Biolabs) overnight by 37 °C. 
Per 10 µl PCR-products was used 20 µl digestion-mix consisting of 0.05 µl AccI 
[10 u/µl], 3 µl NEB4-buffer and 16.5 µl H2O. Digested products were analyzed 
by electrophoresis under the conditions as mentioned above. DNA containing 
the A719G mutation was digested in two fragments of 201 and 62 base pairs, 
whereas wild-type DNA was not digested. 
54 
 Pharmacokinetics of 6-mercaptopurine in IBD patients 
6-TGN and 6-MMPR concentrations 
6-TGN and 6-MMPR concentrations were measured in the laboratory of the 
Department of Clinical Pharmacy, Maasland Hospital, Sittard, using a slightly 
modified assay previously reported by Lennard and colleagues13. Erythrocytes 
are a good surrogate matrix as they are easily obtained, exist in sufficient 
numbers and contain concentrations of 6-TGN that reflect concentrations of 
6-TGN in the less accessible putative target-tissue, the leukocytes14. All 
modified procedures are described. 
Sample preparation 
Whole blood samples were collected in coated lithium heparin tubes at least 
twelve hours after medication intake. The samples were centrifuged at 160 g 
for ten minutes and plasma and “buffy coat” were discarded. RBC were 
washed with a same volume of phosphate buffered saline (PBS) solution, 
mixed and centrifuged at 160 g for ten minutes again. The supernatant was 
removed, RBC were washed following the described procedure once again and 
centrifuged at 640 g for ten minutes. Finally, the RBC were resuspended in the 
same volume of PBS solution and erythrocyte counts were carried out with a 
Cell Dyn 4000 cell counter (Abbott, Hoofddorp, The Netherlands). Samples 
were stored at -20°C until required.  
Extraction  
For measurement of intracellular thionucleotides the free base was obtained by 
acid hydrolysis of the nucleotide back to the purine. In brief, 200 µl RBC 
(approximately 8x108 RBC) were added to a 10-ml round-botommed 
extraction-tube containing 500 µl water and 300 µl of 10 mM DL-dithiothreitol 
(DTT). To this was added 500 µl 1.5 M sulphuric acid and the tubes were 
heated at 100°C for exactly one hour in a ThermoChem heating block (Marius, 
Germany). After cooling, 500 µl 3.4 M sodium hydroxide was added, followed 
by 5 ml of 1 mM phenylmercuric chloride in dichloromethane. After shaking and 
centrifugation at 3500 rpm for five minutes, 3 ml of the organic layer was 
transferred to another 10-ml round-bottomed extraction tube and 200 µl of 
0.1 M hydrochloric acid was added. Again the tubes were shaken and 
centrifuged at 3500 rpm for five minutes. Finally, 10 µl 10 mM DTT was added 
to 100 µl of the acid layer and the solution was transferred to a HPLC injection-
vial.  
HPLC procedure 
For 6-thioguanine nucleotide (6-TGN) determination 40 µl of the acidic extract 
was injected through a 717plus Autosampler (Waters Chromatography BV, 
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Etten-leur, The Netherlands) onto a NovaPak C18 column (3,9x150mm), 4 µm 
particle size (Waters Chromatography BV). 6-TGN was detected by a 2487 
Dual λ Absorbance UV Detector (Waters Chromatography BV) set at 343 nm 
and the chromatographic traces were stored on a personal computer for further 
analysis using Millennium32 Chromatography Manager software (Waters 
Chromatography BV). A model 510 HPLC pump (Waters Chromatography BV) 
was used for solvent delivery. The mobile phase consisted of 50 mM 
orthophosphoric acid and 0.5 mM DTT. For 6-MMPR determination, 30 µl of 
the acidic extract was processed as indicated above with the following 
modifications: the wavelenght was set at 303 nm and the mobile phase 
consisted of a methanol:water mixture (4:96 v/v), containing 150 mM 
triethylamine and 0.5 mM DTT, adjusted to pH 3.2 with orthophosphoric acid 
85%. 
Calibration 
Calibration curves were constructed by spiking RBC with 6-TGN (Sigma, St 
Louis, USA) in the range of 120-3600 pmol/8x108 RBC and 6-MMPR (Sigma, 
St Louis, USA) in the range of 700-36000 pmol/8x108 RBC. These curves were 
lineair with correlation coefficients of 0.992 and 0.998 for 6-TGN and 6-MMPR. 
Control samples were obtained and prepared by pooling blood samples of 
several patients on 6-MP treatment. The run-to-run coefficient of variation was 
6.6% and 9.7% for 6-TGN and 6-MMPR respectively. The lower limit of 
quantification of the assay was determined at 30 pmol/8x108 RBC for 6-TGN 
and 300 pmol/8x108 RBC for 6-MMPR.  
Statistical analysis 
Normality was tested by the Kolmogorov-Smirnov test. Data are expressed as 
means with range or 95% confidence interval (CI95%). Pearson’s correlation 
was used to test the relationship between the measured parameters. The 
χ2 test was used to test the association between TPMT-genotype and the 
occurrence of leukopenia. P values <0.05 were considered significant. SPSS 
for Windows (version 10.0.7) software was used to perform statistics. 
Results 
Patients 
Patient characteristics, reasons for 6-MP initiation and for study failure are 
shown in Table 2.1. Thirty patients were enrolled between March 2001 and 
June 2002. Of the 30 patients that started 6-MP treatment, 23 patients (77%) 
were on 6-MP treatment for four weeks and 17 patients (57%) completed the 
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eight week period. Steady state was reached after a period of four weeks. 
Thirteen patients failed to reach the end of the observed period and three 
failures were classified as non-6-MP related (Table 2.1). Drug intolerance in 
two patients included generalised malaise in one and palpitations/headache in 
the other, latter patient also demonstrating intolerance to previous AZA 
treatment. The other AZA-intolerant patient suffered from acute pancreatitis. 
 
Table 2.1 Patient characteristics. 
 N = 30 
Sex (M/F) 20/10 
Age (yrs) (mean + range) 41 (19-68) 
Disease (CD/UC) 19/11 
Duration of disease (yrs) (mean + CI95%) 6.5 (4.1-8.9) 
Disease activity at baseline  
 CD  remission, CDAI <150 12 
  active, CDAI 150-300 6 
  unknown 1 
 UC remission, TWDAI ≤6 5 
  active, TWDAI >6 4 
  unknown 2 
 Quality of Life at baseline* 62 
 5-ASA / no 5-ASA 28/2 
 5-ASA dose (mg) (median + range) 3000 (1500-4000) 
Reason for 6-MP initiation  
 Disease activity/steroid dependency 28 
 AZA intolerance 2 
 6-MP dose (mg/kg) (mean + CI95%) 0.71 (0.66-0.76) 
TPMT genotype  
 *1/*1 20 
 *1/*3A 2 
 *1/*3C 2 
 *3A/*3A 1 
 not determined 5 
Study failures 13 
 non 6-MP related 3 
 6-MP related 10 
  intolerance 2 (1 AZA intolerant patient) 
  leukopenia 4 
  hepatotoxicity 1 
  pancreatitis 3 (1 AZA intolerant patient) 
N, number of patients ; M, male; F, female; CD, Crohn’s disease; UC, ulcerative colitis; CDAI, 
Crohn’s disease activity index; TWDAI, Truelove-Witts disease activity index; 5-ASA, 
5-aminosalicylic acid (-analogues); 6-MP, 6-mercaptopurine; AZA, azathioprine; TPMT, thiopurine 
S-methyl transferase. 
* according VAS-score (0-100%). 
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Metabolite concentrations and TPMT genotype 
Metabolite concentrations were normally distributed. Mean 6-TGN and 
6-MMPR concentrations are shown in Table 2.2. Individual 6-TGN and 
6-MMPR level curves are shown in Figure 2.2 and 2.3 respectively. No 
correlation was found between steady state 6-TGN and 6-MMPR 
concentrations or between either 6-TGN or 6-MMPR level and dose per kg 
bodyweight. The TPMT genotype (wild type- versus mutant type TPMT) 
showed a significant and clinically important correlation with 6-TGN 
concentrations (0.576, CI95%: 0.18-0.81, p<0.01), but not with 6-MMPR 
concentrations.  
 
Table 2.2 6-TGN and 6-MMPR levels. 
week 6-TGN 
(pmol/8x108 RBC) 
6-MMPR 
(pmol/8x108 RBC) 
1  (N=30) 236 (149-323) 1691 (1316-2066) 
2  (N=26) 306 (223-386) 2783 (2123-3443) 
4  (N=23) 368 (284-452) 2837 (2101-3573) 
8  (N=17) 355 (262-447) 2318 (1327-3308) 
N, number of patients; 6-TGN, 6-thioguanine nucleotides; 6-MMPR, 6-methylmercaptopurine 
ribonucleotides. Data are expressed as means (with 95% confidence interval) 
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Figure 2.2 Individual 6-TGN concentration curves. The four patients that discontinued 6-MP 
therapy due to the occurrence of leukopenia are circled and their corresponding 
TPMT genotypes are displayed. The in literature suggested therapeutic lower- and 
upper limit are indicated6. 
  6-TGN, 6-thioguanine nucleotides; RBC, red blood cell; 6-MP, 6-mercaptopurine; 
TPMT, thiopurine S-methyltransferase.  
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Figure 2.3 Individual 6-MMPR concentrations curves. The three patients that discontinued 
6-MP therapy due to the occurrence of pancreatitis are circled and the one patient 
with drug-induced hepatotoxicity is displayed with a square. The in literature 
suggested therapeutic upper limit is indicated6 . 
 6-MMPR, 6-methylmercaptopurine ribonucleotides; RBC, red blood cells; 6-MP, 
6-mercaptopurine  
Adverse events 
Ten patients discontinued therapy because of adverse events (Table 2.1). Only 
for the occurrence of leukopenia, a significant correlation with TPMT genotype 
was observed with an increase in relative risk (RR) of 12.0 (CI95%: 1.7-92.3) 
(Table 2.3). Notably, 6-TGN concentrations in all four patients who developed 
leukopenia were above 300 pmol/8x108 RBC after one week.  
TPMT genotype was not predictive of drug intolerance, hepatotoxicity or the 
development of pancreatitis. 6-TGN did not show any correlation with 
hepatotoxicity or other adverse events. In this study, 6-MMPR concentrations 
did not correlate with ALT, AST, amylase, lipase, bilirubins or the occurrence of 
hepatotoxicity. In one of the three patients who developed pancreatitis 
however, the 6-MMPR level was considerably high (8224 pmol/8x108 RBC 
after six weeks).  
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Table 2.3 TPMT genotype and metabolite levels of all leukopenic patients. 
Patient TPMT genotype Week RBC 6-TGN level 
(pmol/8x108 RBC) 
RBC 6-MMPR level 
(pmol/8x108 RBC) 
1 *3A/*1 4  628  362 
2 *3A/*3A 1  1284  0 
3 *1/*1 8  670  337 
4 *3C/*1 2  894  2707 
TPMT, thiopurine S-methyltransferase; RBCs, red blood cells; 6-TGN, 6-thioguanine nucleotides; 
6-MMPR, 6-methylmercaptopurine ribonucleotides 
 
Efficacy 
Disease activity was assessed in all patients at baseline and after eight weeks. 
Ten of the 30 patients had active disease at baseline (Table 2.4). The mean 
CDAI of the six CD patients was 229, the mean TWDAI for the four UC patients 
was 10. Three of six CD patients (50%) achieved clinical remission (CDAI 
<150) after the study period of eight weeks, versus three of four UC patients 
(75%).  
Five of the six patients (83%) with active disease at baseline and clinical 
remission at week 8 had 6-TGN concentrations above the recently proposed 
lower therapeutic limit of 235 pmol/8x108 RBC6. Three of the four patients 
(75%) with no clinical improvement had concentrations below the proposed 
threshold. Interestingly, the proposed therapeutic 6-MMPR/6-TGN ratio of 11 
also correlated with clinical efficacy: Four of six IBD patients (67%) with a ratio 
<11 achieved clinical remission within the study period, whereas three of four 
patients (75%) with a ratio >11 failed to do so15.  
 
Table 2.4 Disease activity and metabolite levels in patients with active disease at baseline. 
 Remission 
after 8 wks 
6-MMPR/ 
6-TGN ratio 
Active disease 
after 8 wks 
6-MMPR/ 
6-TGN ratio 
Active Crohn’s disease (CDAI>150) N=3  N=3  
Css RBC 6-MMPR/6-TGN 
level (pmol/8x108 RBC) 
Pt 1 
Pt 2 
Pt 3 
  600/180 
2290/585 
5193/486 
  3.3 
  3.9 
10.7 
2196/134 
4520/364 
1298/156 
16.4 
12.4 
  8.3 
Active ulcerative colitis (TWDAI>6) N=3  N=1  
Css RBC 6-MMPR/6-TGN 
level (pmol/8x108 RBC) 
Pt 1 
Pt 2 
Pt 3 
5412/288 
3166/277 
2295/330 
18.8 
11.4 
  7.0 
3740/203 18.4 
CDAI, Crohn’s Disease Activity Index; Css, steady state level; TWDAI, Truelove-Witts Disease 
Activity Index; N, patient number; Pt, patient; RBC, red blood cells; 6-TGN, 6-thioguanine 
nucleotides; 6-MMPR, 6-methylmercaptopurine ribonucleotides. 
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Discussion  
Despite a large body of recent research on metabolite determination and TPMT 
genotyping in IBD patients treated with thiopurines, there are no uniform 
therapeutic guidelines and it is unclear whether such measurements should 
guide dosing. Recently, it has been stated that the confusion over this “correct” 
dosing of purine analogues was partly caused by “the lack of typical dose-
ranging and pharmacokinetic studies in this patient population”16. We therefore 
prospectively performed such a study in 30 IBD patients. No distinction was 
made between CD and UC patients, because we did not expect a difference in 
thiopurine metabolism or toxicity.  
We found that both 6-TGN and 6-MMPR concentrations showed large inter-
patient variability, similar to results from pharmacokinetic studies in other 
patient populations17,18. 6-TGN and 6-MMPR concentrations reached steady 
state after four weeks, suggesting a half-life of approximately five days. For 
6-TGN concentrations, this was already demonstrated in other studies, but the 
half-life of 6-MMPR has not been previously reported19. At steady state there 
was a seven-fold range in 6-TGN concentrations, and this is an 
underestimation as patients with extremely high 6-TGN concentrations 
discontinued 6-MP treatment after 1-2 weeks because of leukopenia. Steady 
state 6-MMPR concentrations reached an even larger sixteen-fold range.  
As has been reported in children suffering from lymphoblastic leukaemia, no 
correlation was found between 6-TGN and 6-MMPR concentrations18. Drug 
dose per kg bodyweight correlated neither with 6-TGN nor with 6-MMPR 
concentrations. These data do not support the use of standard doses of 
1-2 mg/kg/day as is commonly advised, because this results in unpredictable 
6-MP metabolite concentrations. 
TPMT genotype correlated with 6-TGN concentrations, even though patients 
with mutant TPMT alleles who discontinued 6-MP before reaching steady state 
metabolite concentrations were not included in statistical analysis. It has been 
reported that the presence of mutant alleles of the gene encoding TPMT results 
in elevated 6-TGN concentrations and leukopenia20. In our study five patients 
with mutant alleles were identified and three (60%) developed leukopenia 
within four weeks of treatment. In all leukopenic patients high 6-TGN 
concentrations were measured and the highest 6-TGN level was measured in 
the patient homozygous for the TPMT*3A alleles (1284 pmol/8x108 RBC after 
one week). No leukopenia was observed in the other two patients with 
heterozygous alleles (steady state 6-TGN concentrations of 786 and 427 
pmol/8x108 RBC). One of the 20 patients (5%) with wild type alleles developed 
leukopenia. This patient had a steady state 6-TGN level of 670 pmol/8x108 
RBC, which is substantially higher than the measured mean steady state 
6-TGN level of 368 pmol/8x108 RBC. The risk of developing leukopenia was 
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twelve-fold higher in the patients with mutant alleles compared to patients with 
wild type alleles. Similar results were reported in a rheumatic population treated 
with AZA21. All patients that subsequently developed leukopenia had 6-TGN 
concentrations above 300 pmol/8x108 RBC after one week. Mean steady state 
concentrations would theoretically have been above 500 pmol/8x108 RBC in 
this group of patients (mean 6-TGN level week 4 / 6-TGN level week 1≈1,7). In 
fact, the mean steady state 6-TGN level in leukopenic individuals in another 
study was 490 pmol/8x108 RBC6. Hence, a dose reduction would be 
recommended if a 6-TGN level above 300 pmol/8x108 RBC is measured after 
one week of 6-MP treatment.  
If the results of TPMT genotyping had been known prior to initiation of 6-MP 
treatment, at least one episode of leukopenia (in the patient homozygous for 
the TPMT*3A alleles) would have certainly been prevented and in the patients 
with heterozygous TPMT alleles, a 50% starting-dose reduction in combination 
with weekly TDM until steady state probably would have reduced the risk of 
developing leukopenia. 
This study was not powered to study therapeutic efficacy. However, we found 
therapeutic  efficacy to be associated with a 6-TGN level above the recently 
proposed lower therapeutic limit of 235 pmol/8x108 RBC. Though the described 
number of patients with efficacy data is small, these data are in accordance 
with the results of Dubinsky and colleagues6. In addition, a 6-MMPR/6-TGN 
ratio <11 correlated with drug efficacy as was also previously suggested15. We 
must be reserved in drawing conclusions for the group of non-responders too 
early, as the clinical effect of 6-MP may have a lack-time of 3-6 months. 
Steady state 6-MMPR concentrations did not correlate with any of the hepatic 
or pancreatic parameters. Three patients developed pancreatitis and in one the 
6-MMPR concentration was high: although the 6-MMPR level seemed normal 
after four weeks of treatment (3308 pmol/8x108 RBC), concentrations rapidly 
increased after five weeks (7420 pmol/8x108 RBC) and six weeks (8224 
pmol/8x108 RBC). In the other two patients steady state 6-MMPR 
concentrations were 1558 and 4989 pmol/8x108 RBC respectively. Therefore, 
although high 6-MMPR concentrations are sometimes detected in patients 
developing pancreatitis, pancreatitis often occurs in the absence of toxic 6-
MMPR concentrations (>5700 pmol/8x108 RBC) and the role of 6-MMPR in the 
pathogenesis of pancreatitis is uncertain6,22.  
In one patient (TPMT genotype *1/*1) the 6-MP dose was raised to 100 mg 
once daily because of suboptimal steady state 6-TGN concentrations. As a 
result, 6-MMPR concentrations increased dramatically from 3740 to 
12995 pmol/8x108 RBC in four weeks, and simultaneously ALT and AST 
increased from 47 and 32 U/l to 139 and 61 U/l respectively, suggesting drug-
induced hepatotoxicity and necessitating discontinuation of 6-MP treatment. 
This patient obviously had preferential shunting to 6-MMPR, resulting in an 
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increase of the 6-MMPR/6-TGN ratio from 18.4 to 32.5 after dose escalation. 
Recently, Dubinsky and colleagues found that only 27% of non-responders to 
6-MP treatment respond to a dose escalation15. In most patients dose 
escalation did not significantly increase 6-TGN concentration, but significant 
increased potentially toxic 6-MMPR concentrations. The results of that study 
suggested that metabolite profiles provide a biochemical explanation for 6-MP 
resistance and 6-MMPR related toxicity. In a second patient in our study, high 
6-MMPR concentrations (7155 pmol/8x108 RBC after two weeks) were 
accompanied by palpitations and headache leading to discontinuation of 6-MP 
treatment. Both patients successfully switched from 6-MP to 6-TG 20 mg orally 
once daily, making a causal role of 6-MMPR in the occurrence of adverse 
events even more likely23. 
Conclusions 
Our data indicate that future study designs should consider measurement of 
thiopurine metabolite concentrations after one week (to prevent early toxicity: 
6-TGN <300 pmol/8x108 RBC) and four weeks (to detect suboptimal dosing or 
non-compliance: 6-TGN >250 pmol/8x108 RBC and late toxicity: 6-TGN 
<500 pmol/8x108 RBC) in order to validate our findings.  
In conclusion, in IBD patients on 6-MP treatment, large non-dose related inter-
individual differences in metabolite concentrations occur. Our study clearly 
indicates the usefulness TPMT genotyping and especially TDM in this 
population. Our suggestions need to be confirmed in a prospective, 
randomised intervention study. TPMT genotyping before start of thiopurine 
treatment may prevent early myelotoxicity due to thiopurine treatment in a 
selection of patients. TDM will facilitate the clinician to improve the 6-MP 
efficacy by demonstrating suboptimal dosing, and predicting risks of 
complications such as leukopenia and hepatitis. TDM may also be helpful in 
revealing poor compliance.  
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Abstract  
The thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP) are effective drugs in steroid 
dependant and refractory IBD patients. Therapeutic drug monitoring (TDM) is a new concept to 
improve drug efficacy and prevent toxic adverse events. As thiopurine metabolism is influenced by 
genetic polymorphisms of methylating enzymes, metabolite levels may vary considerably, enabling 
significant adverse effects. In this paper five patients are described to demonstrate the clinical 
usefulness of TDM when applying thiopurines for IBD. Emphasized are patients with liver function 
test abnormalities and myelosuppression due to inappropriate 6-MP metabolite levels and 
subsequently the treatment of these events. In addition, sophisticated 6-MP metabolite levels 
guided therapy, including non-compliance is demonstrated. These cases demonstrate that TDM 
can improve efficacy and safety of thiopurine treatment. 
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Introduction 
The thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP) are 
established drugs in steroid dependent and refractory inflammatory bowel 
disease (IBD)1,2. New ideas in improving drug efficacy and minimizing toxicity 
have emerged last years. In this regard concepts have been developed 
including therapeutic drug monitoring (TDM) by measuring metabolites of AZA 
and 6-MP. After elucidating thiopurine metabolism and analytical procedures of 
metabolite measurement some cases are presented emphasizing the clinical 
usefulness of TDM in thiopurine treated IBD patients. 
Metabolism of AZA and 6-MP 
AZA is rapidly converted to 6-MP by splitting off an imidazole group, and then 
metabolised to the pharmacologically active 6-thioguanine nucleotides (6-TGN) 
and 6-methylmercaptopurine ribonucleotides (6-MMPR). 6-TGN are purine 
nucleotides, which are incorporated into DNA of leucocytes, inducing 
immunosuppression1-4 (Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Thiopurine metabolism.  
 AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MeMP, 6-methylmercaptopurine; 6-TU, 
6-thiouric acid; 6-MeTIMP+6-MeTIDP+6-MeTITP, 6-methylmercaptopurine 
ribonucleotides; 6-TIMP, 6-thioinosine monophosphate; 6-TXMP, 6-thioxanthosine 
monophosphate; 6-TGMP+6-TGDP+6-TGTP, 6-thioguanine nucleotides; 6-MeTGMP+ 
6-MeTGDP+6-MeTGTP, 6-methylthioguanine nucleotides; XO, xanthine oxidase; 
TPMT, thiopurine S-methyltransferase; HPRT, hypoxanthine phosphoribosyl 
transferase; IMPD, inosine monophosphate dehydrogenase; GMPS, guanosine 
monophosphate synthetase; MPK, monophosphate kinase; DPK, diphosphate kinase. 
 Note: laboratory measurements consist of a combination of several metabolites: 
 -Measured 6-MMPR level: 6-MeMP and 6-MeTIMP + 6-MeTIDP + 6-MeTITP 
(6-methylmercaptopurine ribonucleotides) 
 -Measured 6-TGN level: 6-TG and 6-TGMP + 6-TGDP + 6-TGTP (6-thioguanine 
nucleotides) 
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Historically, controlled trials demonstrated that AZA at a dose of 
2.0-3.0 mg/kg/day and 6-MP at 1.5 mg/kg/day (equivalent of AZA of 
3.0 mg/kg/day) are effective and generally well tolerated1,5-8. More recently, 
Cuffari and Dubinsky found in paediatric IBD patients that the clinical response 
only correlates with 6-TGN levels and not with other variables, such as drug 
dose9,10. These observations were the first indices of the usefulness of TDM in 
thiopurine treated patients. Otherwise, conflicting results in adult IBD patients 
have been described11,12. Furthermore, it was demonstrated that red blood cell 
(RBC) 6-TGN levels correlate with bone marrow suppression, while on the 
other hand 6-MMPR levels correlate with hepatotoxicity9,10. The lower 
therapeutic limit of 6-TGN was established at 235 pmol/8x108 RBC, whereas 
6-MMPR levels above 5700 pmol/8x108 RBC seemed potentially hepatotoxic. 
Hepatitis is found in 4-17% of patients9,10,14. 
A drawback of AZA and 6-MP is the occurrence of side effects, leading to 
discontinuation of thiopurine therapy in 10-20% of patients14-16. Approximately 
10% of AZA treated patients have non specific side effects, disappearing after 
changing to 6-MP17. The cleaved imidazole derivative may be the cause of 
these side effects18. Opposite, when patients do not tolerate 6-MP, AZA is not 
tolerated as well, because 6-MP originates from AZA. Bypassing the first step 
of thiopurine metabolism by giving 6-MP in stead of AZA may improve 
therapeutic efficacy. 
Adverse events in thiopurine treatment can also be non-metabolic, like 
pancreatitis. This complication occurs in 4-17% of patients9,10,14. 
Toxicity due to metabolites may be explained by polymorphisms of the gene 
encoding thiopurine S-methyltransferase (TPMT), the enzyme that methylates 
6-MP to 6-MMPR. Eighty-nine percent of individuals have normal to high 
enzyme activity. These individuals are homozygous TPMTH/H for the wildtype *1 
allele19. Eleven percent has intermediate (heterozygous TPMTH/L) and 0.3 % 
has low to absent enzyme activity (homozygous TPMTL/L)9. TPMT *3A is the 
most frequently occurring variant allele (TPMTL) in Caucasians19,20. Other 
mutations are *2, *3B, *3C, *3D, *4, *5, *6, *7 and *8. In case of reduced 
enzyme activity toxic 6-TGN levels may arise on regular doses of AZA or 6-MP 
causing myelosuppression21. Alternatively, in some patients high 6-MMPR 
levels are noted, while 6-TGN levels remain subtherapeutic. Theoretically, the 
available 6-MP is largely transformed into 6-MMPR due to preferential 
metabolism through TPMT, increasing the risk of hepatitis. There is no clinical 
evidence for this hypothesis yet. We recently performed a study with TDM and 
TPMT genotyping in 6-MP treated IBD patients and found no relation between 
TPMT and hepatotoxicity22.  
Theoretically, 6-TG would be a good alternative in patients with AZA and 6-MP 
intolerance. The idea of using a metabolite at the end of the enzymatic pathway 
in stead of a prodrug like AZA or 6-MP seems to be an attractive approach. In 
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theory toxicity by potentially toxic metabolites may be avoided. There still is a 
lot of debate on this issue (see Discussion). 
Analytical procedures 
Blood samples are taken at least twelve hours after medication intake and 
centrifuged to isolate erythrocytes. A slightly modified high-performance liquid 
chromatography (HPLC) assay as reported by Lennard et al. has been 
implemented to measure thiopurine metabolites in erythrocytes23. It should be 
emphasised that 6-TGN and 6-MMPR levels consist of a sum of several 
metabolites including 6-mercaptopurine ribonucleotides and 6-thioguanine 
phosphates as shown in Figure 3.1. The run-to-run coefficient of variation in 
our laboratory is 6.6% and 9.7% for 6-TGN and 6-MMPR respectively. The 
detection limit of the assay is 30 pmol/8x108 RBC for 6-TGN and 300 
pmol/8x108 RBC for 6-MMPR.  
Case reports 
Case 1 
A 48-year-old man known with left sided ulcerative colitis (UC) for eleven years 
was unsuccessfully treated with betamethasone enemas, mesalazine and 
azathioprine 100 mg daily (1.0 mg/kg). After detecting zero levels of 6-MMPR 
and 6-TGN the patient admitted that he had not taken azathioprine for a year 
but had not dared to tell his gastroenterologist. 
Case 2 
A 50-year-old man with left sided UC for fourteen months had been 
unsuccessfully treated with budenoside, mesalazine enemas and prednisone 
30 mg daily. When starting 50 mg 6-MP daily (0.6 mg/kg), he had moderately 
severe disease activity according to Truelove-Witts24. 
Because of insufficient clinical improvement and subtherapeutic 6-TGN levels 
(203 pmol/8x108 RBC) 6-MP dose was increased to 100 mg daily (1.2 mg/kg) 
after four weeks. Three days later the patient complained about nausea and 
slightly increased serum transaminase levels were measured (ALAT 139 U/l 
(5-50) and ASAT 73 U/(5-40)). Two weeks after dose escalation his 6-TGN 
level had risen to 348 pmol/8x108 RBC and 6-MMPR even to 8686 pmol/8x108 
RBC. After changing 6-MP treatment to 20 mg 6-thioguanine (6-TG) (Lanvis®, 
GlaxoSmithKline) (0.3 mg/kg), nausea disappeared and serum transaminases 
normalised as 6-MMPR levels decreased to zero. Steady state 6-TGN level 
was 884 pmol/8x108 RBC after eight weeks of therapy. Afterwards, TPMT 
genotyping revealed a wildtype or homozygous TPMTH/H (*1/*1) genotype. This 
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patient has been treated for more than one year now and still has a mild 
disease activity with stable 6-TGN levels. There are still no signs of 
myelosuppression or hepatotoxicity.  
Case 3 
A 60-year-old man with UC for eleven years treated with olsalazine 1000 mg 
t.i.d. experienced a flare of the disease combined with a perianal abscess. The 
latter was treated surgically. Thereafter 6-MP 50 mg (0.7 mg/kg) was added to 
treatment. After one week he already had 6-TGN levels of 425 and 6-MMPR of 
482 pmol/8x108 RBC. Two months later it was decided to decrease 6-MP dose 
to 25 mg (0.4 mg/kg) daily because of high 6-TGN levels (628 pmol/8x108 
RBC) compared to 6-MMPR (362 pmol/8x108 RBC). On this dose steady state 
6-TGN levels are 417 pmol/8x108 RBC while 6-MMPR is undetectable. Disease 
activity is in remission. Subsequently, TPMT analysis showed a heterozygous 
genotype: TPMTL/H (*3A/*1). 
Case 4 
A 32-year-old man with UC eight years was treated with mesalazine and 
prednisolone without effect. One week after starting 50 mg 6-MP daily 
(0.5 mg/kg) he had an extremely high 6-TGN level (1284 pmol/8x108 RBC). 
Because of suspected poor TPMT metabolism therapy was interrupted. He did 
not show up for follow up and visited another hospital were AZA 50 mg daily 
was started (without knowledge of the former high 6-TGN level). After several 
weeks he developed a severe leucopenia. Genotyping revealed a poor 
metaboliser: TPMTL/L (*3A/*3A). 
Case 5 
A 23-year-old female with Crohn’s disease (CD) for three months had ongoing 
disease activity in spite of mesalazine and prednisolone 25 mg daily. 6-MP was 
started at 1.7 mg/kg without controls of metabolite levels. After seven weeks 
she had fever. Laboratory analysis showed a pancytopenia: haemoglobin 4.3 
mmol/(7.5-9.9), leucocytes 1,5x109/l (4.0-12.0), neutrophils 16%, thrombocytes 
13x109/l (150-350). 6-MP was discontinued and she was successfully treated 
with a broad spectrum antibiotic. No clear focus of inflammation was found 
except her CD. Metabolite levels showed an extremely rare profile: 6-MMPR 
57000 and 6-TGN 126 pmol/8x108 RBC. Pancytopenia recovered 
spontaneously within a few weeks. Genotyping revealed a wildtype TPMTH/H 
(*1/*1) genotype. 
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Discussion  
TDM is an established way of improving efficacy and preventing toxicity of 
many drugs, like gentamicin, digitoxin, antiepileptics and immunosuppressives 
(eg. tacrolimus and ciclosporine). The described cases emphasize the 
potentials of TDM in thiopurine treated IBD patients. All patients are part of a 
study group of 46 which has been partially described previously or will be 
soon22,25. 
Case 1 is a typical case of non-compliance, as is often seen in chronic patients 
in general. TDM is the only method to detect this phenomenon.  
The second case shows that high 6-MMPR levels may give rise to a toxic 
hepatitis. This patient with wildtype TPMTH/H genotype has a preferential 
metabolism of 6-MP to 6-MMPR, resulting in a failure to achieve adequate 
clinical benefit from 6-MP treatment even after dose increasement. Recently, 
Dubinsky found that only 27% of non-responders to 6-MP treatment (median 
dose 0.9 mg/kg) respond to a dose escalation26. The other 73% had minimal 
changes in 6-TGN levels after escalation, but prominent elevations of 
potentially toxic 6-MMPR levels. This study suggests that metabolite profiles 
provide a biochemical explanation for 6-MP resistance. Thereby it shows that 
TDM can reveal a subgroup of patients resistant to 6-MP treatment, in danger 
of hepatotoxicity when 6-MP dose is increased.  
Case 2 also demonstrates that TDM can give the clinician a false sense of 
security. It is important that levels are measured early, enabling a quick 
intervention. In this case we received the results too late to prevent 
hepatotoxicity. 
Besides, case 2 is an example of treatment with 6-TG, a product near the end 
of the metabolic pathway of thiopurines as mentioned before (Figure 3.1). It 
was given in an experimental setting including intensive clinical and laboratory 
evaluations and TDM, as described earlier25. After one year of treatment no 
signs of myelosuppression or liver function disturbance were found.  
As mentioned before, there is still a lot of debate on the use of 6-TG. Until now 
few short term studies in 6-TG treated IBD patients have been published, which 
showed no clinically relevant toxic adverse events25,27. Recently the first long 
term study described improvement of disease activity in 82% of 21 AZA or 
6-MP intolerant, 6-TG treated patients28. Four patients (19%) had a harmless 
hypersensitivity reaction and no serious adverse events occurred. 6-TG was 
presented as an effective and safe treatment under strict monitoring in this 
study. Surprisingly, in a more recent report from the same authors it is 
concluded that 6-TG should not be considered for IBD patients because of a 
high frequency of nodular regenerative hyperplasia (NRH) in the liver29. This 
conclusion should be discussed. At first, preceding immunosuppressive 
medication could have contributed to these findings as well, especially because 
73 
Chapter 3 
92% of patients had used AZA or 6-MP for more than one year before 6-TG 
treatment, accompanied by liver function disturbances in 40% of these patients. 
NRH may well have been started in this period, as reported previously in AZA 
treated patients30. Besides, high 6-TGN levels of 1230-1280 pmol/8x108 RBC 
were reported, while no median dose was mentioned. Based on median 
duration of 6-TG treatment and median cumulative dose this must have 
exceeded 40 mg daily. In the past it is demonstrated AZA may lead to veno-
occlusive disease due to dose dependent toxicity to murine sinusoidal 
endothelial cells and hepatocytes31.  
In another study, follow-up of 50 AZA or 6-MP intolerant IBD patients treated 
with 6-TG for more than one year did not reveal hepatotoxicity correlated to 
6-TG32. In the latter study substantially lower doses of 6-TG were used  (mean 
6-TG dose 21 mg daily, range 10-40 mg) and consequently lower 6-TGN levels 
achieved (mean 650 pmol/8x108 RBC, range 158-1402)31. Nevertheless, NRH 
was also found in leukemic children, but again high 6-TG or 6-MP doses were 
used, resulting in high 6-TGN levels (median 1592 pmol/8x108 RBC, range 
1240-1965)33.  
In conclusion, more and prolonged experiences with 6-TG treatment are 
warranted before widespread use or expel of it. 
In case 3 relatively high 6-TGN and low 6-MMPR levels were measured. 
Sufficient 6-TGN levels were reached at 50% starting dose. This patient is an 
example of an intermediate metaboliser (heterozygous TPMTL/H). It also 
illustrates the inter-individual differences in TPMT activity and corresponds with 
earlier findings of Dubinsky et al. in which clinical response only correlates with 
6-TGN levels and not with any other variable such as drug dose10.  
The fourth case represents the one out of 300 patients with no functional TPMT 
activity (TPMTL/L) showing extremely high 6-TGN levels within just one week of 
6-MP treatment. This patient had a homozygous variant allele (TPMT *3A/*3A). 
In this case 6-TG treatment is considered. 
Case 5 is extraordinarily interesting, presenting reversible pancytopenia due to 
extremely high 6-MMPR levels. This phenomenon has not been published 
previously and points out the capacity of myelotoxicity due to all 6-MP 
metabolites and not 6-TG alone. 
The question remains when to perform TDM. In case of preferential metabolism 
to 6-MMPR or 6-TGN rapid elevations of either level may be expected in the 
first week. Steady state levels of either metabolite are reached within four 
weeks22. Therefore we suggest to do TDM combined with liver function tests, 
amylase/lipase and blood cell count after one week to exclude early 
myelotoxicity and after four weeks to detect myelotoxicity, suboptimal dosing, 
high 6-MMPR levels or non-compliance. At least TDM is recommended in case 
of any leucopenia, suspected hepatotoxicity or non-compliance. Finally, TDM 
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may provide new data on thiopurine metabolism, such as in case five, proving 
myelotoxicity due to 6-MMPR. 
TDM is not the only way of improving thiopurine treatment efficacy and safety. 
TPMT genotyping before starting thiopurine treatment enables identification of 
patients at risk for early myelosuppression20,34. Heterozygous patients like case 
3 should have a dose reduction and intensive TDM, while homozygous poor 
metabolisers (TPMTL/L) like case 4 are candidates for treatment with 6-TG or a 
significant dose reduction, according to a recent report35. On the other hand, 
several studies demonstrated that there is no role for TPMT genotyping in 
established thiopurine treatment20,36.  
When comparing the use of TDM and TPMT genotyping we prefer TDM. 
Metabolite levels correlate better with efficacy and toxicity of thiopurine 
treatment than TPMT genotype. Costs for thiopurine metabolite measurements 
and TPMT genotyping are similar (50-60 Euro´s). 
Conclusions 
TDM already is an important tool in accomplishing safe and effective drug 
therapy in many diseases, especially when potentially toxic drugs are 
employed. The present article illustrates that it is worthwhile employing TDM 
during thiopurine treatment because of great inter-individual differences in 
metabolism. TDM improves efficacy of treatment and diminishes risks of 
serious complications such as myelosuppression and hepatitis. For this 
purpose thiopurine metabolite levels, blood cell count, liver function tests and 
amylase should be measured after one and four weeks. TDM can also be used 
to reveal bad compliance or undertreatment in steady state treated patients 
and might help clinicians to overcome their fear for overdosing.  
TPMT-genotyping before starting thiopurine treatment may be complementary 
to TDM. The TPMT genotype predicts the chance of early neutropenia, while 
TDM can be used to adjust 6-TGN and 6-MMPR levels. However, TPMT 
genotyping is not useful in established thiopurine treatment. Nevertheless, 
genotyping may be considered in case of neutropenia or high 6-TGN levels to 
reveal intermediate and poor metabolisers to further adjust thiopurine 
treatment. 
Increasing experiences of TDM in AZA and 6-MP stimulate the already growing 
interest in pharmacogenetics and -kinetics in general. TDM might also be of 
use for other medications in future. 
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Abstract  
Introduction 
Azathioprine (AZA) is widely used in the treatment of steroid dependant and refractory 
inflammatory bowel disease (IBD). The efficacy of this treatment is based on the production of 
6-thioguanine nucleotides (6-TGN), but extremely elevated levels may cause bone marrow 
suppression. Other AZA metabolites, 6-methylmercaptopurine ribonucleotides (6-MMPR), are 
associated with hepatotoxicity. Therapeutic drug monitoring (TDM) may be of help in optimizing 
AZA treatment, but data on TDM in established AZA therapy are lacking. Therefore we measured 
metabolite levels in a small cohort of patients established on AZA. 
 
Patients and methods 
6-Thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMPR) levels 
in erythrocytes were measured in fifteen IBD out-patients established on AZA for at least three 
months at t=0, 1, 4 and 8 weeks after inclusion (mean duration of treatment 28 months; range 7-67 
months). Disease activity was evaluated by CDAI (Crohn’s disease) or Truelove-Witts (Ulcerative 
Colitis) scores. Metabolite levels were measured by a modified high-performance liquid 
chromatography assay (HPLC). Primary outcome measures were 6-TGN and 6-MMPR metabolite 
levels and 95% confidence intervals (CI95%). Secondary outcomes were correlations between 
metabolite levels and drug dose, disease activity and laboratory parameters and compliance. 
Statistical analysis was done by Pearson´s correlation test. P values <0.05 were considered 
significant. 
 
Results 
One patient had active disease during the study period. Eleven out of fifteen patients (73%) 
completed the eight week study period. Drop out reasons were non-compliance in one patient 
(7%), intolerance in one (7%) or incomplete data in two patients (13%). 
Primary outcomes: At baseline mean 6-TGN levels were 158 (CI95%: 113-203) pmol/8x108 RBC, 
steadily increasing over the eight week study period, but not significantly. Two patients had zero 
levels. Another two had significantly increasing levels also suggesting non-compliance. 
Mean 6-MMPR levels showed almost a similar pattern. At baseline levels were 2213 (CI 95%: 722-
3704) pmol/8x108 RBC. 
Secondary outcomes: Correlations were found between all RBC 6-MMPR levels and AZA dose 
(mg/kg bodyweight) (r=0.43 and p=0.001) and also between 6-MMPR/6-TGN ratio and AZA dose 
(mg/kg) (r=0.36 and p=0.010). There was no correlation between RBC 6-TGN or 6-MMPR levels 
and hematological parameters or disease activity scores. No hepatic, pancreatic or myelotoxicity 
occurred.  
 
Discussion 
Thirtheen of fifteen patients (87%) had baseline steady state 6-TGN levels below the therapeutic 
threshold of 235 pmol/8x108 RBC. Forty percent (6/15) of our patients was non-compliant (40%). 
TDM revealed this non-compliance in four of six patients. 
 
Conclusions 
Our small study demonstrates that TDM may give insight in individual pharmacokinetics. 
Nevertheless, TDM seems not useful in IBD patients established on AZA and without disease 
activity. TDM may be helpful in worsening IBD activity to elucidate non-compliance or inefficient 
treatment. 
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Introduction 
Thiopurines are known for more than 40 years, and were originally used in 
treatment of childhood leukemia, transplantation medicine and rheumatic 
disorders1-3. Since 1990 azathioprine (AZA) and 6-mercaptopurine (6-MP) are 
widely used for immunosuppressive therapy in steroid dependant or refractory 
inflammatory bowel disease (IBD) and have proven to be effective for inducing 
and maintaining remission of disease activity4-7. For IBD, AZA is generally used 
in Europe while there seems a preference for 6-MP in North America, 
especially in case of AZA intolerance. Recently 6-thioguanine (6-TG) has been 
introduced in thiopurine therapy of IBD8. 
 
Despite the widespread use of thiopurines the precise mechanism of action 
was only discovered in recent years (Figure 4.1)9. AZA is a prodrug which is 
non-enzymatically transformed to 6-MP, and then metabolised to the 
pharmacological active 6-thioguanine nucleotides (6-TGN) and 
6-methylmercaptopurine ribonucleotides (6-MMPR). 6-TGN are purine 
nucleotides, which were believed to be incorporated into DNA of leucocytes, 
blocking the de novo purine synthese and thereby inducing 
immunosuppression.  
Until 1996 controlled trials demonstrated effective dosages of AZA at 
2.0-3.0 mg/kg/day and 6-MP at 1.5 mg/kg/day in IBD patients4,10-13. From 1996 
on the first publications about therapeutic drug monitoring (TDM) appeared, 
based on the knowledge of the metabolic pathway. It was shown that clinical 
response only correlates with 6-TGN metabolite levels and not with other 
variables, like drug dose14,15. Besides, it was demonstrated that red blood cell 
(RBC) 6-TGN levels correlate with bone marrow suppression, while RBC 
6-MMPR levels correlate with hepatotoxicity14,16. The lower limit of therapeutic 
6-TGN level was established at 235 pmol/8x108 RBC, an upper limit was not 
described. In the same study however, a mean 6-TGN level of 490 pmol/8x108 
RBC was measured, in patients developing leucopenia. 6-MMPR levels above 
5700 pmol/8x108 RBC correlated with hepatotoxicity14,15. 
Others found conflicting data. Lowry was one of the first to describe 
pharmacokinetic results of long term AZA treatment in 170 adult IBD patients17. 
He found lower mean 6-TGN levels (163 pmol/8x108 RBC) and no correlation 
between 6-TGN levels and disease activity. A study in 55 children with IBD also 
showed no relation between 6-TGN levels and clinical remission18. On the 
other hand Cuffari described a threshold therapeutic 6-TGN level, which was 
even higher: 250 pmol/8x108 RBC19. These findings were based on 82 AZA or 
6-MP treated IBD adults. 
Besides, in studies on direct administration of 6-TG, higher levels of 6-TGN 
were found, without correlation between 6-TGN levels and clinical response or 
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toxicity20-22. This may reflect other involved mechanisms or that 6-TGN levels 
are not exclusively responsible for thiopurine efficacy or toxicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Thiopurine metabolism.  
 AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MeMP, 6-methylmercaptopurine; 6-TU, 
6-thiouric acid; 6-MeTIMP+6-MeTIDP+6-MeTITP, 6-methylmercaptopurine 
ribonucleotides; 6-TIMP, 6-thioinosine monophosphate; 6-TXMP, 6-thioxanthosine 
monophosphate; 6-TGMP+6-TGDP+6-TGTP, 6-thioguanine nucleotides; 6-MeTGMP+ 
6-MeTGDP+6-MeTGTP, 6-methylthioguanine nucleotides; XO, xanthine oxidase; 
TPMT, thiopurine S-methyltransferase; HPRT, hypoxanthine phosphoribosyl 
transferase; IMPD, inosine monophosphate dehydrogenase; GMPS, guanosine 
monophosphate synthetase; MPK, monophosphate kinase; DPK, diphosphate kinase. 
 Note: laboratory measurements consist of a combination of several metabolites: 
 -Measured 6-MMPR level: 6-MeMP and 6-MeTIMP + 6-MeTIDP + 6-MeTITP 
(6-methylmercaptopurine ribonucleotides) 
 -Measured 6-TGN level: 6-TG and 6-TGMP + 6-TGDP + 6-TGTP (6-thioguanine 
nucleotides) 
 
 
More recently new details in the mechanism of action of thiopurines have been 
discovered. AZA and its metabolites were found to be responsible for T cell 
apoptosis by modulation of Rac1 activation upon CD28 costimulation23. 
Rac1, a small GTPase that plays a role in inhibiting T cell apoptosis is a target 
for 6-thioguanine triphosphate (6-thio-GTP), a metabolite of AZA, which is one 
of the measured nucleotides of the 6-TGN level (see Figure 4.1). 6-Thio-GTP 
binds to Rac1 in stead of GTP, thereby suppressing the activation of Rac1 
target genes like mitogen activated protein kinase MEK, NF-κB and bcl-xL, 
leading to apoptosis. CD28 is a transmembrane protein which plays a role in 
the anti-apoptotic signaling pathway as well. T-cell apoptosis by 6-thio-GTP is 
increased upon co-stimulation of Rac1 by CD28. It was demonstrated that 
especially specific T memory lymphocytes (CD45RO), which are the main 
effector cells in IBD, become apoptotic. These recent findings suggest a new 
molecular mechanism of action of AZA. In future, 6-thio-GTP derivatives with 
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more affinity for Rac1 may be designed, leading to stronger and more specific 
immunosuppressive effects. 
 
Toxicity due to thiopurine metabolites may be explained by gene 
polymorphisms encoding thiopurine S-methyltransferase (TPMT), the enzyme 
that methylates 6-MP to 6-MMPR. Eighty-nine percent of individuals have 
normal to high enzyme activity, corresponding to homozygous/wildtype TPMTH. 
Eleven percent has intermediate (heterozygote TPMTH/TPMTL) and 0.3% has 
low to absent enzyme activity (homozygous TPMTL)14,24. Reduced enzyme 
activity leads to toxic 6-TGN levels on regular doses of AZA or 6-MP25. 
Alternatively, in some patients high 6-MMPR levels are noted, while 6-TGN 
levels remain subtherapeutic. Due to preferential metabolism to 6-MMPR these 
patients are at risk for hepatitis. Pancreatitis is an idiosyncratic side effect of 
thiopurine treatment without any relation to metabolite levels. There may be a 
relationship between pancreatitis and 6-MMPR metabolites though, because it 
has not been described in patients treated with 6-TG, the third thiopurine which 
more directly leads to the formation of 6-TGN. The overall incidence of hepatitis 
and pancreatitis varies between 4-17% for both independently14,16,26. AZA and 
6-MP treatment are discontinued in 10-20% of patients because of side 
effects26,27. 
More recently, 6-TG as such was introduced as an alternative in IBD-patients 
with AZA and 6-MP intolerance. The idea of using a metabolite at the end of 
the enzymatic pathway seems to be an attractive approach. After the 
publication of just a few articles on nodular regenerative hyperplasia (NRH) of 
the liver there is a lot of debate on the safety of this treatment20-22,28. More 
studies should be performed before conclusions can be made. 
 
Taken together, thiopurines are back in business due to new insights in their 
metabolic pathway last years. New concepts like therapeutic drug monitoring 
(TDM) and genotyping of TPMT are based on these new data, but 
controversies remain8.The aim of our study was to add more clinical 
information to this topic. We examined our IBD out-patients established on AZA 
by questionnaire, examination, laboratory controls and TDM at week 0, 1, 4 
and 8 after inclusion. 
Patients and methods 
Patient selection 
Fifteen IBD patients were recruited, aged between 18 and 75 years, 
established on AZA (ImuranTM, tablet 100 mg, Glaxo Wellcome, Zeist, The 
Netherlands) for at least three months, attending the out-patient clinics of 
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Maasland Hospital Sittard and St.Laurentius Hospital Roermond, the 
Netherlands.  
Study design 
A prospective open-label multicentre study was carried out. At 0, 1, 4 and 8 
weeks after inclusion blood was drawn for measurement of RBC 6-TGN and 
6-MMPR levels, haemoglobin, leucocytes and differentiation, platelets, bilirubin, 
alanine and aspartate transaminase, lipase, amylase and C-reactive protein 
(CRP). Crohn´s Disease Activity Index (CDAI) or Truelove-Witts (for Ulcerative 
Colitis) scores were collected at each visit (CDAI<150: remission; CDAI>150: 
active disease)29. Dose adjustments of AZA were not carried out during the 
study period. Concomitant 5-aminosalicylic acid (5-ASA) medication was 
continued. 
Ethics 
The protocol was approved by the local medical ethics committee and in 
accordance with the Helsinki Declaration. Written informed consent was 
obtained before inclusion. 
Outcome measures 
Primary outcome measures were mean RBC 6-TGN and 6-MMPR levels and 
95% confidence intervals (CI95%) during the eight week period. Secondary 
outcomes were compliance, the correlation between steady state RBC 6-TGN 
and 6-MMPR levels and other parameters like dose per kg bodyweight, 
CDAI/Truelove-Witts scores and laboratory parameters. 
Analytical procedures 
6-TGN and 6-MMPR levels were measured by the laboratory of the 
Department of Clinical Pharmacy, Maasland Hospital in Sittard. Blood samples 
were taken at least twelve hours after medication intake and centrifuged to 
isolate erythrocytes. A slightly modified high-performance liquid 
chromatography assay (HPLC) as reported by Lennard and our group has 
been implemented to measure thiopurine metabolites in erythrocytes30,31. The 
run-to-run coefficient of variation in our laboratory is 6.6% and 9.7% for 6-TGN 
and 6-MMPR respectively. The lower limit of quantification of the assay is 
30 pmol/8x108 RBC for 6-TGN and 300 pmol/8x108 RBC for 6-MMPR.  
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Statistical analysis 
Data are expressed as means with range or CI95%. Pearson´s correlation test 
was used for determination of correlation. P values <0.05 were considered 
significant.  
External sources 
This study was not sponsored by external sources. 
Results 
Fifteen IBD patients established on AZA for at least three months (mean 
duration 28 months; range 7-67 months) were followed for eight weeks. Mean 
age was 45 years (range 29-55), six patients were male and nine were female. 
Ten patients had CD (67%), four had UC (27%) and one had indeterminate 
colitis (6%). Mean bodyweight was 73 kg (CI95%: 67-79). Mean AZA dose was 
1.71 mg/kg (CI95%: 1.48-1.95). All patients used 5-ASA as concomitant 
medication. 
Nearly all patients had a stable disease activity during the study interval 
according to CDAI and Truelove-Witts scores. Fourteen patients had remission 
of disease (CDAI<150; Truelove-Witts: mild-moderate disease). In one patient 
mean CDAI was 182, implying a mild disease activity. Eleven of fifteen patients 
(73%) completed the eight week study period. Drop out reasons were non-
compliance in three patients (20%) and intolerance in one (7%: unexplained 
muscle pains, without signs of rhabdomyolysis, reoccurring after rechallenge). 
Primary outcomes 
At baseline mean 6-TGN levels were 158 (CI95%: 113-203) pmol/8x108 RBC 
(n=15), at the first week 184 (CI95%: 146-223) pmol/8x108 RBC (n=15), after 
four weeks 222 (CI95%: 200-243) pmol/8x108 RBC (n=14) and 282 (CI95%: 
183-380) pmol/8x108 RBC at week 8 (n=11) (Figure 4.2A).  
At baseline mean 6-MMPR levels were 2213 (CI 95%: 722-3704) pmol/8x108 
RBC (n=15), at the first week 2639 (CI95%: 1225-4053) pmol/8x108 RBC 
(n=15), after 4 weeks 3221 (CI95%: 1443-4999) pmol/8x108 RBC (n=14) and 
2353 (CI95%: 970-3752) pmol/8x108 RBC at week 8 (n=11) (Figure 4.2B).  
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Figure 4.2 Median and mean 6-TGN levels on AZA (all doses) (A), median and mean 6-MMPR 
levels on AZA (all doses) (B). 
 
 
Secondary outcomes 
There was no correlation between RBC 6-TGN and 6-MMPR levels. There also 
was no correlation between RBC 6-TGN levels and dose per kg bodyweight 
(Figure 4.3) idem. RBC 6-MMPR levels and dose per kg bodyweight showed a 
significant correlation (r=0.43 and p=0.001). Either did 6-MMPR/6-TGN ratio 
and AZA dose (mg/kg) (r=0.36 and p=0.010). 
There was no correlation between RBC 6-TGN or 6-MMPR levels and CDAI or 
Truelove-Witts scores. There was also no correlation between RBC 6-TGN or 
6-MMPR levels and haematological parameters. 
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Figure 4.3 Mean 6-TGN and 6-MMPR levels against AZA dose all measurements 
Discussion  
Notably, in our study thirteen of fifteen patients (87%) had baseline steady 
state 6-TGN levels below 235 pmol/8x108 RBC, which is the lower therapeutic 
level according to Dubinsky14. During the study period 6-TGN levels steadily 
increased, but not significantly, whilst not employing dose escalation (Figure 
4.2A). This suggests that most patients were treated suboptimally. However, all 
patients but one had a stable disease in remission on these subtherapeutical 
levels. A possible explanation is the fact that the mentioned threshold levels 
were set by studies in a paediatric population and our population mainly 
consists of adults14,16,32. On the other hand it seems very difficult to define a 
single therapeutic window for IBD patients, because of the great inter-individual 
differences in disease phenotype.  
 
Another consideration based on our results is that TDM may not be helpful in 
established AZA treated IBD patients without disease activity. In practice, 
metabolite levels of AZA will not change the therapeutic strategy when patients 
have an IBD in remission and without adverse events. The initiating period in 
thiopurine treatment seems more crucial because adverse events occur most 
times in this stage of treatment. Furthermore, a steady state treated population 
is biased, because all patients with adverse events are already excluded. This 
is demonstrated in this study as well: all patients except one had no disease 
activity, without toxicity, despite two patients who had potentially toxic 6-MMPR 
levels. 
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The only indication for TDM in steady state treated patients may be worsening 
disease activity or possibly related adverse events like hepatotoxicity and 
myelotoxicity. In that case metabolite levels can help excluding non-compliance 
or inefficient treatment. 
This theory has been mentioned for TPMT genotyping as well. Recent studies 
showed no benefit of TPMT genotyping in steady state treated patients14,15,33-35. 
Likely, this may be explained by the fact that most of these studies were 
performed retrospectively. Patients with adverse events had already 
discontinued thiopurine treatment leading to a biased steady state population.   
 
Secondly, it is striking how many of our patients were non-compliant. Non-
compliance is a well known problem in treatment of chronic patients in general. 
In this study TDM revealed non-compliance in four patients (27%). Two of them 
had zero levels at baseline, leading to discontinuation of follow up in one 
patient after one week therefore. The other one had significantly increasing 
levels without dose escalation. Eight weeks after the study interval, this patient 
mentioned worsening disease activity. 6-TGN and 6-MMPR levels at this time 
were zero again. The two other patients were suspected to be non-compliant 
because of significant higher 6-TGN levels at week 1, 4 and/or 8 than at 
baseline. The described drop out of two patients because of incomplete data 
was caused by forgetting to let draw blood. This behaviour may also be 
considered as poor compliance. Altogether 40% (6/15) of our study group was 
non-compliant! This percentage exceeds the 10% non-compliance described in 
previous studies36,37. 
Statistical analysis for the nine true compliant patients reveals no differences 
compared to the previous analysis, but this number of patients is too small to 
make conclusions.  
 
This brings us to a critical reflection of our study. We are aware of the 
limitations of a study based on fifteen patients. Powered statistical analysis is 
hardly to perform and therefore important conclusions can not be made. When 
studying patients on established AZA therapy, there is always some selection 
bias because of loss of patients with adverse events in the initiating period of 
this therapy. Nevertheless, TDM has proven its value to unmask non- 
compliance, even in this small study. 
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Conclusions 
Great inter-individual differences in pharmacokinetics occur in thiopurine 
treated IBD patients. TDM is known to help getting insight in individual 
pharmacokinetics. This study demonstrates two striking facts. At first, it shows 
the limited usefulness of TDM in steady state AZA treated patients with IBD in 
remission. Secondly, it illustrates that TDM can unmask non-compliance. 
In clinical practice, there still seems to be a role for TDM in established AZA 
therapy in case of worsening disease activity or possibly related adverse 
events like hepatotoxicity and myelotoxicity. TDM can also help to exclude non-
compliance or inefficient treatment in these situations.  
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Abstract  
Backgrounds 
Therapeutic drug monitoring (TDM) of thiopurines is a relatively new concept. Proposed therapeutic 
6-thioguaninenucleotides (6-TGN) levels in IBD are ≥235 pmol/8x108 erythrocytes, but prospective 
studies in adult patients are lacking. 
 
Aims 
Comparing 6-TGN levels between exacerbations and remissions of IBD and redefining the 
therapeutic 6-TGN cut-off level in adult patients. 
 
Methods 
Consecutive thiopurine treated IBD patients were included. Primary outcomes: (correlations 
between) CDAI or CAI scores, metabolite levels and calculated therapeutic 6-TGN cut-off level. 
Secondary outcomes: (correlations between) demographic data, thiopurine dose, thiopurine 
S-methyltransferase (TPMT) activity. 
 
Results 
Forty-one patients had exacerbations, 59 were in remission. Zero or low 6-TGN levels, suggesting 
non-compliance, were found in 16% (12% of exacerbations, 19% of remissions). 6-TGN levels 
were only significantly different between exacerbations and remissions after exclusion of non-
compliant remittent patients (237 versus 320 pmol/8x108 erythrocytes, p=0.0007). In this 
subanalysis, 6-TGN and disease activity correlated (r=-0.24, CI95% -0.42- -0.029). The therapeutic 
cut-off 6-TGN level was 235-250 pmol/8x108 erythrocytes, but sensitivity, specificity and positive 
predictive value were low (71, 73 and 67%). Nevertheless, active disease was found in 52% of 
patients below, versus 30% above this threshold (OR 2.5, CI95% 1.11-5.75, p=0.04). 
 
Discussion 
Differences in 6-TGN levels between exacerbations and remissions were only found after exclusion 
of non-compliant remittent patients. Importantly, a high rate of non-compliance was found. 
 
Conclusions 
The therapeutic 6-TGN cut-off level of 235 pmol/8x108 erythrocytes was confirmed, but less 
convincing than in previous reports. TDM seems useful in case of thiopurine refractory IBD to 
reveal non-compliance, but has a minor role in detecting under-dosing and unfavourable metabolite 
profiles. 
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Introduction 
Gastroenterologists, treating inflammatory bowel disease (IBD) patients, are 
often confronted with exacerbations or refractory disease during 
immunomodulatory therapy, such as the thiopurines azathioprine (AZA) and 
6-mercaptopurine (6-MP), cyclosporin or methotrexate. In those patients, a 
therapy switch to biologicals or surgery is frequently considered, without 
deeper insight in the efficacy of the therapy presently used. In case of 
thiopurine therapy, therapeutic drug monitoring (TDM) of metabolite 
concentrations is a theoretical option1,2. Thiopurine metabolism has large inter-
individual variations due to enzyme polymorphisms. Thiopurine 
S-methyltransferase (TPMT) is the most important enzyme influencing the 
balance between immunosuppressive 6-thioguanine nucleotides (6-TGN) 
levels and hepatotoxic 6-mercaptopurine ribonucleotides (6-MMPR) (Figure 
5.1)3-6.  
In recent years, therapeutic ranges of thiopurine metabolite concentrations 
were described: 6-TGN metabolites between 235 and 500 pmol/8x108 red 
blood cells (RBC) have been correlated with clinical response1,3. 6-TGN levels 
above 500 pmol/8x108 RBC increase the risk for leucocytopenia, and 6-MMPR 
levels higher than 5700 pmol/8x108 RBC are correlated with hepatotoxicity1,2. A 
6-MMPR/6-TGN ratio higher than 11 is correlated with a lower frequency of 
clinical respons2,7. Although these studies find no correlation between 
metabolite levels and drug dose, due to inter-individual differences in 
metabolism, thiopurine is still dosed on patient’s bodyweight in clinical practice 
(AZA 2-3 mg/kg and 6-MP 1-1.5 mg/kg)8.  
Some remarks have to be made about the proposed metabolite thresholds. 
These were often based on retrospective studies, described relatively small 
patient numbers, or were performed in pediatric IBD cohorts1,2,7,9-17. Recently, a 
meta-analysis of six studies showed that higher 6-TGN levels are correlated 
with clinical remission of IBD: 62% of the patients with 6-TGN levels above 
230-260 pmol/8x108 RBC were in remission versus 36% remissions with 
6-TGN levels lower than 230 pmol/8x108 RBC10,14-17. 
One reason for performing TDM could be inter-individual differences in 
thiopurine metabolism.  Another reason may be the relative high prevalence of 
non-compliance in chronic diseases in general, especially in asymptomatic 
conditions18. In IBD treatment it has been demonstrated that non-adherence 
can arrive at 60% with sulphasalazine, mesalazine and azathioprine, especially 
during remission9-24. 
The aim of the present study is: 1) to compare thiopurine metabolite levels 
between adult IBD patients with an exacerbation and those in clinical remission 
in a prospective study, and 2) to find the best possible threshold 6-TGN level 
for therapeutic efficacy in adult IBD patients. These endpoints are relevant to 
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determine the role of TDM in clinical decision making in case of an 
exacerbation of IBD during thiopurine treatment in adult IBD patients, in order 
to either optimise thiopurine dosage or to choose for an alternative therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Proposed thiopurine metabolism. 
 AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-TUA, 6-thiouric acid; 6-MMP,  
 6-methylmercaptopurine; 6-TIMP, 6-thioinosine-5’-monophosphate; 6-MMPR level,  
 6-methylmercaptopurine ribonucleotides; 6-TITP, 6-thioinosine 
 triphosphate; 6-TIDP, 6-thioinosine diphosphate; 6-TG, 6-thioguanine; 6-TGN level,  
 6-thioguanine nucleotides; 6-MTG, 6-methylthioguanine; HPRT,  
 hypoxanthine phosphoribosyltransferase; XO, xanthine oxidase; ITPA, inosine 
 triphosphate pyrophosphohydrolase; MPK, monophosphokinase; DPK, 
diphosphokinase; TPMT, thiopurine S-methyltransferase; IMPDH, inosine 
monophosphate dehydrogenase; GMPS, guanosine monophosphatase synthetase 
 6-MTIMP, 6-MTIDP and 6-MTITP together form the 6-methylmercaptopurine 
ribonucleotides (6-MMPR). 6-TGMP, 6-TGDP and 6-TGTP together form the 
6-thioguanine nucleotides (6-TGN). In therapeutic drug monitoring, 6-MMPR levels 
consist of the sum of 6-MMP, 6-MTIMP, 6-MTIDP and 6-MTITP levels, while 6-TGN 
levels consist of the sum of 6-TGMP, 6-TGDP, 6-TGTP (if AZA or 6-MP is 
administered) and 6-TG (if 6-TG is administered as such) levels. 
Patients and methods 
Patient selection 
A prospective study was performed in a group of IBD patients in four hospitals 
in the southern part of the Netherlands: one university hospital (University 
Hospital Maastricht) and three general district hospitals (Maasland Hospital 
Sittard, Laurentius Hospital Roermond and Catharina Hospital Eindhoven). 
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Between November 1st, 2005 and November 1st, 2006, consecutive adult IBD 
patients treated with a steady maintenance dose of AZA or 6-MP for at least 
three months, presenting with an acute exacerbation at the outpatient clinic or 
during admission, were asked to participate. Subsequently, consecutive IBD 
patients in clinical remission, treated with a steady maintenance thiopurine 
dose for at least three months, were asked to join the study during their regular 
visit to the outpatient clinic. Also, concomitant medication had to be stable for 
three months. At inclusion, haematological and biochemical analyses were 
performed (haemoglobin, haematocrit, erythrocytes, leucocytes, thrombocytes, 
bilirubin, aspartate transaminase (ASAT), amylase, C-reactive protein and 
albumin), 6-TGN and 6-MMPR metabolite levels and TPMT activity were 
measured. All patients completed either a Crohn´s Disease Activity Index 
(CDAI) or a Colitis Activity Index (CAI) score list25. These parameters were all 
taken immediately after informing the patients about the study and having them 
sign the informed consent, thus making sure that the metabolite levels were 
realistic and not influenced by the notification of inclusion in a study. In this way 
camouflage of non-compliance was excluded. 
Outcome measures 
Primary outcome measures were 6-TGN and 6-MMPR metabolite levels, to be 
used for correlations with CDAI or CAI scores and the calculation of a 
therapeutic 6-TGN threshold level. An exacerbation was defined as a CDAI 
score ≥200 for Crohn’s disease patients or a CAI score ≥8 for patients with 
ulcerative colitis (UC) or indeterminate colitis. Remission was defined as a 
CDAI score <150 or CAI <8. Patients with CDAI scores between 150 and 200 
were excluded. This had been decided before initiation of the study, to be 
assured of a clear distinction between exacerbations and remissions, and thus 
excluding patients with possible irritable bowel syndrome-like complaints. 
Secondary outcomes were correlations between primary outcomes and drug 
dose, 6-MMPR/6-TGN ratio, TPMT activity and CDAI or CAI disease activity 
scores. 
Analytical procedures 
6-TGN and 6-MMPR levels are measured with the modified high performance 
liquid chromatography (HPLC) method of Lennard as published previously2,26. 
This method is equal to that used in other reports about TDM in thiopurine 
therapy of IBD1,3. TPMT activity was measured in erythrocyte lysates as 
described by Jacques-Aigrain27. Briefly, the washed erythrocyte lysate was 
incubated with 6-mercaptopurine in a dithiothreitol and S-adenosylmethionine 
containing phosphate buffer at pH 7.5 at 37°C for one hour. 2-Amino-
6-methylmercaptopurine (6-AMMP) was used as the internal standard. After 
the incubation period, the reaction was stopped by the addition of hydrogen 
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chloride, followed by neutralization with a basic ammonium chloride solution. 
6-MP, 6-MMP and 6-AMMP were extracted with dichloromethane/2-propanol. 
After evaporation of the organic solvent, the samples were dissolved in buffer 
and analyzed using reversed-phase HPLC. The inter-assay co-variation of the 
procedure was less than 10%, the typical recovery was 99%. 
Statistical analysis 
Normality was tested by the Kolmogorov-Smirnov normality test. Data are 
expressed as means with 95% confidence interval (CI95%) or range. 
Pearson´s correlation test is used for correlations. P values <0.05 are 
considered significant. Statistics are based on a clinically relevant difference of 
6-TGN levels of 50 pmol/8x108 RBC and a standard deviation of 75 pmol/8x108 
RBC, according to our previous reports2,19. Based on these data a power 
analysis, demonstrated that 74 patients (37 in either group) should be included 
to show a significant difference in 6-TGN levels between both groups with a 
probability of 80%. A total of 100 patients was aimed at before initiation of the 
study. The study was to be closed when at least 40 exacerbations were 
included. To find a therapeutic threshold 6-TGN level several analyses were 
performed, with in- or exclusion of non-compliant patients. Receiver Operating 
Characteristic (ROC) curves of the 6-TGN levels have been plotted to find a 
6-TGN cut-off level with an optimal sensitivity, specificity, positive predictive 
value and accuracy. At last, a quartile analysis was performed according to the 
original report of Dubinsky, to compare 6-TGN thresholds
 
1. 
Medical ethics 
The study was approved by the local Medical Ethical Committee of the 
Maasland Hospital Sittard. 
Results 
From November 1st, 2005 until November 1st, 2006, 123 IBD patients were 
asked to join the study (Figure 5.2). Fifteen patients refused, had incomplete 
data or were pregnant. Inclusion criteria were met by 108 patients, of whom 
eight patients with a CDAI between 150 and 200 were excluded. Thus, 100 
patients were enrolled for primary analysis, 41 patients with an exacerbation 
and 59 patients with IBD in remission. Patient characteristics are summarized 
in Table 5.1. Outcome measures of all patients are described in Table 5.2. No 
significant differences were found in drug dose or thiopurine metabolite levels 
between patients with Crohn’s disease and ulcerative colitis. Therefore, all 
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further analyses were performed for all IBD phenotypes together. No hepato- or 
pancreaticotoxicity was found, neither leucopenia. 
In five of 41 patients (12%) with an exacerbation no metabolites were 
measurable, suggesting non-compliance (Figure 5.2). In eleven of 59 patients 
(19%) in remission no or very low metabolite levels were measured, suggesting 
non-compliance. The non-compliance rate for all 100 patients was 16%, 
without a significant difference between exacerbations and remissions (Table 
5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123 patients
100 patients included (81%)
15 refused, pregnant
or incomplete data
8 patients CDAI 150-200
41 exacerbations
(41%)
59 remissions
(59%)
33 treated with AZA
8 treated with 6-MP
34 treated with AZA
25 treated with 6-MP
z
 
ero levels in 4 patients
zero levels in 1 patient
zero levels in 3 patients
very low levels
in 5 patients
zero levels in 1 patients
very low levels 
in 2 patients
 
Figure 5.2 Flow chart of inclusion.  
 CDAI, Crohn’s Disease Activity Index; AZA, azathioprine; 6-MP,  
 6-mercaptopurine. 
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Table 5.1 Characteristics of the included patients. 
 All patients Exacerbation Remission p-value 
N 100 41 59  
mean age in years (range) 42.3 (15-79) 38.6 (15-79) 44.6 (18-75) 0.057 
male/female 60/40 19/22 41/18 0.024 
mean bodyweight (kg) 75.4 73.7 76.5 0.34 
CDAI 157 281 72 <0.0001 
CAI 6.8 11.9 3.1 <0.0001 
IBD     
type   
  Crohn 
  Ulcerative colitis 
  Indeterminate colitis 
 
57 
40 
3 
 
23 
16 
2 
 
34 
24 
1 
1.0 
location 
  proctosigmoid 
  colon 
  ileocolon 
  terminal ileum 
  perianal disease 
  upper GI tract 
 
 35 (35%) 
 24 (24%) 
 23 (23%) 
 12 (12%) 
 7 (7%) 
 2 (2%) 
 
 15 (37%) 
 9 (22%) 
 11 (27%) 
 5 (12%) 
 3 (7%) 
 1 (2%) 
 
 20 (34%) 
 16  (27%) 
 12 (20%) 
 7 (12%) 
 4 (7%) 
 1 (2%) 
0.99 
mean disease duration 
 in months (range) 
 
98.7 (3-624) 
 
99.9 (3-432)
 
97.9 (5-624)
 
0.93 
Medication     
Azathioprine (N) 
  mean AZA dose in mg  (range) 
  mean AZA dose in mg/kg (range) 
67 
140 (50-225) 
2.0 (0.6-3.0) 
33 (80%) 
136 (50-200)
1.9 (0.8-2.5) 
34 (58%) 
145 (50-225)
1.8 (0.6-3.0) 
0.02 
0.33 
0.75 
6-Mercaptopurine (N) 
  mean 6-MP dose in mg (range) 
  mean 6-MP dose in mg/kg (range) 
33 
56 (50-100) 
1.0 (0.45-1.22) 
8  (20%) 
56 (50-100) 
0.8 (0.6-1.2) 
25 (42%) 
56 (50-100) 
0.8 (0.4-1.2) 
0.02 
0.96 
0.99 
N, number of patient; kg, kilograms bodyweight; IBD, inflammatory bowel disease; upper GI tract,  
upper gastrointestinal tract; AZA, azathioprine; mg, milligrams; 6-MP, 6-mercaptopurine; CDAI,  
Crohn’s Disease Activity Index; CAI, Colitis Activity Index; pmol, picomoles; p <0.0.5 is considered 
significant. 
 
 
Table 5.2 Outcome measures of all included patients. 
Mean outcome measures  All 
patients 
Exacerbations
(N=41) 
Remissions 
(N=59) 
p-value 
6-TGN (pmol/8x108 RBC) 260 237 274 0.30 
6-MMPR (pmol/8x108 RBC) 1493 1461 1525 0.89 
6-MMPR/6-TGN ratio 7.3 7.3 7.4 0.97 
Number of non-compliant patients (%) 16 (16) 5 (12) 11 (19) 0.42 
TPMT activity (pmol/mg Hb/hr) 7.0 6.7 7.2 0.16 
N, number of patients; kg, kilograms bodyweight; mg, milligrams; 6-TGN, 6-thioguanine nucleotides 
level; 6-MMPR, 6-methylmercaptopurine ribonucleotides level; pmol, picomoles; RBC, red blood 
cells; TPMT, thiopurine S-methyltransferase; Hb, haemoglobin; hr, hour; p <0.05 is considered 
significant. 
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No correlation was found between thiopurine dose and metabolite levels or 
6-MMPR/6-TGN ratio. 6-TGN levels and TPMT activity were negatively 
correlated (r=-0.318, p=0.01), without significant differences in TPMT activity 
between exacerbations and remissions. High TPMT activity was found in five 
patients (5%, including one exacerbation) and low TPMT activity in two patients 
(2%, one exacerbation). Both patients with low TPMT activity had high 6-TGN 
levels (712 and 934 pmol/8x108 RBC) and low 6-MMPR levels (zero and 225 
and pmol/8x108 RBC respectively). Low TPMT activity was not related with 
myelotoxicity in this study. 
  
In the following, the correlations between the outcome measures on one side 
and exacerbations/remissions on the other, will be presented in three different 
selections of the patient group: a) all patients (N=100), b) all patients with 
exacerbations (N=41) compared to a control group of compliant patients in 
remission (N=48) and c) all compliant patients (N=84). 6-TGN levels and their 
predictive accuracy for exacerbation versus remission are given in Table 5.3. 
 
Table 5.3 Optimal therapeutic 6-TGN cut-off level (pmol/8x108 RBC) for several analyses. 
Patients All patients All except non-
compliant patients in 
remission 
All compliant 
patients 
N (E/R) 100 (41/59) 89 (41/48) 84 (36/48) 
Mean 6-TGN levels E (CI95%) 237 (183-291) 237 (183-291) 270 (216-323) 
Mean 6-TGN levels R (CI95%) 274 (229-319) 320 (275-365) 320 (275-365) 
Significant difference 6-TGN E vs R no yes no 
Correlation 6-TGN and disease activity 
(CI95%) 
no yes, r =-0.24 
(-0.42 - -0.029) 
no 
6-TGN cut-off  (AUC) 235-250 (0.59) 235 (0.70) 235 (0.66) 
Sensitivity (%) 67 72 72 
Specificity (%) 56 64 60 
Positive predictive value (%) 52 67 52 
Negative predictive value (%) 72 70 70 
Accuracy (%) 61 69 67 
p-value 6-TGN cut-off 0.02 0.0007 0.007 
Odds ratio 2.5 4.7 3.8 
N, number of patients; E, exacerbations; R, remissions; CI95%, 95% confidence interval; AUC, 
area under the curve; p-value <0.05 is considered as significant. 
a) outcome measures of all included patients (N=100) 
No correlation was found between 6-TGN levels and disease activity score. No 
significant difference in mean 6-TGN levels between exacerbations and 
remissions was found (237 versus 274 pmol/8x108 RBC, Table 5.3). The 
optimal 6-TGN cut-off was approximately 235-250 pmol/8x108 RBC with a 
positive predictive value of 52% for exacerbations when having 6-TGN levels 
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below 235 and a negative predictive value of 73% when having 6-TGN levels 
above 250 pmol/8x108 RBC in case of remissions (Table 5.4). Twenty-six of the 
41 patients with active IBD (63%) had 6-TGN levels below the proposed 
therapeutic threshold of 235 pmol/8x108 RBC, versus 24 of 59 patients in 
remission (41%). On the contrary, 30% of patients with 6-TGN levels above 
235 pmol/8x108 RBC had exacerbations versus 52% of the patients with 
6-TGN levels below 235. Both differences were significant (p=0.04). The odds 
ratio (OR) for having a 6-TGN level below 235 pmol/8x108 RBC in case of 
active disease was 2.5 (CI 95% 1.1-5.8). 
b) outcome measures of all exacerbations versus compliant 
patients in remission (N=89) 
All patients with an exacerbation (N=41) had a mean 6-TGN level of 
237 pmol/8x108 RBC, versus the control group of compliant patients in 
remission (N=48), having mean 6-TGN levels of 320 pmol/8x108 RBC 
(SD 155). This analysis showed significantly different 6-TGN levels, a 
therapeutic 6-TGN cut-off of 235-250 pmol/8x108 RBC, with a sensitivity and 
specificity of 72% and 64% respectively, a positive and negative predictive 
value of 67% (<235) and 73% (>250), an area under the curve (AUC) of 0.70 
and an OR of 4.7 (Table 5.3 and 5.4). 
c) outcome measures of all compliant patients (N=84) 
The compliant patients with an exacerbation (N=36) had mean 6-TGN levels of 
270 pmol/8x108 RBC, versus 320 pmol/8x108 RBC in the control group of 
compliant patients in remission. This analysis showed no significantly different 
6-TGN levels. The optimal cut-off 6-TGN value was 235-250 pmol/8x108 RBC, 
with a sensitivity and specificity of 72% and 60% respectively, a positive and 
negative predictive value of 62% and 73%, AUC of 0.66 and an OR of 3.8 
(Table 5.3 and 5.4). 
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Table 5.4 Cut-off 6-TGN levels (pmol/8x108 RBC). 
 Cut-off 
6-TGN 
level 
Sensitivity
(%) 
Specificity
(%) 
Positive 
predictive 
value (%)
Negative 
predictive 
value (%)
p-value Likelihood 
ratio 
Odds ratio and 
CI95% 
All patients (N = 100) 
 100 12 88 42 59 1.0 1.0  1.0 (0.3-1.5) 
 150 24 78 43 59 0.8 1.1  1.1 (0.4-2.9) 
 200 39 69 47 62 0.4 1.3  1.5 (0.6-3.4) 
 235 63 59 52 70 0.04 1.6  2.5 (1.1-5.7) 
 250 71 54 52 73 0.02 1.5  2.9 (1.6-6.7) 
 300 83 37 48 76 0.04 1.3  2.9 (1.1-7.6) 
All patients, except non-compliant patients in remission (N = 89) 
 100 12 98 83 57 0.09 5.9  6.5 (0.7-58) 
 150 24 94 77 59 0.03 3.9  4.8 (1.2-19) 
 200 39 85 70 62 0.01 2.7  3.7 (1.4-10.3) 
 235 60 73 67 70 0.0007 2.3  4.7 (1.9-11.5) 
 250 70 67 64 73 0.0006 2.1  4.6 (2.0-12.0) 
 300 83 46 57 76 0.006 1.5  4.1 (1.5-11.1) 
 350 85 27 50 68 0.2 1.2  2.2 (0.74-6.3) 
All compliant patients (N = 84) 
 100   0 98 0 57 1.0 0  0.02 (0.04-11.0) 
 150 14 94 63 59 0.3 2.2  2.4 (0.5-10.9) 
 200 31 85 61 62 0.1 2.1  2.6 (0.9-7.5) 
 235 58 73 62 70 0.007 2.2  3.8 (1.5-9.4) 
 250 67 67 60 73 0.004 2.0  4.0 (1.6-10.0) 
 300 81 46 53 76 0.02 1.5  3.5 (1.3-9.5) 
 350 83 27 46 68 0.3 1.1  1.9 (0.6-5.5) 
6-TGN, 6-thioguanine nucleotides level; RBC, red blood cells; CI95%, 95% confidence interval;  
N, number of patients; p<0.05 is considered significant. 
Discussion  
In the longstanding discussion about TDM of thiopurines in the maintenance 
treatment of IBD, this study provides some novel insights for adult patients. At 
first, an important result is the overall high prevalence of non-compliance in 
case of both remissions and exacerbations. Non-compliance is very important 
in treatment of chronic diseases, but often underestimated in clinical 
practice18-24. TDM is the only way to reveal non-compliance, indicating an 
important role for TDM in case of refractory disease. The results of this study 
subscribe this, although no significant difference in non-compliance was found 
between exacerbations and remissions. Alternatively, zero or very low 6-TGN 
levels could theoretically be caused by thiopurine malabsorption, a (yet 
unknown) enzyme defect or extremely high enzyme activity. Recently, very 
high XO-activity was suggested to be a cause of zero 6-TGN levels in a case 
report28. 
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Secondly, no significant differences in 6-TGN or 6-MMPR metabolite levels 
between patients with exacerbations and remissions were found, neither a 
correlation between 6-TGN levels and disease activity, when examining the 
originally included patients. These are disappointing results with regard to TDM 
of thiopurines, but they are in accordance with several other reports10,14-16.  
Thirdly, the previously indicated therapeutic threshold 6-TGN level of 
235 pmol/8x108 RBC does really discern patients with exacerbations from 
those with remissions in this study, but with a low predictive value for individual 
patients, especially if non-compliance is not taken into account. However, after 
creating a control population of compliant patients in remission, the 
discriminative value of 6-TGN levels is more convincing, with the highest 
sensitivity and specificity between 235-250 pmol/8x108 RBC, resulting in 
moderate predictive values and an OR of 4.7 for having 6-TGN levels below 
this threshold in case of an exacerbation.  
In all calculations in this study a cut-off therapeutic 6-TGN level is found 
between 235-250 pmol/8x108 RBC, however having a low sensitivity, specificity 
and positive predictive value of maximum 71, 73 and 67% respectively, 
resulting in an accuracy of 69%. This cut-off level is similar to the proposed 
6-TGN threshold of 235 pmol/8x108 RBC in a study in paediatric IBD patients1. 
A quartile analysis of the present results, performed according to the method 
used in that study, finds corresponding therapeutic threshold 6-TGN levels. 
Only in that study metabolite levels were significantly different between 
exacerbations and remissions (199 versus 312 pmol/8x108 RBC).  We find a 
significant difference between exacerbations and remissions in reaching the 
proposed 6-TGN threshold of 235 pmol/8x108 RBC: 37% of patients with an 
exacerbation versus 59% in remission, in accordance with the findings of a 
recent meta-analysis, which indicated 38% and 62% respectively17. The OR for 
having clinical remission in case of 6-TGN levels above the threshold, in the 
analysis of all compliant patients is 3.8 in the present study, also comparable to 
the findings of the meta-analysis: 3.3.17 When excluding only non-compliant 
patients in remission, this OR is even better: 4.7. 
The present study gave also the possibility to study the potential influence of 
genetically determined metabolic pathways by measuring TPMT activity. 
Abnormal TPMT activity had a relatively low prevalence, in contrast with 
previous reports1,6,7,29-32. Probably this is due to the fact that all patients had 
used a thiopurine for at least three months. Therefore, patients with early 
toxicity had already been excluded. Nevertheless, an expected negative 
correlation between 6-TGN levels and TPMT activity was found (r=-0.318 and 
p=0.014) and both patients with low TPMT activity had low or zero 6-MMPR 
and high 6-TGN levels. 
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Some remarks should be made about this study. We are conscious of the fact 
that this evaluation is based on a quite narrow selection of patients, regarding 
their number, the artificial exclusion of an intermediate group of patients with 
mildly active Crohn’s disease (CDAI 150-200) and the fact that all patients had 
used thiopurines for at least three months, thereby excluding early adverse 
events. It was decided on beforehand to exclude patients with mildly active 
Crohn’s disease to get a more pronounced definition of exacerbation. Irritable 
bowel like complaints have a relatively large weight in the CDAI and may bias 
the score. These overlap patients made the discussion about the efficacy of 
thiopurines somewhat unclear in the past: e.g. one of the first studies, based on 
a population with a mean CDAI of only 152, concluded that thiopurines had low 
efficacy, but in fact the included patients did not have clearly active disease33,34. 
Secondly, we realise that the included patients have a broad spectrum of IBD 
phenotypes, although demographic characteristics were very similar. However, 
this criticism counts for many IBD studies. Thirdly, both AZA and 6-MP treated 
patients were included. AZA is a prodrug of 6-MP (Figure 1). When using a 
conversion factor of 0.5, AZA dose is equivalent with 6-MP dose. Efficacy is 
equal for both drugs25. Fourthly, the effect of other concomitant medication 
-contributing to therapeutic response- was not considered in this study, though 
co-treatment had to be stable before inclusion. Nevertheless, this is the fifth 
study demonstrating a threshold 6-TGN between 230-260 pmol/8x108 RBC, 
with significant differences in the prevalence of exacerbations and remissions 
above and below this cut-off, confirming some value of TDM, but indicating a 
low sensitivity and specificity1,2,9,13. At last, this study is in fact descriptive, 
although prospectively performed. A future prospective study on usefulness of 
TDM in efficacy and safety of thiopurines should follow treatment from the start, 
comparing a group of patients with dose optimization by TDM with a group with 
conventional follow up, in a randomised way, examining failures of treatment, 
efficacy and toxicity at several time points. However, that type of study should 
include more than 250 patients in both groups to find significant results, based 
on the known prevalence of leukopenia (2-5%), hepatotoxicity (10-15%) and 
other adverse events. This study would take years and probably necessitates a 
(multi)national approach. 
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Conclusions 
The clinical consequences of our findings seem to be the following: in an 
individual IBD patient with an exacerbation, TDM of 6-TGN metabolite levels 
should at first be used to exclude non-compliance. If TDM shows 6-TGN levels 
below 235 pmol/8x108 RBC, an attempt to dose increase could be made. 
However, the sensitivity and specificity of the confirmed cut-off therapeutic 
6-TGN level of 235 pmol/8x108 RBC is rather low. 
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Abstract  
Introduction 
In vitro studies suggest interactions between mesalazine (5-ASA) and thiopurines by thiopurine-
S-methyltransferase (TPMT) inhibition, influencing the balance of hepatotoxic 
6-methylmercaptopurine ribonucleotides (6-MMPR) and immunosuppressive 6-thioguanine 
nucleotides (6-TGN) metabolites. 
 
Aims 
Examining the in vivo interaction between mesalazine and 6-mercaptopurine (6-MP) in IBD 
patients. 
 
Methods 
A prospective study was performed in quiescent IBD patients using the combination of 6-MP and 
5-ASA. Laboratory parameters, 6-MMPR and 6-TGN levels and TPMT activity in erythrocytes 
(RBC) were measured at stable medication, after 5-ASA discontinuation and 5-ASA reintroduction. 
6-MP was continued. 
 
Results 
17 patients participated. Mean 6-MP dose was 0.78 mg/kg/day, median 5-ASA dose 3000 mg/day. 
After 5-ASA discontinuation, mean 6-TGN levels changed significantly from 262 to 209 pmol/8x108 
RBC, increasing to 270 after reintroduction. Mean 6-MMPR levels were 1422, 2149 and 1503 
pmol/8x108 RBC respectively. Mean 6-MMPR/6-TGN ratio increased significantly from 6.3 at 
baseline to 11.2. Mean baseline TPMT activity was 0.58 pmol/106 RBC/hour and stable. All patients 
had wildtype TPMT genotypes. Leukocyte counts were stable. 
 
Discussion 
Significantly higher 6-TGN levels and improving 6-MMPR/6-TGN ratio were found during 
5-ASA/6-MP combination. Theoretically, 5-ASA inhibits TPMT activity. In vivo TPMT activity did not 
change, however. 
 
Conclusions 
5-ASA has synergistic effects on 6-MP therapy, but the mechanism is unclear. Combining these 
drugs may be further indication for 5-ASA in IBD treatment. 
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Introduction 
5-aminosalicylic acid compounds (5-ASA) are widely used in inflammatory 
bowel disease (IBD). Several compounds of 5-ASA exist: sulfasalazine, the 
newer mesalazine products and azo-bond formulations (eg balsalazide and 
olsalazide)1. Nowadays, mesalazine is the most frequently used compound.  
All 5-ASA products have a direct effect on the gut mucosa by a combination of 
anti-inflammatory effects like inhibition of prostaglandin synthesis, a decrease 
in radical formation due to oxygen radical scavenging and an inhibition of 
activation of lymphocytes2.  
In ulcerative colitis (UC) 5-ASA has proven to be effective in induction of 
remission and in maintenance treatment3,4. In treatment of Crohn's disease 
(CD) however, there is much debate on the use of mesalazines. Meta-analyses 
show only weak evidence for benefit in induction of remission and maintenance 
treatment in subgroups of patients (eg postsurgical, ileitis or prolonged disease 
duration)5-7. Also, they might protect against colorectal cancer in ulcerative and 
Crohn´s colitis8. 
 
6-Mercaptopurine (6-MP), a thiopurine, is widely used in steroid dependent or 
refractory IBD. Its pro-drug, azathioprine (AZA), is used for the same 
indications. Thiopurines are metabolised by several enzymes (Figure 6.1). 
Thiopurine S-methyltransferase (TPMT) is one of the most critical, because of 
its genetic polymorphism, responsible for large interindividual differences in 
activity. Recently, inosine triphosphate pyrophosphatase (ITPase) was 
discovered as another important enzyme in thiopurine metabolism9-11. TPMT 
activity influences the balance between two types of thiopurine metabolites: the 
immunosuppressive 6-thioguanine nucleotides (6-TGN) and hepatotoxic 
6-methylmercaptopurine ribonucleotides (6-MMPR). 
 
 
In recent years the interest in therapeutic drug monitoring of thiopurines has 
been accentuated by pharmacokinetic and genomic studies12,13. Threshold 
levels of thiopurine metabolites were described: 6-TGN levels higher than 235 
pmol/8x108 red blood cells (RBC) were defined as therapeutic and 6-MMPR 
levels higher than 5700 pmol/8x108 RBC were associated with 
hepatotoxicity13-15. Some other studies could not confirm these cut off 
levels16,17. A 6-MMPR/6-TGN ratio of less than 11 was found to correlate with 
response to 6-MP treatment18. Above this point a lack of efficacy is seen, even 
after dose elevation. 
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Figure 6.1 Thiopurine metabolism.  
 AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-TUA, 6-thiouric acid; 6-MMP, 
6-methylmercaptopurine; 6-TIMP, 6-thioinosine 5’-monophosphate; 6-MMPR level, 
6-methylmercaptopurine ribonucleotides; 6-TITP, 6-thioinosine triphosphate; 
6-TIDP, 6-thioinosine diphosphate; 6-TG, 6-thioguanine; 6-TGN level, 6-thioguanine 
nucleotides; 6-MTG, 6-methylthioguanine; HPRT, hypoxanthine 
phosphoribosyltransferase; XO, xanthine oxidase; ITPA, inosine triphosphate 
pyrophosphatase; MPK, monophosphokinase; DPK, diphosphokinase; TPMT, 
thiopurine S-methyltransferase; IMPDH, inosine monophosphate dehydrogenase; 
GMPS, guanosine monophosphatase synthetase. 
 
The gene encoding TPMT is subject to a genetic polymorphism, causing great 
inter-individual differences in metabolite levels. More than twenty mutant TPMT 
alleles are known19. High TPMT activity is associated with the wildtype 
TPMTH/H genotype (*1 allele), seen in 89% of the Caucasian population and 
leading to normal or high 6-MMPR levels. Intermediate and low TPMT activity 
is associated with mutant alleles (TPMTL/H genotype in 11% and TPMTL/L in 
0.3% of Caucasians, respectively), leading to high 6-TGN levels, with an 
increased risk of developing myelosuppression. Some reports showed elevated 
6-TGN levels and leukopenia in presence of mutant TPMT alleles20,21. A 
prospective study showed an increased relative risk of 12 on myelosuppression 
in patients with at least one mutant allele22. 
 
Several medications can interact with thiopurine metabolism. TPMT is inhibited 
by angiotensine I converting enzyme inhibitors and diuretics (eg. furosemide, 
bendroflumethiazide and trichlorthiazide)23. In vitro studies showed that 
sulfasalazine and other 5-ASA containing products inhibit TPMT24,25. These 
investigators demonstrated that IC50 values (the concentration of an agent 
halving TPMT activity) were 31, 104, 197 and 1380 µmol/l, respectively, for 
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olsalazine, sulfasalazine, balsalazide and 5-ASA. The same group performed 
an in vivo interaction study showing an increase in 6-TGN levels and 
prevalence of leukopenia due to the concurrent use of 5-ASA. TPMT activity 
did not change significantly for sulfasalazine and balsalazide and even 
increased after 8 weeks of mesalazine treatment26. Another in vivo interaction 
study on thiopurines and 5-ASA showed decreasing 6-TGN levels after 5-ASA 
discontinuation, but again without significant changes in TPMT activity27.  
Recently an ex vivo study in red blood cells showed that only sulfasalazine 
would have the potential to inhibit TPMT in vivo, based on human plasma 
concentrations of sulfasalazine, 5-ASA and its metabolites28.  
Only two in vivo studies were published yet about the interaction between 
5-ASA and thiopurines. Therefore, a prospective in vivo interaction study was 
performed in our IBD patients, using the combination of 6-mercaptopurine and 
5-ASA, by measuring the relevant metabolite levels and TPMT activity. 
Patients and methods 
Patient selection 
We traced all IBD patients in a general district hospital (Maasland Hospital 
Sittard, the Netherlands) using the combination of 6-MP and one of the oral 
mesalazine products. Patients were considered for the study when using 6-MP 
and 5-ASA in a stable dose for at least three months. Exclusion factors were 
age under 16 years and active disease (moderate to severe disease according 
to the Truelove-Witts disease activity index for Ulcerative Colitis and the 
Crohn's disease activity index (CDAI) >150)29. All included patients signed an 
informed consent form.  
Study design 
A prospective open-label study was carried out. Laboratory parameters (blood 
cell counts, bilirubin, aspartate transaminase (ASAT), alanine transaminase 
(ALAT), amylase, lipase, albumin and C-reactive protein), 6-MMPR, 6-TGN 
levels and TPMT activity were measured at baseline (t=0 w), four weeks after 
5-ASA discontinuation (t=4 w) and four weeks after reintroduction of 5-ASA 
(t=8 w) (Table 6.1). 6-MP was continued on a steady dose throughout the study 
interval. TPMT genotype was determined once. 
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Outcome measures 
Primary study outcomes were 6-TGN and 6-MMPR metabolite levels and 
TPMT activity at t=0, 4 and 8 weeks. Secondary outcomes were correlations 
between 6-TGN, 6-MMPR, TPMT activity, 6-MP and 5-ASA dose in mg/kg 
bodyweight, laboratory parameters and disease activity. 
 
Table 6.1 Time table. 
 
 
 
 
 
 
Baseline (t = 0) t = 4 weeks t = 8 weeksTime
Action
t   ks t = 8 
Haematology biochemistry
6-MP metabolite levels
TPMT genotype and activity
Stop 5-ASA
Haematology biochemistry
6-MP metabolite levels
TPMT activity
Restart 5-ASA
Haematology biochemistry
6-MP metabolite levels
TPMT activity
 
Analytical procedures 
6-TGN and 6-MMPR levels were measured with the modified high performance 
liquid chromatography (HPLC) method of Lennard as published previously22. 
TPMT genotyping of leukocyte DNA was performed using a previously reported 
assay22. TPMT activity in erythrocyte lysates was measured as described by 
Jacques-Aigrain and colleagues30. Briefly, the washed erythrocyte lysate was 
incubated with 6-mercaptopurine in a dithiothreitol and S-adenosylmethionine 
containing phosphate buffer at pH 7.5 at 37°C for one hour. 2-Amino-
6-methylmercaptopurine (6-AMMP) was used as the internal standard. After 
the incubation period, the reaction was stopped by the addition of hydrogen 
chloride, followed by neutralization with a basic ammonium chloride solution. 
6-MP, 6-MMP and 6-AMMP were extracted with dichloromethane/2-propanol. 
After evaporation of the organic solvent, the samples were dissolved in buffer 
and analyzed using reversed-phase HPLC. The inter-assay co-variation of the 
procedure was 10%, the typical recovery was 99%. 
Statistical analysis 
Normality of metabolite levels and TPMT activity was tested by the 
Kolmogorov-Smirnov normality test. Data are expressed as means with with 
range or 95% confidence interval (CI95%). Pearson´s correlation test was used 
for correlations. P values <0.05 were considered significant.  
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Results 
Twenty-seven patients of the total IBD cohort of 679 patients in the Maasland 
Hospital in Sittard, the Netherlands were using the combination of 6-MP 
simultaneously with an oral mesalazine product (Table 6.2). Oral 5-ASA 
products used were Salofalk® (Tramedico, Weesp, the Netherlands), Pentasa® 
(Ferring, Hoofddorp, the Netherlands) and Asacol® (Altana Pharma, Hoofddorp, 
the Netherlands). 
 
Table 6.2 Characteristics of the patients. 
 
Total IBD cohort Maaslandhospital Sittard 679 patients 
   Patients using 5-ASA and 6-MP 27 
      Included 17 
      Excluded Active disease 3 
 Refused 7 
   Characteristics patients at inclusion  
      Male / Female 10 / 7 
      Age (mean + range) 45 years  (16-72) 
      CD / UC 0.78 mg/kg  (0.69-0.86) 
      6-MP dose (mean + CI95%) 12 / 5 
      5-ASA dose (median + range) 3000 mg  (2400-3000)  
      5-ASA preparation  
 Salofalk® 9 
 Pentasa® 6 
 Asacol® 2 
 
 
Mean 6-TGN levels were 262 pmol/8x108 RBC (CI95% 212-312) at baseline 
(t=0 w), 209 (170-247) after four weeks of discontinuation of 5-ASA (t=4 w) and 
270 (217-322), four weeks after reintroduction of 5-ASA (t=8 w) (Figure 6.2A). 
Mean 6-TGN levels were significantly lower at t=4 w than at baseline and at 8 
w (p<0.01). 
Mean 6-MMPR levels were 1422 (CI95% 721-2122), 2149 (730-3568) and 
1503 (721-2284) pmol/8x108 RBC at t=0, 4 and 8 w respectively, but did not 
change significantly (figure 2B). 
Mean 6-MMPR/6-TGN ratio was 6.3 at baseline (range 1.0-20.6). At t=4 w this 
ratio increased significantly to 11.2 (p=0.04, CI95% -9.6 to -0.25). At t=8 w the 
ratio decreased again to 6.2, but not significantly (p=0.07 and CI95% -0.41 to 
10.4). 
TPMT genotyping showed a wildtype TPMTH/H (TPMT*1/*1) genotype in all 
patients. TPMT activity was evaluated in 16 of 17 patients, due to a missing 
sample in one of the ulcerative colitis patients. At baseline mean TMPT activity 
was 0.58 pmol/106 RBC/hour (CI95% 0.48-0.69). Four weeks after 5-ASA 
discontinuation mean TPMT activity was 0.57 (CI95% 0.45-0.70) and 4 weeks 
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after reintroduction 0.61 (CI95% 0.50-0.72). Statistical analysis showed no 
significant change in mean TPMT activity during the study interval (p=0.52 and 
p=0.29).  
Mean leukocyte counts were comparable (6.5, 6.6 and 6.2x109/l at the 
respective timepoints, range 3.8-11.2), no leukopenia with counts below 
3.5x109/l occurred. All other laboratory parameters did not change significantly. 
No correlations were found between 6-MMPR or 6-TGN levels or between 
these levels and 6-MP dose. No correlation was found between TPMT activity 
and 6-TGN or 6-MMPR levels or 6-MMPR/6-TGN ratio. TPMT activity did not 
correlate with 5-ASA or 6-MP dose. Leukocyte counts did not correlate with 
6-TGN levels or TPMT activity. 
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Figure 6.2 Mean 6-TGN and 6-MMPR levels in pmol/8x108 RBC.  
Discussion  
This open, prospective study on the interaction of 5-ASA and 6-MP in 17 IBD 
patients shows a significant decrease of 20% in 6-TGN levels after 
discontinuation of mesalazine, reversible after reintroduction. These results are 
in accordance with previous publications26,27. Only, we found baseline 6-TGN 
levels above the therapeutic threshold of 235 pmol/8x108 RBC according to 
Dubinsky et al. as Dewit found mean 6-TGN levels of 148 pmol/8x108 RBC13,27. 
These therapeutic levels decreased under the threshold after 5-ASA 
discontinuation. 
Dubinsky proposed a 6-MMPR/6-TGN ratio of 11 as a cut off point above which 
the frequency of response to 6-MP treatment decreases and other 
immunosuppressive therapies should be considered18. Although our study was 
not powered to make conclusions about therapeutic efficacy, it is noticeable 
that after discontinuation of 5-ASA the mean 6-MMPR/6-TGN ratio increased 
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above the proposed cut off of 11. Apparently, 5-ASA improves metabolite 
profiles, thereby potentiating efficacy of 6-MP treatment. Theoretically, the risk 
of a leukopenia increases due to the shift towards 6-TGN metabolites. Lowry 
found leukocyte counts lower than 3.0x109/l in 10 % of patients after initiation of 
5-ASA next to steady state azathioprine or 6-MP therapy26. Leukocyte counts 
lower than 3.5x109/l were found in 50% of patients. We neither found a 
variation in leukocyte counts nor a case of leukopenia, but all patients had 
already been treated with an established combination of 5-ASA and 6-MP. 
Patients with (early) myelotoxicity were thus excluded. Still, the increase of 6-
TGN levels is important in clinical practice, emphasizing the possible need for 
6-MP dose adjustment and for regular checks of leukocyte counts, when 
prescribing 6-MP in combination with 5-ASA.  
The significantly higher concentration of 6-TGN metabolites during combination 
therapy of 5-ASA and 6-MP could theoretically be explained by inhibition of the 
TPMT enzyme, as was suggested by two in vitro studies24,25. However, none of 
the two in vivo interaction studies performed so far could demonstrate a 
significant change in TPMT activity in patients26,27. In accordance with these 
findings, no significant change in TPMT activity after discontinuation of 
mesalamine was seen in this study. By coincidence, all patients had a wild type 
TPMT genotype, excluding bias due to the influence of TPMT genotype on 
phenotype or activity. 
What is the explanation for the effect of 5-ASA products on 6-MP metabolism 
then? Possibly the analytical procedure of TPMT activity measurement itself 
explains the unchanged TPMT activity during the study interval. During 
preparation of the erythrocyte lysates all metabolites are washed out. It is 
unknown whether 5-ASA metabolites are washed out as well or whether 5-ASA 
metabolites irreversibly inhibit TPMT. If these metabolites are removed during 
TPMT analysis this might lead to normalisation of inhibition of TPMT activity. 
Alternatively, other and even still unknown enzymes of the thiopurine 
metabolism could be influenced by 5-ASA. 
Conclusions 
Oral 5-ASA products lead to an increase of 6-TGN levels in combination with 
6MP therapy. They potentate efficacy of 6-MP treatment by improving the 
6-MMPR/6-TGN ratio, which is related to treatment response. Theoretically, 
this combination therapy gives a higher risk for myelosuppression due to higher 
6-TGN concentrations. No study demonstrated any effect of 5-ASA on TPMT 
activity yet. The reasons for the observed interaction remain unexplained. 
Clinicians should be prepared to use lower 6-MP doses when combining 6-MP 
with 5-ASA and check leukocyte counts regularly in these patients. 
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The synergistic effect of 5-ASA with 6-MP may support the indication for 5-ASA 
in maintenance therapy of CD. 
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Abstract  
Introduction 
6-Thioguanine (6-TG) seems to be an attractive alternative in both AZA and 6-MP intolerant and 
resistant IBD populations. However, little is known of 6-TG pharmacokinetics in IBD patients, 
metabolite levels and their correlation with drug efficacy and toxicity. 
 
Aims 
This study reports the 6-TG pharmacokinetics in a population of IBD patients and the predictive 
value of metabolite concentrations. 
 
Patients and methods 
Red blood cell (RBC) 6-thioguanine nucleotides (6-TGN) concentrations were measured in twenty-
eight IBD-patients at t = 1, 2, 4 and 8 weeks after starting 6-TG 20 mg once daily. Outcome 
measures included mean 6-TGN concentrations (±95% confidence interval (CI95%)), and their 
associations with TPMT genotype, 6-TG dose, hematologic, hepatic, pancreatic and efficacy 
parameters during the 8 week period. 
 
Results 
Steady state 6-TGN concentrations were reached after four weeks, indicating a half life of 
approximately five days, and measured 856 (CI95%: 715-997) pmol/8x108 RBC. Large inter-patient 
variability occurred at all time-points. No correlation was found between steady state 6-TGN 
concentrations and drug dose per kg bodyweight. No significant differences in 6-TGN 
concentrations were found between patients with adverse events versus patients without any 
event. Also, mean 6-TGN concentrations did not differ in patients with active disease versus 
patients in remission. 
 
Discussion and conclusions 
In IBD patients on 6-TG treatment, large interindividual differences in metabolite concentrations 
occur. In our population, we could not demonstrate a clear relationship between 6-TGN 
concentrations on one hand and toxicity and efficacy on the other, like in AZA and 6-MP treated 
patients. 
130 
 Pharmacokinetics of 6-thioguanine in IBD 
Introduction 
6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) have proven 
efficacy in the treatment of inflammatory bowel disease (IBD)1-3. Thiopurines 
themselves are inactive and require intracellular metabolism (Figure 7.1) to the 
active 6-thioguanine nucleotides (6-TGN), which are incorporated into DNA, 
causing immunosuppression4,5. Also, 6-thioguanine triphosphate (6-TGTP), 
one of the 6-TGN, is considered to contribute to the immunosuppressive effects 
due to inhibition of Rac1, inducing apoptosis6. However, these 
immunosuppressives are ineffective in one-third of patients7 and 10-20% of 
AZA or 6-MP treated patients is forced to discontinue drug therapy due to the 
occurrence of adverse events8-10. Administration of 6-thioguanine (6-TG), an 
agent much closer to effective 6-TGN, seems to be an attractive alternative in 
both AZA and 6-MP intolerant11,12 and resistant populations13,14. Recently 
discovered disturbing high frequencies of nodular regenerative hyperplasia 
(NRH) in the liver in patients treated with 6-TG tempered initial enthusiasm15. 
In patients treated with 6-MP it is shown that red blood cell (RBC) 6-TGN levels 
correlate with both drug efficacy and myelotoxicity and a therapeutic window of  
250-500 pmol/8x108 RBC was proposed16,17. However, in patients treated with 
6-TG much higher metabolite levels develop without any sign of myelotoxicity12. 
In fact, very little is known of 6-TG pharmacokinetics in IBD patients, metabolite 
levels and their correlation with drug efficacy and toxicity. Therefore, we 
performed a prospective pharmacokinetic study of 6-TG in a population of IBD 
patients. 
Material and methods 
Patient selection 
IBD patients in which 6-TG was indicated, aged between 18 and 75 years and 
attending the out-patient clinics of Maasland Hospital Sittard or St. Laurentius 
Hospital Roermond, were eligible for the study. Considered as indications for 
6-TG treatment were steroid-dependency, steroid-resistancy and AZA- or 6-MP 
intolerance (both hypersensitivity reactions and dose-dependent events). 
Exclusion criteria were: pregnancy or expected pregnancy within six months, 
inadequate contraception in women, lactation, presence of active infection, 
history of tuberculosis, HIV, hepatitis B or C, severe pancreatitis (necrotizing 
pancreatitis or pancreatitis leading to multi organ failure), malignancy, ongoing 
treatment with other immunosuppressive drugs like cyclosporin, methotrexate, 
thalidomide or infliximab, impaired renal function (serum creatinin >2 times 
normal upper limit), elevated liver function tests (>2 times normal upper limit) 
and bone marrow suppression. 
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Figure 7.1 Thiopurine metabolism. 
 AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MMP, 6-methylmercaptopurine; 
6-TUA, 6-thiouric acid; 6-TIMP, 6-thioinosine monophosphate; 6-MTIMP, 
6-methylthioinosine monophosphate; 6-TIDP, 6-thioinosine diphosphate; 6-TITP, 
6-thioinosine triphosphate; 6-TXMP, 6-thioxanthosine monophosphate; 6-TGMP, 
6-thioguanine monophosphate; 6-TGDP, 6-thioguanine diphosphate; 6-TGTP, 
6-thioguanine triphosphate; 6-TGN; 6-thioguanine nucleotides; 6-TG, 6-thioguanine; 
6-MTG, 6-methylthioguanine; XO, xanthine oxidase; TPMT, thiopurine 
S-methyltransferase; HPRT, hypoxanthine phosphoribosyl transferase; IMPD, 
inosine monophosphate dehydrogenase; GMPS, guanosine monophosphate 
synthetase; MPK, monophosphate kinase; DPK, diphosphate kinase; ITPase, 
inosine triphosphatase. 
Study design 
The trial design was a prospective open-label multicentre study. At entry 
patient demographics and clinical history were collected as well as medication-
use during the past year. Subsequently, 6-TG (LanvisTM, tablet 40 mg, Glaxo 
Wellcome, Zeist, the Netherlands) was prescribed as a single oral 20 mg 
evening dose. Therefore, the commercially available 40 mg tablets were 
divided into half by a tablet-splitter in the production-unit of the Department of 
Clinical Pharmacy, Maasland Hospital, Sittard. Concomitant medication was 
continued: aminosalicylates were allowed as stable comedication throughout 
the study and steroid dose could be tapered according to clinical response. 
Laboratory parameters, disease activity scores (Crohn’s Disease Activity Index 
(CDAI) for CD and Truelove-Witts Disease Activity Index (TWDAI) for UC) and 
quality of life (according VAS-score) were obtained at 0 (baseline), 1, 2, 4 and 
8 weeks after start of medication. Blood was drawn each visit for measurement 
of 6-TGN concentrations, alanine transaminase (ALT), aspartate transaminase 
(AST), bilirubins, amylase, lipase, leukocytes (plus differentiation), platelets and 
haemoglobin (Hb). Additionally, in three randomly chosen patients with 6-TGN 
concentrations at steady state blood was drawn for the measurement of 6-TGN 
concentrations during a twenty-four hours period at 0, 2, 4, 8, 12 and 24 hours 
after 6-TG intake to study concentration fluctuations during the day. 
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Ethical considerations 
The protocol was approved by the local medical ethics committee and in 
accordance with the Helsinki Declaration. Informed written consent was 
obtained before enrolment. 
Outcome measures 
Outcome measures were individual 24-hours- and eight-week curves, mean  
6-TGN concentrations ±95% confidence interval (CI95%), correlation between 
steady state 6-TGN concentrations with several other parameters including 
dose per kg bodyweight, TPMT genotype (TPMT*1/TPMT*2/TPMT*3A/ 
TPMT*3B/TPMT*3C), the occurrence of myelotoxicity (leukocyte count 
<4.0x109/l, platelet count <100x109/l), the occurrence of hepatic toxicity 
(ALT>80 U/l, AST>80 U/l, bilirubins >40 µmol/l), pancreatic toxicity (amylase 
>220 U/l, lipase >120 U/l (elevations >2 times normal upper limit)), CDAI (CD) 
or TWDAI (UC) during the eight week period. The relationship of adverse 
events with the use of 6-TG was established by the following method: 
unrelated, no temporal relation and other aetiology likely; possibly related, 
potential temporal relation and other aetiologies possible; probably related, 
potential temporal relation and other aetiologies unlikely; related, clear 
temporal relation not otherwise explained. 
Analytical procedures 
6-TGN concentrations were measured in the laboratory of the Department of 
Clinical Pharmacy, Maasland Hospital, Sittard, using a previously published 
assay17. Erythrocytes are a good surrogate matrix as they are easily obtained, 
exist in sufficient numbers and contain concentrations of 6-TGN that reflect 
concentrations of 6-TGN in the less accessible putative target-tissue, the 
leukocytes18. In brief, the thiopurines are separated by reversed-phase HPLC 
and quantified using UV-detection. For measurement of intracellular 
thionucleotides the free base is obtained by acid hydrolysis of the nucleotide 
back to the purine. The resulting purines are extracted from the biological 
matrix by forming a phenyl mercury adduct into dichloromethane. During back-
extraction with hydrochloric acid the adduct is splitted and the free thiopurine is 
liberated into the acid layer once again. The run-to-run coefficient of variation 
was 6.6%. The lower limit of quantification of the assay was determined at 
30 pmol/8x108 RBC. 
TPMT-genotyping of leukocyte DNA was carried out by the laboratory of the 
Department of Gastroenterology and Hepatology, Academic Medical Centre, 
Amsterdam, based on a previously reported assay19. 
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Statistical analysis 
Normality was tested by the Kolmogorov-Smirnov test. Data are expressed as 
means with range or CI95%. Pearson’s correlation was used to test the 
relationship between the measured parameters. P values <0.05 were 
considered significant. SPSS for Windows (version 10.0.7) software was used 
to perform statistics. 
Results 
Patient characteristics and reasons for 6-TG initiation are shown in Table 7.1. 
Twenty-eight patients were enrolled between May 2001 and November 2003. 
Of the 28 patients, 27 patients (96%) were on 6-TG treatment for four weeks 
and 24 patients (86%) completed the eight week period. Steady state was 
reached after a period of four weeks. Four patients failed to reach the end of 
the observed period because of the occurrence of adverse events.  
 
Table 7.1 Patient characteristics (n=28). 
Sex (M/F)  6/22 
Age (yrs) (mean + range) 38 (19-70) 
Disease (CD/UC) 16/12 
Location of disease CD small bowel 5 
  large bowel 6 
  combination 5 
 UC distal colitis 9 
  pancolitis 3 
Duration of disease (yrs) (mean + CI95%) 10.0 (7.4-12.6) 
Disease activity at baseline CD  remission, CDAI<150 5 
   active, CDAI 150-300 11 
  UC remission, TWDAI≤6 7 
   active, TWDAI>6 5 
Quality of Life at baseline* 56 
5-ASA / no 5-ASA 23/5 
5-ASA dose (mg) (median + range) 3000 (1500-3200) 
Reason for 6-TG initiation Disease activity/steroid dependency 1 
 AZA intolerance 9 
 6-MP intolerance 8 
 AZA and 6-MP intolerance 8 
 Other 2 
6-TG dose (mg/kg) (mean + CI95%) 0.32 (0.29-0.34) 
TPMT genotype   
 *1/*1 17 
 not determined 11 
M, male; F, female; CD, Crohn’s disease; UC, ulcerative colitis; CDAI, Crohn’s disease activity 
index; TWDAI, Truelove-Witts disease activity index; 5-ASA, 5-aminosalicylic acid (-analogues); 
6-TG, 6-thioguanine; 6-MP, 6-mercaptopurine; AZA, azathioprine; TPMT, thiopurine 
S-methyltransferase. *according VAS-score (0-100%). 
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Metabolite concentrations 
Metabolite concentrations were normally distributed. Mean 6-TGN 
concentrations are shown in Table 7.2. Individual eight week and 24-hours 
6-TGN curves are shown in Figure 7.2 and 7.3 respectively. Seven patients 
had measurable 6-TGN concentrations at inclusion because AZA or 6-MP 
therapy was discontinued only recently. 6-TGN concentrations reached steady 
state concentrations after four weeks in all but one patient with questionable 
compliance. No correlation was found between steady state 6-TGN 
concentrations and dose per kg bodyweight, as shown in Figure 7.4. 
 
Table 7.2 6-TGN concentrations 
Week N Mean 6-TGN level range 
  (pmol/8x108 RBC)  
1 27 481 35-1254 
2 25 678 123-1763 
4 27 856 192-2112 
8 24 848 284-1888 
N, number of patients; 6-TGN, 6-thioguanine nucleotides.  
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Figure 7.2 Individual 6-TGN concentrations curves (eight weeks). 6-TGN, 6-thioguanine 
nucleotides; RBC, red blood cells. 
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Figure 7.3 Individual steady state 6-TGN concentrations curves (24 hours). 6-TGN, 6-thioguanine 
nucleotides; RBC, red blood cells. The depicted standard deviations express the 
margin of error of our assay for 6-TGN measurement. 
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Figure 7.4 Correlation between 6-TGN concentrations and dose per kg bodyweight. 6-TGN, 
6-thioguanine nucleotides; RBC, red blood cells. 
 
 
TPMT genotype 
TPMT genotype was determined in 17 of 28 patients (61%) and all genotyped 
subjects possessed wild type alleles (Table 7.1). In two of the four patients 
intolerant to 6-TG TPMT genotype could not assessed because of loss to 
follow-up. In the other two patients a wild type TPMT genotype was found. The 
patient with the clearly highest 6-TGN concentrations possessed wildtype 
alleles.  
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Adverse events 
Four patients discontinued therapy because of adverse events. Adverse events 
leading to discontinuation of 6-TG treatment are summarized in Table 7.3. In 
these patients, 6-TGN concentrations varied considerably. No myelotoxicity or 
hepatotoxicity occurred in the observed period. In one patient amylase (158 
U/l) and lipase (273 U/l) levels temporarily increased without any symptoms of 
a clinically present pancreatitis.  
 
Table 7.3 Adverse events leading to discontinuation of 6-TG treatment. 
No. Dose Last 6-TGN level Time to AE Character of AE Relationship TPMT 
 (mg/kg) (pmol/8x108 RBC) (days)    
1 0.26 552 24 nausea*, diarrhoea*, 
stomach cramps* 
probably 
related 
*1/*1 
2 0.29 1013 42 total malaise* possibly 
related 
*1/*1 
3 0.20 229   7 fever*, erythema 
nodosum*, arthralgia*
related n.d. 
4 0.34 -   7 nausea*, stomach 
cramps, headache* 
probably 
related 
n.d. 
6-TGN, 6-thioguanine nucleotides; AE, adverse events; TPMT, thiopurine S-methyltransferase; 
n.d., not determined. * same AE as previously shown on AZA or 6-MP. 
 
Efficacy 
Disease activity was assessed in all patients at baseline and after eight weeks. 
Sixteen of the 28 patients had active disease at baseline (Table 7.4). The mean 
CDAI of the eleven CD patients was 224 and the TWDAI of the five UC patients 
was 10. Five of the eleven (45%) CD patients achieved clinical remission 
(CDAI<150) after the study period of eight weeks versus two of the five (40%) 
UC patients. In the CD patients, the mean 6-TGN concentration in patients with 
active disease was 933 pmol/8x108 RBC (CI95%: 677-1190) compared to 916 
pmol/8x108 RBC (CI95%: 810-1023) in patients that achieved clinical 
remission. In the UC patients both means were 590 (CI95%: 238-942) and 675 
(CI95%: 393-957) for active disease and remission respectively. No significant 
differences in mean 6-TGN concentrations were found. 
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Table 7.4 Disease activity and metabolite levels in 16 patients with active disease at baseline. 
Active Crohn’s disease disease  
(CDAI >150) 
Remission 
after 8 weeks 
(N=5) 
 Active disease 
after 8 weeks 
(N=6) 
Css RBC 6-TGN levels  
(pmol/8x108 RBC) 
Pt 1 
Pt 2 
Pt 3 
Pt 4 
Pt 5 
 
1013 
  819 
  996 
1001 
  753 
 
Pt 6 
Pt 7 
Pt 8 
Pt 9 
  Pt 10 
  Pt 11 
1269 
1060 
1009 
  411 
  696 
1155 
Active ulcerative colitis (TWDAI >6) (N=2) (N=3) 
Css RBC 6-TGN levels 
(pmol/8x108 RBC) 
Pt 12 
Pt 13 
 
  531 
  819 
 
  Pt 14 
  Pt 15 
  Pt 16 
  863 
  423 
  483 
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; N, number of patients; Css, steady 
state level; UC, ulcerative colitis; TWDAI, Truelove-Witts Disease Activity Index; RBC, red blood 
cells; 6-TGN, 6-thioguanine nucleotides; Pt, patient. 
Discussion  
6-TG has been available for decades for the treatment of patients suffering 
from leukaemia, but its use was virtually abandoned by the arrival of other 
more effective regimens. Recently, the interest in 6-TG has been renewed as it 
may be an alternative for AZA or 6-MP intolerant or -resistant IBD patients. It is 
much debated whether the measurement of 6-TG derived 6-TGN, the main 
metabolites, should guide dosing11,12. That is, therapeutic drug monitoring is 
suggested in AZA or 6-MP treated patients16,17. Similar pharmacokinetic studies 
with 6-TG derived 6-TGN are scarce20 and we therefore performed such a 
study in 28 IBD patients. No distinction was made between CD and UC 
patients because we did not expect a difference in thiopurine metabolism.  
The absorption of oral 6-TG is incomplete and variable, resulting in a 
bioavailability of 14-46%21,22. Plasma 6-TG concentrations may range up to 
thirty-fold23. After six hours 6-TG becomes undetectable in plasma24,25, 
whereas it is rapidly transported into the cell in which 6-TG is immediately 
metabolised to 6-TGN.  
We found that 6-TGN concentrations showed large inter-patient variability. 
6-TGN concentrations reached steady state after four weeks, suggesting a 
half-life of approximately five days. Twenty-four hour curves showed almost 
constant 6-TGN concentrations. At steady state there was a five-fold range in 
6-TGN concentrations, which is considerable however less pronounced than 
the range in 6-TGN originating from AZA or 6-MP17. Theoretically, this was to 
be expected as 6-TGN derived from 6-TG are formed in one single step 
compared to multiple steps when originating from AZA and 6-MP. Also, 6-TG is 
138 
 Pharmacokinetics of 6-thioguanine in IBD 
less affected by TPMT and a poor substrate for xanthine oxidase (XO) when 
compared to 6-MP25 and genetic polymorphisms of these metabolizing 
enzymes are of less influence. Despite this fact, Herrlinger and colleagues 
identified one patient with TPMT heterozygosity (TPMT*1S/*3A) with bone 
marrow toxicity on 6-TG after a dose escalation from 40 to 80 mg/day in a 
cohort of 26 CD patients20. Furthermore, 6-TG caused severe and prolonged 
pancytopenia in an eight year-old boy suffering from acute lymphoblastic 
leukaemia with inherited TPMT deficiency26. In our cohort all genotyped 
subjects possessed wild type alleles, so the high variability in metabolite levels 
could not be explained by genetic polymorphisms. Unfortunately, in half 
number of patients with 6-TG intolerance TPMT genotype was not assessed 
and conclusions about the contribution of pharmacogenetics can not be drawn. 
In this study, drug dose in milligrams per kilogram bodyweight did not correlate 
with 6-TGN concentrations. In a previous study with 6-MP we were not able to 
demonstrate correlation between drug dose and 6-TGN concentrations either17.  
6-TGN concentrations were considerably higher when compared with those in 
patients receiving standard treatment with AZA (2-3 mg/kg/d) or 6-MP 
(1-2 mg/kg/d). Similar results were found by others: four to nine-fold higher 
concentrations are reported on daily doses from 10-80 mg11,12,20. Despite 
6-TGN concentrations well above the proposed therapeutic upper limit of 
approximately 500 pmol/8x108 RBC in patients using AZA or 6-MP, no 
myelotoxicity occurred in our cohort of patients, herewith confirming the results 
of a still increasing number of studies11-14. It was speculated that 6-TG derived 
6-TGN are biochemically different from 6-MP derived 6-TGN11. A more 
convincing explanation was offered by Lancaster and colleagues: despite the 
accumulation of significantly higher erythrocyte 6-TGN concentrations for 6-TG 
compared with 6-MP, the accumulation of leucocyte 6-TGN in patients taking 
6-TG was similar to the range of leucocyte 6-TGN in patients taking 6-MP27. In 
other words, when correlating intracellular 6-TGN to efficacy and myelotoxicity, 
RBC 6-TGN concentrations will be higher for patients taking 6-TG than in those 
taking 6-MP, whereas this is not the case in the putative target-tissue, the 
leukocytes.  
In addition to this explanation, 6-methylmercaptopurine ribonucleotides 
(6-MMPR), which arise from 6-MP but not from 6-TG, are believed to contribute 
to the immunosuppressive and myelotoxic effects by inhibition of de novo 
purine synthesis28. The methylated 6-TGN, the 6-methylthioguanine 
nucleotides (6-MTGN), also inhibit the first step in de novo purine synthesis 
and consequently also have cytotoxic potential20. The 6-MTGN however, were 
not assessed in present study.  
No hepatotoxicity occurred in the observed period of time. In a former study 
with patients on 6-MP treatment, hepatotoxicity correlated with 6-MMPR 
concentrations above 5700 pmol/8x108 RBC16. 6-MMPR concentrations in our 
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cohort on 6-TG treatment were undetectable as we demonstrated before in a 
short-term safety assessment12. This is an obvious finding because 6-MMPR 
are not formed when 6-TG instead of 6-MP is given (see Figure 7.1). Recently, 
Dubinsky and colleagues discouraged using 6-TG in IBD because of serious 
liver injury15,29. Disturbing high frequencies of NRH were reported in an IBD 
population treated with 6-TG. Steady state 6-TGN concentrations measured in 
Dubinsky’s population (~1250 pmol/8x108 RBC) were significantly higher than 
in our population (~850 pmol/8x108 RBC). 6-TG induced NRH may in fact be 
dependent of the reached 6-TGN concentrations. 
In one patient amylase and lipase levels temporarily increased, but no 
pancreatitis developed and levels normalised without discontinuation of 6-TG. It 
is at least questionable whether this temporary elevation of enzymes was 
caused by 6-TG, because in AZA or 6-MP treated patients is thought to be an 
idiosyncratic reaction, independent of drug dose or metabolite levels30. That is, 
dose-independent drug related side effects cannot disappear without drug 
withdrawal. 
Four patients discontinued 6-TG within the observed eight weeks, mainly due 
to the same adverse events as previously shown on AZA or 6-MP. 6-TGN 
concentrations were measured in three of four patients. In the patients with a 
probable and obvious relationship between 6-TG use and the occurrence of 
adverse events, 6-TGN levels were below the mean steady state 
concentration, herewith making a relationship between 6-TGN concentrations 
and discontinuation of 6-TG very unlikely. 
Although our study was not primarily designed to study drug efficacy, we 
compared 6-TGN concentrations in patients with active disease with those in 
patients in remission after eight weeks of 6-TG treatment. Mean 6-TGN 
concentrations in both groups did not significantly differ. Similar results were 
reported by Herrlinger and colleagues20. Besides, our data do not support the 
proposed therapeutic lower limit of 1300 pmol/8x108 RBC in IBD patients on 
6-TG treatment31. All the patients who achieved remission in the observed 
period had 6-TGN concentrations below the proposed value. These findings 
are supported by the results from another study in which lower therapeutic 
target 6-TGN levels were proposed14. 
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Conclusions 
In IBD patients on 6-TG treatment, large inter-individual differences in 
metabolite concentrations occur. In our population, we could not demonstrate a 
clear relationship between 6-TGN concentrations on one hand and toxicity and 
efficacy on the other like in AZA and 6-MP treated patients. It may be advisable 
however not to exceed 6-TGN concentrations of 1000 pmol/8x108 RBC hereby 
reducing the risk of developing NRH and veno-occlusive disease subsequently. 
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Abstract  
Introduction 
6-Mercaptopurine (6-MP) and azathioprine (AZA) have proven efficacy in the treatment of 
inflammatory bowel disease (IBD). However, adverse events leading to discontinuation may occur 
in 10-20% of patients. The efficacy of AZA and 6-MP is based on formation of their active 
metabolites, the 6-thioguanine nucleotides (6-TGN). Therefore, 6-thioguanine (6-TG), an agent 
more directly leading to formation of 6-TGN and until recently only used in patients suffering from 
leukaemia, may be an alternative in case of AZA or 6-MP intolerance.  
 
Aims 
The purpose of our study was to assess short-term safety of 6-TG. 
 
Methods 
Thirty-two IBD patients with previously established AZA or 6-MP intolerance were treated with 
6-TG as such in a dose of 20 mg (n=19) or 40 mg (n=13) once daily. Safety parameters were 
obtained at 0, 1, 2, 4 and 8 weeks after start of medication. Primary outcome measures were the 
ability to tolerate 6-TG and the occurrence of adverse events. Secondary outcome definitions 
included laboratory parameters. 
 
Results 
Twenty-six (81%) patients were able to tolerate 6-TG during the first eight weeks. In three of six 
patients, side effects leading to discontinuation were probably (n=2) or obviously (n=1) 6-TG 
related. No clinically relevant hematological events or hepatotoxicity occurred in the observed 
period. Steady state 6-TGN levels were significantly higher on 40 mg (1621±828 pmol/8x108 RBC) 
than on 20 mg once daily (937±325 pmol/8x108 RBC, p=0.001). 
 
Conclusions 
6-TG treatment seems promising in AZA or 6-MP intolerant IBD patients. However, long-term 
safety and efficacy have yet to be determined. 
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Introduction 
Thiopurine analogues 6-mercaptopurine (6-MP) and its prodrug azathioprine 
(AZA) are widely used in the second-line treatment of inflammatory bowel 
disease (IBD). These immunosuppressive agents have proven to be effective 
for both inducing and maintaining long-term remission of Crohn’s disease (CD) 
and ulcerative colitis (UC)1-3. AZA is rapidly converted to 6-MP by a non-
enzymatic reaction, which is further metabolised to the pharmacological active 
6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine 
ribonucleotides (6-MMPR). 6-TGN are purine nucleotides, which are 
incorporated into DNA, inducing cytotoxicity and immunosuppression4. In 
patients treated with 6-MP it is shown that red blood cell (RBC) 6-TGN levels 
correlated with drug efficacy and bone marrow suppression and 6-MMPR 
levels, on the other hand, correlated with hepatotoxicity5. In patients treated 
with AZA or 6-MP the lower limit therapeutic 6-TGN level has recently been 
established on 235 pmol/8x108 RBC, whereas 6-MMPR levels above 
5700 pmol/8x108 RBC were associated with hepatotoxicity6.  
A drawback of AZA and 6-MP is the occurrence of side effects. Adverse events 
leading to discontinuation may occur in approximately 10-20% of patients7-9. In 
general, adverse events may be distinguished in hypersensitivity reactions and 
dose dependent events. Hypersensitivity reactions to thiopurines or their 
metabolites occur mostly within 3-4 weeks and result in immune-mediated 
symptoms such as fever, rash, and arthralgia10,11.  
Furthermore dose-dependent, pharmacological explainable reactions 
characterised by myelosuppression, increased susceptibility to infections and 
hepatotoxicity may occur. These reactions seem to be directly associated with 
high RBC 6-TGN or 6-MMPR levels and often reveal themselves in a 
subsequent stage.  
Toxicity due to the 6-TGN metabolites may be explained by polymorphisms in 
the gene encoding thiopurine S-methyltransferase (TPMT), the enzyme that 
methylates 6-MP to 6-MMPR. In case of reduced enzyme activity toxic 6-TGN 
levels may be reached on regular doses of AZA or 6-MP12. Alternatively, some 
patients develop high 6-MMPR levels, whereas 6-TGN levels remain 
subtherapeutic. In these patients the available 6-MP is largely transformed into 
6-MMPR due to preferential metabolism through TPMT, while the enzymatic 
pathway through hypoxanthine phosphoribosyltransferase (HPRT) leading to 
the formation of 6-TGN is hardly exploited. Recently Dubinsky and colleagues 
successfully treated seven out of ten non-responding IBD patients with 
preferential 6-MMPR formation on 100 mg 6-MP with 6-TG 40 mg once daily. 
In these patients 6-MMPR levels were undetectable and no hepatic or 
haematologic toxicity was observed13. Until recently 6-TG as such only was 
used in patients suffering from lymphoblastic leukaemia.  
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Theoretically, therapy with 6-TG is a good alternative in patients with AZA and 
6-MP intolerance of any kind. The idea of using a metabolite at the end of the 
enzymatic pathway seems to be an attractive approach. In this study we 
prospectively studied 6-TG short-term safety in AZA and 6-MP intolerant IBD 
patients.  
Material and methods 
Patient selection 
Patients aged between 18 and 75 years attending the out-patient clinics of 
Maasland Hospital Sittard, University Medical Center Nijmegen or Rijnstate 
Hospital Arnhem were eligible for the study if CD or UC was diagnosed for 
more than six months and an established AZA or 6-MP intolerance was 
observed. Exclusion criteria were: pregnancy or expected pregnancy within six 
months, inadequate contraception in women, lactation, presence of active 
infection, history of tuberculosis, HIV, hepatitis B or C, severe pancreatitis 
(necrotizing pancreatitis or pancreatitis leading to multi organ failure), 
malignancy, ongoing treatment with other immunosuppressive drugs like 
ciclosporine, methotrexate, thalidomide or infliximab, impaired renal function 
(serum creatinin >2 times normal upper limit), impaired hepatic function (>2 
times normal upper limit) and persistent bone marrow suppression.  
Study design 
The trial design was a prospective open-label multicentre study. At entry 
patient demographics and anamnesis were recorded and medication-use 
during the past year was obtained from the community pharmacy. 6-TG 
(LanvisTM, tablet 40 mg, Glaxo Wellcome) was administered orally once daily in 
the evening in a dose of 20 mg (two centres) or 40 mg (one centre). 
Concomitant medication was continued. Safety parameters were obtained at 0 
(base-line), 1, 2, 4 and 8 weeks after start of medication. Blood was drawn 
each visit for measurement of RBC 6-TGN and 6-MMPR levels, alanine 
transaminase (ALT), aspartate transaminase (AST), bilirubins, amylase, lipase, 
leukocytes (plus differentiation), platelets and haemoglobin (Hb). Dose-
adjustments of 6-TG were carried out by the attending physician based on one 
or more of the parameters mentioned above.  
Ethics 
The protocol was approved by the local medical ethics committee and in 
accordance with the Helsinki Declaration. Informed written consent was 
obtained before enrolment. 
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Outcome measures 
Primary outcome measures were the ability to tolerate 6-TG and the 
occurrence of adverse events during eight weeks of 6-TG treatment. The 
relationship of the adverse event with the use of 6-TG was established by the 
following method: unrelated, no temporal relation and other aetiology likely; 
possibly related, potential temporal relation and other aetiologies possible; 
probably related, potential temporal relation and other aetiologies unlikely; 
related, clear temporal relation not otherwise explained. Secondary outcome 
definitions included RBC 6-TGN and 6-MMPR levels, the occurrence of 
haematological events (leukocyte count <4.0x109/l, platelet count <100x109/l) 
and the occurrence of hepatic toxicity (ALT>80 U/l, AST>80 U/l, bilirubins >40 
µmol/l, amylase >220 U/l, or lipase >120 U/l (elevations >2 times normal upper 
limit)).  
Analytical procedures 
Blood samples were taken at least twelve hours after medication intake. The 
samples were centrifuged to isolate erythrocytes and after washing with PBS 
buffer solution, erythrocyte counts were done. Samples were stored at –20°C 
until required. RBC 6-TGN and 6-MMPR levels were measured in the 
laboratory of the Department of Clinical Pharmacy, Maasland Hospital Sittard, 
using a slightly modified assay previously reported by Lennard and 
colleagues14. In brief, the thiopurines are separated by reversed-phase HPLC 
and quantified using UV-detection. For measurement of intracellular 
thionucleotides the free base is obtained by acid hydrolysis of the nucleotide 
back to the purine. The resulting purines are extracted from the biological 
matrix by forming a phenyl mercury adduct into dichloromethane. During back-
extraction with hydrochloric acid the adduct is splitted and the free thiopurine is 
liberated into the acid layer once again. The run-to-run coefficient of varation 
was 6.6% and 9.7% for 6-TGN and 6-MMPR respectively. The detection limit of 
the assay was 30 pmol/8x108 RBC for 6-TGN and 300 pmol/8x108 RBC for 
6-MMPR.  
Statistical analysis 
Data are expressed as means±standard deviation. Significance was evaluated 
by the Student t test for paired or independent data, p values <0.05 were 
considered significant. Pearson’s correlation was used to test the relationship 
between the measured parameters. SPSS for Windows (version 10.0.7) 
software was used to perform statistics. 
Role of the funding source 
This study was not sponsored by external sources. 
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Results 
Patients 
Thirty-two patients were enrolled, of whom seven (22%) were male and 25 
(78%) were female. The mean age at entry was 37 years (range 19-64). 
Twenty-two patients (69%) were suffering from CD and in ten patients (31%) 
UC was diagnosed. Twenty-one patients (66%) emerged AZA-intolerant, five 
(16%) could not tolerate 6-MP and six (19%) patients showed intolerance for 
both thiopurines. AZA or 6-MP intolerance was established with rechallenge in 
twelve patients (38%). The adverse events leading to discontinuation of AZA or 
6-MP included total malaise (41%), nausea and vomiting (38%), fever (25%), 
arthralgia (13%), amylase elevations (13%), epigastric pains (13%), 
pancreatitis (amylase elevations with symptoms) (9%), indefinite symptoms 
(9%), headache (6%), diarrhoea (3%), myalgia (3%), erythema nodosum (3%), 
edema (3%) and pruritus (3%). In ten patients AZA or 6-MP intolerance 
manifested itself within two weeks, in five within one month, in six within two 
months and in six after two months. In four patients time to intolerance was not 
documented. The initial dose of 6-TG was 20 mg daily in 19 patients and 
thirteen received 40 mg a day. The mean initial 6-TG dose was 0.40±0.03 
mg/kg/day. The mean 6-TG dose during the eight week period was 25.9 
mg/day (range 10-40).  
Primary outcomes 
Twenty-six (81%) of the 32 subjects were able to tolerate 6-TG 20 or 40 mg 
1dd during the first eight weeks. In six patients (19%) 6-TG was discontinued 
because of adverse effects. Data of the 6-TG intolerant patients are 
summarised in Table 8.1. 
In two patients indefinite joints pains occurred on 40 mg 1dd that resolved after 
dose-reduction to 20 mg 1dd. One patient temporary stopped after developing 
nausea on 40 mg 1dd that disappeared after restart on 20 mg 1dd. Another 
patient had a dry cough and was not feeling well on 20 mg 1dd which resolved 
after dose-reduction to 20 mg every two days.  
Secondary outcomes 
RBC 6-TGN and 6-MMPR levels 
Base-line RBC 6-TGN levels were negative in all but four patients who just 
recently stopped AZA (n=2) or 6-MP (n=2) therapy. Steady state 6-TGN levels 
were significantly higher on 40 mg 1dd (1621±828 pmol/8x108 RBC) than on 20 
mg 1dd (937±325 pmol/8x108 RBC, p=0.001) according on treatment analysis. 
RBC 6-TGN levels were considered to reach steady state after four weeks, 
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having a half life of approximately five days15. RBC 6-MMPR levels were 
undetectable at all times during treatment with 6-TG, except at base-line in the 
four patients mentioned before. Correlation was found between dose and RBC 
6-TGN level (0.70, p=0.01). The mean RBC 6-TGN level increased most during 
in the first part of the eight week period and levelled out between four and eight 
weeks (Figure 8.1). 
 
Table 8.1 Adverse events leading to discontinuation of 6-thioguanine treatment. 
No. Initial dose 
(mg) 
Final dose 
(mg) 
Time to AE 
(days) 
Character of AE Relationship AE 
with 6-TG 
1 20 20 24 nausea*, diarrhoea*,  
stomach cramps* 
probably related 
2 20 10 42 total malaise* possibly related 
3 20 20 7 fever*, erythema nodosum*, 
arthralgia* 
related 
4 20 10 7 nausea*, stomach cramps, 
headache* 
probably related 
5 20 20 35 rigid fingers probably related 
6 40 40 10 stomach symptoms possibly related 
AE, adverse events; 6-TG, 6-thioguanine; *same AE as previously shown on AZA or 6-MP 
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Figure 8.1 Mean RBC 6-TGN levels during the first eight weeks of 6-TG treatment.  
 
Haematological events 
No clinically relevant myelotoxicity occurred in the eight week period. However, 
the mean leukocyte count decreased significantly from base-line 
(11.4±3.9x109/l) to eight weeks of 6-TG treatment (10.0±4.1x109/l, p=0.008). 
Leukocyte counts were never below 4.0x109/l, no leukopenia was observed. 
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RBC 6-TGN levels showed moderate correlation with leukocyte counts (-0.29, 
p=0.01). A minor thrombocytopenia was observed in one patient (platelet 
count: 130x109/l). In this cohort of 32 patients, platelet count neither decreased 
nor correlated with RBC 6-TGN level in the observed period. In addition no 
change in Hb was established. 
Hepatotoxicity 
The ALT level was elevated >80 U/l in one patient, but this was the case at 
base-line already. The mean ALT level did increase significantly from 
19.8±19.9 U/l at base-line to 23.5±25.7 U/l at eight weeks, even though not 
clinically relevant. Amylase level was above 220 U/l (234 U/l) in one patient. 
Moderate correlation was found between RBC 6-TGN level and amylase level 
(0.30, p=0.01). No AST, bilirubins or lipase elevations were observed and 
mean levels did not change during the eight weeks. No correlation was found 
between RBC 6-TGN level on the one hand and ALT, AST, bilirubins or lipase 
for another. 
Discussion  
6-TG was well tolerated during the first eight weeks of treatment in 81% of 
patients with previously established AZA or 6-MP intolerance. In some patients 
intolerance for AZA or 6-MP manifested itself after eight weeks. Therefore, we 
must be reserved in drawing firm conclusions as the number of patients with 
adverse events on 6-TG may increase over time. Six patients (19%) were 
unable to complete the eight week period on 6-TG. The relationship of adverse 
events with 6-TG was unclear but possible in three of the six patients whose 
6-TG treatment ended prematurely. In two patients the side effects were 
probably 6-TG related. In these patients, adverse events on 6-TG were very 
similar to the previous side effects on AZA or 6-MP, suggesting a causal role 
for 6-TGN in the development of these events. Moreover, these adverse events 
resolved after discontinuation of 6-TG. In one patient the side effects were 
obviously 6-TG related, being identical and occurring at exactly the same time 
as previously shown on AZA. Also, in this patient adverse events disappeared 
with discontinuation of 6-TG. In four other patients transient side-effects 
occurred, which all dissolved after a 50% dose-reduction (three patients from 
40 mg to 20 mg daily and one patient from 20 mg to 10 mg daily).  
Mean RBC 6-TGN levels were high in comparison with 6-TGN levels measured 
in AZA or 6-MP treated patients. In the latter group we previously measured 
mean 6-TGN level of 246 and 264 pmol/8x108 RBC on AZA 100 mg 1 dd and 
6-MP 100 mg 1dd, respectively16. The mean steady state 6-TG levels after 
6-TG as such once daily (20 mg: 937 pmol/8x108 RBC; 40 mg: 1621 
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pmol/8x108 RBC) were approximately four- to seven-fold higher. This is 
consistent with the observations of Dubinsky and colleagues13. In present 
study, RBC 6-TGN levels were well above the proposed lower limit of 235 
pmol/8x108 RBC for therapy with AZA and 6-MP, which was associated with 
efficacy. However, it remains unclear whether the same level should be used 
when 6-TG is given as such. Therefore, efficacy data from prospective 
randomised trials are needed.  
RBC 6-TGN level correlated significantly with the dose given. However, major 
inter-individual differences occur as is seen with the other thiopurines17,18. 
Therapeutic drug monitoring (TDM) may be a helpful tool in dosing 6-TG. In 
this study we used TDM to control patient compliance and to prevent extremely 
high RBC 6-TGN levels (>2500 pmol/8x108 RBC). The presumed period 
necessary to reach steady state of four weeks seems reliable, as the RBC 
6-TGN concentrations levelled out somewhere between four and eight weeks 
after start of medication. In patients treated with AZA or 6-MP, myelotoxicity is 
a major concern, which seems to be associated with the RBC 6-TGN level. 
However, in the present study, despite high RBC 6-TG levels no leukopenia 
was observed in our 6-TG treated patients. Although the mean leukocyte count 
decreased from base-line (11.4x109/l) to eight weeks of 6-TG treatment 
(10.0x109/l), the clinical relevance is restricted as there still is a large margin to 
the critical lower limit of 4.0x109/l. A moderate inverse correlation of leukocyte 
count with RBC 6-TGN level was observed and because 6-TGN levels seemed 
to have reached a steady state, further leukocyte count reduction is unlikely. 
The fact that no leukopenia occurred may be explained by the absence of the 
6-MMPR metabolite, which seems to have antiprolerative properties of its 
own5,19. No 6-MMPR is formed, when a patient is given 6-TG as such. In AZA 
or 6-MP treated patients however, substantial 6-MMPR levels arise, which may 
contribute to myelotoxicity. The role of 6-MMPR needs further elucidation. In 
spite of absence of leukopenia in this cohort of patients, alertness remains 
mandatory as leukopenia is a serious complication.  
Mild thrombocytopenia occurred in one patient. This patient had a history of 
open heart surgery and was still receiving antithrombotic prophylaxis during 
6-TG treatment. Thrombocyte count normalised without 6-TG dose-reduction 
and therefore a relationship between thrombocytopenia and 6-TG treatment 
seems unlikely. 
No serious hepatotoxic events occurred in the observed period, not even in the 
five patients which showed earlier hepatic or pancreatic events (amylase- or 
ALT elevations) on AZA or 6-MP. In one patient the ALT level was elevated, 
but as this already was the case before inclusion this elevation can not be 
accounted for by 6-TG treatment. Furthermore, in this patient ALT level 
decreased with ongoing therapy with 6-TG. Although mean ALT levels builded 
up during 6-TG treatment to a value of 23.5 U/l, the increase was of no clinical 
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importance, as this is far from the standard upper limit of 40 U/l. In another 
patient the amylase level was slightly elevated which normalised after 6-TG 
dose was reduced from 40 mg to 20 mg once daily. Three patients with non-
severe pancreatitis within four weeks of AZA or 6-MP treatment, did not 
develop pancreatitis in eight weeks of 6-TG treatment. Unfortunately in only 
one of these patients a RBC 6-MMPR level was previously measured on 6-MP 
treatment and this level was substantial (4893 pmol/8x108 RBC after two weeks 
on 6-MP 50 mg once daily). This may indicate a role for 6-MMPR in the 
development of pancreatitis in this patient. Although high RBC 6-MMPR levels 
are often detected in patients developing pancreatitis, sometimes pancreatitis 
ensues despite the absence of 6-MMPR5,6. The role of 6-MMPR levels in the 
occurrence of pancreatitis is still unclear. 
Conclusions 
Treatment with 6-TG seems a promising alternative in AZA and 6-MP intolerant 
IBD patients. The results on short-term safety are encouraging for the future. 
However, long-term safety in IBD has yet to be determined as adverse events 
like veno-occlusive disease and portal hypertension are reported in 6-TG 
treatment of leukaemia. Also efficacy has to be proven before 6-TG can be 
added to standard therapy. For future trials a dose of 20 mg once daily results 
in presumably adequate RBC 6-TGN levels and seems well tolerated. The 
impact of high 6-TGN levels during a longer period of time remains unclear and 
merits further exploration for both efficacy- and safety reasons. 
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Abstract  
Introduction 
The use of 6-thioguanine (6-TG) may lead to an avoidance of toxic pathways as it is directly 
converted to the pharmacologically active metabolites (the 6-thioguanine nucleotides (6-TGN)).  
 
Aims 
The aim of our study was to determine the tolerability and safety profile of a low-dose maintenance 
therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant IBD patients over a 
treatment period of at least one year. 
 
Methods 
Database analysis. 
 
Results 
Twenty out of 95 (21%) patients discontinued 6-TG (mean dose 24.6 mg) within one year. Reasons 
for discontinuation were GI-complaints (31%), malaise (15%) and hepatotoxicity (15%). 
Haematological events occurred in three patients, one discontinued treatment. In the 6-TG tolerant 
group 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 
54% of patients, one patient had splenomegaly. 
 
Conclusions 
The majority of AZA or 6-MP intolerant IBD patients (79%) is able to tolerate maintenance 
treatment with 6-TG (dosages between 0.3 to 0.4 mg/kg/day). 6-TG may still be considered as an 
escape maintenance immunosuppressant in this difficult to treat group of patients, taking into 
account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is 
worrisome and 6-TG should therefore only be administered in prospective trials. 
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Introduction 
Until now, no definite medical or surgical therapy is available for the treatment 
of inflammatory bowel disease (IBD) as the aetiology remains essentially 
unknown. Therefore, the aims of medical therapy in IBD are to relief symptoms 
and to prevent long-term complications. Maintenance therapy should preferably 
be efficient, safe and cost-effective. The immune modulating thiopurines 
6-mercaptopurine (6-MP) and its pro-drug azathioprine (AZA) have proven 
efficacy in active IBD and in maintenance of an induced clinical remission1. 
These thiopurines are prescribed on a large scale in IBD and are considered as 
a mainstay treatment option. However, issues concerning delayed onset of 
activity, refractoriness and toxicity have limited the general use of AZA and 
6-MP. In previous reports, up to 20% of patients discontinued AZA or 6-MP 
prematurely due to adverse events2. The metabolism of thiopurines has been 
partly elucidated in recent years (Figure 9.1). The toxicity profile depends at 
least partly on the generated metabolites of AZA and 6-MP3. At first, AZA is 
converted to 6-MP by a non-enzymatic reaction, which is then converted by a 
multi-step enzymatic pathway into a number of active, inactive or toxic 
metabolites. The efficacy of AZA and 6-MP appears to be correlated with the 
formation of the 6-thioguanine nucleotides (6-TGN). During this complex 
metabolisation process possible hepatotoxic metabolites are generated under 
influence of the enzyme thiopurine methyltransferase (TPMT). The methylation 
products of 6-MP, 6-methylmercaptopurine (6-MMP) and their ribonucleotides 
(6-MMPR), may be associated with hepatotoxicity3. Furthermore, flu-like 
symptoms, rash, pancreatitis and neutropenia induced by AZA or 6-MP have 
recently been related to mutations in the inosine triphosphate pyrophosphatase 
(ITPase) gene leading to accumulation of the proposed metabolite thio-inosine 
triphosphate4. A possible strategy to avoid AZA or 6-MP induced toxicity is the 
administration of a thiopurine, which is metabolically closer to the 6-TGN. The 
thiopurine 6-thioguanine (6-TG) is an attractive candidate, which has the 
advantage of being directly converted to 6-TGN5. Therefore, treatment and 
safety outcomes might be less sensitive for intra- and inter-individual metabolic 
variations. Furthermore, due to the relative simple metabolisation, the number 
of possibly toxic metabolites is strongly reduced. Several open label studies in 
patients with IBD have shown promising efficacy and acceptable short-term 
toxicity of 6-TG6.7. More recently, the use of 6-TG has been associated with the 
induction of nodular regenerative hyperplasia of the liver (NRH). The aim of the 
present study was to determine the tolerability and safety profile of a low-dose 
maintenance therapy with 6-TG in AZA or 6-MP intolerant IBD patients over a 
treatment period of at least one year. 
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Figure 9.1 Metabolisation process of thiopurines. 
AZA is degraded to 6-MP and nitromethyl-imidazole, via a non-enzymatic step. 
Three competing enzymes metabolize 6-MP. Xanthine oxidase (XO) inactivates 
6-MP to thiouric acid (TUA). Thiopurine S-methyltransferase (TPMT) methylates 
6-MP, the formed 6-methylmercaptopurine (6-MMP) is associated with 
hepatotoxicity. By hypoxanthine phosphoribosyl transferase (HPRT) 6-MP is 
catalysed to 6-thio inosine monophosphate (6-TIMP), then via inosine 
monophosphate dehydrogenase (IMPD) to 6-thioxanthosine monophosphate 
(6-TXMP), ultimately leading to the pharmacologically active 6-thioguanine 
nucleotides (6-TGN) via the enzyme guanosine monophosphate synthetase 
(GMPS). 6-TIMP can also be methylated to 6-methyl thio inosine monophosphate 
(6-MTIMP). In a normal useless cycle 6-TIMP is phosphorylated by monophosphate 
kinase (MPK) to 6-thio inosine diphosphate (6-TIDP), subsequently by diphosphate 
kinase (DPK) to 6-thio inosine triphosphate (6-TITP) and ultimately back to 6-TIMP 
due to the inosine triphosphate pyrophosphatase (ITPase). When ITPase activity is 
impaired or lacking, 6-TITP accumulates. 6-Thioguanine (6-TG) is directly converted 
by HPRT to the 6-TGN. XO and TPMT metabolize 6-TG to 6-methyl thioguanine 
(6-MTG) and 6-thiouric acid, respectively. ITPase has no known role in the 
metabolism of 6-TG. 
Material and methods 
Patient selection 
The study is a retrospective database analysis exploring the tolerability and 
safety of 6-TG over at least a one-year treatment period in AZA or 6-MP 
intolerant IBD patients, treated in participating university and district hospitals in 
the Netherlands. In each patient, the attending physician judged the indication 
for administration of 6-TG. Some patients have been described earlier in a 
short safety assessment of 6-TG6. Patients were eligible for the study if they 
met the following in- and exclusion criteria. Inclusion criteria were: age between 
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18 and 75 years, presence of confirmed CD or UC with an indication for 
immunosuppressive therapy but in whom standard AZA or 6-MP therapy failed 
due to adverse events. Immunosuppression was indicated in case of chronic 
active disease, corticosteroid dependency or recurrent disease. Exclusion 
criteria were pregnancy, lactation, presence of active infection, history of 
tuberculosis, HIV, hepatitis B or C, history of severe pancreatitis (necrotizing 
pancreatitis or pancreatitis leading to multi-organ-failure), ongoing treatment 
with concomitant immunosuppressive drugs (e.g. cyclosporine, methotrexate, 
thalidomide or infliximab), impaired renal function (serum creatinin >2 times 
normal upper limit), impaired hepatic function (>2 times normal upper limit) and 
persistent bone marrow suppression.  
Study design 
In all patients, 6-TG (Lanvis®, tablet 40 mg, Glaxo Wellcome) was 
administered orally in a dose of 20 to 40 mg once daily based on the decision 
of the attending physician. The following data were collected: patient 
demographics, history of thiopurine exposure, type of thiopurine intolerance, 
the use of concomitant medication, blood cell counts and liver enzymes were 
recorded. Dose of 6-TG, duration of 6-TG, occurrence of adverse events, blood 
cell counts and liver enzymes were reviewed after a minimum of twelve months 
after initiation of 6-TG treatment. During the described period the genotyping of 
TPMT became available and in a subgroup of patients the TPMT status was 
determined. Red blood cell (RBC) 6-thioguanine nucleotide (6-TGN) levels 
were determined at least four weeks after giving a stable dose in order to 
obtain steady-state levels of 6-TGN. Dose adjustments were left to the 
discretion of the attending physician, but when 6-TGN levels were above 1000-
1500 pmol/8x108 RBC, dose reduction was contemplated. In case of a 
leukocyte count below 3.5x109/l, dose reduction was advocated and in case of 
severe leukopenia (below 1.0x109/l) 6-TG had to be discontinued. Additionally, 
in order to explore signs of hepatotoxicity, an abdominal ultrasonography was 
advised after at least one-year 6-TG administration. Special attention was paid 
to splenomegaly, signs of portal hypertension and hepatic changes. 
Outcome measurements 
Primary outcome measures were the ability to tolerate 6-TG and the 
occurrence of adverse events leading to discontinuation of 6-TG over the one-
year period. The relationship of any adverse event with the use of 6-TG was 
established by the following method: unrelated, no temporal relation and other 
aetiology likely; possibly related, potential temporal relation and other 
aetiologies possible; probable related, potential temporal relation and other 
aetiologies unlikely; related, clear temporal relation not otherwise explained. 
Secondary outcome measures were the occurrence of haematological events 
161 
Chapter 9 
(defined as leukocyte count <4.0x109/l or platelet count <100x109/l), the 
occurrence of hepatotoxicity (defined as a rise of at least two times the upper 
normal limit of a single liver enzyme level), pancreaticotoxicity (serum amylase 
>220 U/l) and signs of liver related abnormalities on the abdominal ultrasound. 
The following data concerning disease activity were analysed as well: 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum albumin 
and a global physician assessment score (features were same, better or 
worse). 
6-TG metabolite monitoring and genotyping of TPMT  
Blood samples for 6-TGN measurements were obtained at least four weeks 
after the onset of a stable 6-TG dose. The samples were centrifuged to isolate 
erythrocytes and after washing with PBS buffer solution, erythrocyte counts 
were done. Samples were stored at –20 °C until required. RBC 6-TGN levels 
were measured in the laboratory of the Department of Clinical Pharmacy, 
Maasland Hospital Sittard, using a proprietary modified previously published 
assay8. The lower limit of quantification of the assay was 30 pmol/8x108 RBC 
for 6-TGN levels with a run-to-run coefficient of variation of 6.6%. Extra blood 
samples were drawn once during the one-year period to assess TPMT 
(G238C, G460A and A719G, i.e. TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, 
TPMT*3C) genotypes in a sub-group of patients, independent of the 
biochemical or clinical status. The genotyping was performed at the 
Department of Gastroenterology and Hepatology at the Academic Medical 
Centre in Amsterdam.   
Statistical analysis 
Data are expressed as mean±standard deviation (SD). Significance was 
evaluated by a t test for paired or independent data; p values of less than 0.05 
were considered significant. Pearson’s correlation was used to determine 
relationships between parameters. A Χ2 test was used to determine the 
significance between the TPMT genotype and 6-TG intolerance. SPSS for 
windows version 11.0 was used for statistical analysis. 
Results 
Patients 
In ninety-five patients treatment with 6-TG was initiated in the period June 2001 
to July 2003. Fifty-eight patients (61%) were female (mean age: 40 years, 
range: 20-74) and 37 (39%) were male (mean age:47 years, range: 20-71). 
Forty-two (44%) patients were diagnosed with UC compared to 53 (56%) 
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patients with CD. All patients were intolerant to AZA, 6-MP or both. The 
adverse events leading to discontinuation of AZA or 6-MP use were 
gastrointestinal complaints, general malaise, allergic reactions, hepatotoxicity 
or myelotoxicity. The patients characteristics are given in detail in Table 9.1. 
The mean initial 6-TG dose was 24.6 mg (range 20-40 mg). The mean initial 
6-TG dose adjusted to bodyweight was 0.37 mg/kg (SD 0.16). 
 
Table 9.1 Patient characteristics. 
 N=95 patients 
Female / male 58 / 37 patients 
Age 43 years (range 20-74) 
UC : CD 42 : 53 patients 
Duration of IBD at start 6-TG 10.4 years (SD 9.4) 
AZA intolerance 78 patients (82%) 
6-MP intolerance 4 patients (4%) 
AZA and 6-MP intolerance 13 patients (14%) 
AZA or 6-MP rechallenge 36 patients (38%) 
Adverse events on AZA or 6-MP 30% = gastrointestinal complaints  
 20% = general malaise 
 14% = allergic reactions 
 10% = pancreaticotoxicity 
   6%  = hepatotoxicity 
   5%  = myelotoxicity  
 14%  = rest (e.g. myalgia or alopecia) 
6-TG dosage at the start 24.6 mg (range 20-40 mg) 
N, number of patients; UC, ulcerative colitis; CD, Crohn’s disease; IBD, inflammatory bowel 
disease; 6-TG, 6-thioguanine; AZA, azathioprine; 6-MP, 6-mercaptopurine. 
 
Primary outcomes 
Seventy-five (79%) of the 95 patients were able to tolerate 6-TG during one 
year use. In twenty (21%) patients the administration was discontinued due to 
side effects. The twenty intolerant patients (nine females and eleven males) 
encountered 26 side effects. The data concerning the adverse events leading 
to withdrawal and the relationship with 6-TG use are summarized in Table 9.2. 
No mortality was reported. The mean 6-TG dosage was 0.30 mg/kg in the 
tolerant group compared to 0.34 mg/kg in the intolerant group (NS).  
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Table 9.2 Adverse events (N=26) leading to discontinuation of 6-TG use in 20 patients. 
AE on 6-TG Frequency (%) Mean time to AE 
(days) 
Relationship with 6-TG 
G.I. complaints   8/26 (31)  43  Probably 6/8 Possibly 2/8 
Hepatotoxicity  4/26 (15)  182  Probably 2/4 Possibly 1/4 
 Unrelated 1/4 
Myelodepression   1/26 (4)  50  Related 
Pancreaticotoxicity  1/26 (4)  103  Possibly 
General malaise  4/26 (15)  51  Probably 3/4 Possibly 1/4 
Allergic reaction  1/26 (4)  1  Related 
Other AE  7/26 (27)  39  Related 1/7 Probably 2/7 
 Possibly 4/7 
AE, adverse event; 6-TG, 6-thioguanine; G.I. complaints, gastrointestinal complaints 
 
Secondary outcomes 
Haematological events 
Three patients had signs of myelosuppression. One patient had a leukocyte 
count of 3.2x109/l and a platelet count of 70x109/l after 50 days of 6-TG use 
(20 mg). Subsequently, 6-TG was discontinued. The second patient had a 
leucopenia (leucocytes 3.5x109/l) and a third patient had a thrombocytopenia 
(platelets 87x109/l) at one year measurements, both did not discontinue 6-TG. 
All other patients, both tolerant and intolerant to 6-TG, had platelet and 
leucocyte counts above the set lower limits. However, the mean platelet count 
decreased significantly from baseline (309x109/l) to one year of 6-TG treatment 
(290x109/l, p=0.033). The mean leucocyte count decreased as well (from 11.9 
to 7.8x109/l) though not significantly. The 6-TGN level did not correlate with the 
decrease in both leucocytes and platelets counts. Haemoglobin levels 
remained unchanged in both patient groups.  
Hepatotoxicity and pancreaticotoxicity 
In the 6-TG tolerant group the ASAT, ALAT, GGT and AF levels were 
determined in 65%, 71%, 60% and 68% of patients at one year 6-TG use, 
respectively. The mean levels of ASAT, ALAT, GGT and AF were 24.7 U/l 
(range 6-118), 24.5 U/l (range 5-206), 48 U/l (range 6-535) and 84 U/l (range 
42-322), respectively. A significant increase in liver enzymes during treatment 
in the tolerant group was not established. No correlation was found between 
the 6-TGN level and ALAT, ASAT, GGT or AF levels. At one year use, in 9% of 
patients (seven of 75) hepatotoxicity occurrence on 6-TG treatment could be 
classified. Four patients of the intolerant group of 20 patients discontinued 
6-TG use due to hepatotoxicity. All had normal liver tests at entry and three of 
these patients encountered allergic reactions but no hepatotoxicity on the prior 
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AZA therapy. Three patients had a serum amylase level above 220 U/l before 
the start of 6-TG that all became normal during treatment. One patient 
developed a transitory symptomatic pancreatitis with a serum amylase level of 
430 U/l during 6-TG treatment and discontinued treatment.  
Abdominal ultrasonography and liver histology 
In 51 patients (54%) an abdominal ultrasonography was performed after at 
least one year 6-TG use. Five ultrasounds (10%) were considered as 
abnormal: three patients with steatosis, one patient had a choledocholithiasis 
and the last patient had a hydrops of the gallbladder and a splenomegaly 
(spleen size 13 cm). The latter two patients were also classified as having 
hepatotoxicity on 6-TG treatment.  
Disease activity parameters 
No significant decrease in CRP (15 to 11 mg/l) or ESR level (15 to 14 mm) was 
established in the 6-TG tolerant group. The albumin level increased (37.6 to 
40.1 g/l) significantly in the tolerant group (p=0.002). A significant decrease of 
albumin level (38.5 to 36.6 g/l) was established in the intolerant group (p=0.03). 
The global physician score was determined at one year 6-TG use in 85% 
(64/75) of the tolerant patients. Forty-seven patients (73%) were classified as 
better, fifteen patients (23%) as the same and four patients (6%) as worse 
during 6-TG treatment.      
6-TG metabolite monitoring and genotyping of TPMT 
The mean steady state 6-TGN level, determined in 63% (47/75) of the tolerant 
patients, was 540 pmol/8x108 RBC (SD 245, range 0–1404). In the eight 
intolerant patients in whom metabolite levels were measured (40%), the 6-TGN 
level was 725 pmol/8x108 RBC (SD 422, range 229–1563). The difference in 
6-TGN levels between tolerant and intolerant patients was not significant. No 
statistical significant correlations were established between laboratory 
parameters (leucocytes, platelets, haemoglobin, AF, GGT, ASAT and ALAT) 
and 6-TGN level. The TPMT genotyping was performed in 51 patients (54%). 
Two patients (3.9%) had one mutant non-functional allele (TPMT*3A and 
TPMT*3C) and both patients were intolerant for 6-TG (myelodepression and 
hepatotoxicity) (significant, p=0.003). The 6-TGN level was not determined in 
both patients. Patients with two mutant non-functional alleles of TPMT 
(homozygous mutants) were not found in our population.  
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Discussion  
In this group of AZA or 6-MP intolerant IBD patients, we demonstrated that 
6-TG in dosages of 0.3 to 0.4 mg/kg daily was well tolerated over a period of 
one year as a maintenance immunosuppressant in 79% of the patients. This 
result suggests that during the metabolisation process of AZA or 6-MP 
metabolites are generated that induce side effects which at least in part are not 
generated during the 6-TG metabolism. No mortality was reported due to 6-TG 
use. When 6-TG was discontinued, the side effects leading to withdrawal 
resolved spontaneously. One patient developed a myelodepression that may 
be explained by the impaired TPMT activity, probably shunting 6-TG away from 
methylation by TPMT towards the formation of 6-TGN which have been 
associated with myelotoxicity. Unfortunately, no 6-TGN level was determined in 
this patient. The real incidence of 6-TG related histological liver abnormalities 
like NRH or veno-occlusive disease (VOD) in the present study remains 
unknown, as liver biopsies were not performed. The incidence of 6-TG related 
increase in liver enzymes probably will be lower than seven out of 75 patients, 
as two patients already had abnormal liver tests before the start of 6-TG and 
one patient had symptomatic choledocholithiasis.  
 
In the present study we found a mean 6-TGN level of 540 pmol/8x108 RBC in 
the tolerant group which is above the proposed therapeutic threshold of 250 
pmol/8x108 RBC and even higher than the proposed upper limit of efficacy (450 
pmol/8x108 RBC) under AZA or 6-MP therapy3,9. This is consistent with 
previous observations6,7. It remains to be elucidated whether the same 6-TGN 
limits should be used when 6-TG is administered. In our study 73% clinically 
benefited from 6-TG by using the global physician score and the mean albumin 
level increased significantly. However, due to the retrospective nature of the 
study, we must be reserved in drawing firm conclusions as no standard efficacy 
parameters as the Crohn’s disease activity index (CDAI) or Truelove-Witts 
index were used. Despite the fact that we have not demonstrated a significant 
relationship between 6-TGN levels, laboratory results and adverse events, we 
believe that therapeutic drug monitoring may be a helpful tool in dosing 6-TG. 
Extremely high 6-TGN levels, which have been associated with an increased 
risk of developing myelotoxicity, can be prevented and compliance can be 
monitored.   
 
The TPMT status has been associated with the ability to tolerate AZA or 6-MP. 
Patients with impaired TPMT activity are more prone to develop a 
myelodepression10. However, our study demonstrates that in AZA or 6-MP 
intolerant patients only two patients (3.9%) had one mutant TPMT allele which 
is even lower than the incidence in the normal Caucasian population11. 
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Interestingly, both patients did not develop a myelodepression on AZA therapy. 
This indicates that other metabolic pathways may lead to toxicity of AZA or 
6-MP as was recently demonstrated for the ITPase routing12. However, both 
patients with one mutant TPMT allele discontinued the use of 6-TG. 
Unfortunately, in these patients no 6-TGN concentrations were measured 
before discontinuation of 6-TG. Possibly, an impaired TPMT activity leads to 
more 6-TG being metabolised by the enzymes hypoxanthine guanine 
phosphoribosyl transferase or xanthine oxidase leading to higher 6-TGN and 
6-thiouric acid levels, respectively (Figure 9.1). The accumulation of these 
metabolites may lead to intolerance of 6-TG.   
 
Recently, the use of 6-TG in IBD patients has been associated with the 
induction of NRH and VOD13. In the present study, we performed an abdominal 
ultrasonography after at least one year 6-TG use to screen for possible 
hepatotoxicity in 51 patients. Only one patient showed signs of portal 
hypertension indicated by an enlarged spleen. NRH has been associated with 
a thrombocytopenia and in our evaluation only two patients had platelets 
counts below 100 U/l13. We are well aware of the fact that by using 
biochemistry and ultrasound outcomes, we probably underestimate the real 
incidence of 6-TG induced NRH, as the golden standard is based on histology. 
Additionally, liver tests abnormalities were shown not to be indicative for NRH. 
Conversely, it should be taken into account that AZA and 6-MP can induce 
NRH or VOD as well but performing liver biopsies during treatment with these 
compounds is not recommended in clinical practice.  
 
Currently, the use of 6-TG in IBD is abandoned due to potential 
hepatotoxicity13. However, low dose 6-TG may still be considered as an escape 
maintenance strategy in AZA or 6-MP intolerant IBD patients whom are 
refractory for alternative therapies. The number of proven effective medical 
maintenance options is scarce for these patients. Methotrexate (MTX) has a 
reasonable toxicity profile and seems effective in CD, comparable with AZA or 
6-MP but the potential use of MTX in UC patients has yet to be proven14. In 
addition, long-term use of MTX may be limited15 Cyclosporine seems to have 
no role as a maintenance immunosuppressive alternative in IBD16. Infliximab 
can be administered as a maintenance option in CD with acceptable toxicity 
and may be effective in treating UC. However, concomitant immuno-
suppressive therapy with thiopurines or MTX next to infliximab therapy seems 
mandatory to reduce the immunogenic response17. 
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Conclusions 
Treatment with 6-TG is well tolerated in AZA and 6-MP intolerant IBD patients 
and seems to be effective. We believe that low dosed 6-TG (0.3 to 0.4 mg per 
kilogram daily) maintenance therapy may still be an escape option for this 
difficult to treat group of patients. The benefit of 6-TG use in this sub-group 
may balance its toxicity profile, especially taking into account the toxicity and 
efficacy of other therapeutic alternatives. Still, the reported hepatotoxicity is 
worrisome and 6-TG should therefore only be administered in prospective 
clinical trials.  
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Abstract  
Background 
6-Thioguanine (6-TG) is used in inflammatory bowel disease (IBD) since 2001, with promising short 
term results. In 2003, liver histology of some 6-TG treated patients showed nodular regenerative 
hyperplasia (NRH). Recently, MRI revealed NRH in patients with normal histology. 
 
Aims 
Investigating the presence of NRH in longterm 6-TG treated patients. 
 
Patients and methods 
IBD patients, using 6-TG minimally 24 months, were asked to undergo liver biopsy and MRI. 
 
Results 
Fourteen patients used 6-TG minimally 24 months, thirteen participated. Mean 6-TG therapy 
duration, daily dose and 6-TGN levels were: 36 months, 18.8 mg (0.28 mg/kg) and 705 pmol/8x108 
erythrocytes respectively. Liver histology and MRI showed no NRH. 
 
Discussion 
Liver biopsy and MRI showed no NRH in these longterm 6-TG treated IBD patients. 6-TG dose and 
metabolite levels were lower compared with previous NRH reports, suggesting dose or metabolite 
level-dependent effects. Otherwise, NRH is related with IBD itself and immunosuppressives, 
including azathioprine and 6-mercaptopurine. 
 
Conclusions 
6-TG is debated due to NRH. We found no NRH in IBD patients with longterm, low dosed 6-TG, 
suggesting metabolite level-dependent effects. Therefore, 6-TG still seems useful, but in selected 
patients, intolerant for other immunosuppressives, low dosed and under close surveillance of 
metabolite levels and hepatotoxity. 
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Introduction 
Since the early nineties both azathioprine (AZA) and 6-mercaptopurine (6-MP) 
are widely used in steroid refractory or dependent inflammatory bowel disease 
(IBD)1,2. These thiopurines are metabolised by several enzymes, but thiopurine 
S-methyltransferase (TPMT) is considered as the most important3. TPMT has a 
genetic polymorphism and determines the balance between hepatotoxic 
6-methylmercaptopurine ribonucleotides (6-MMPR) and the effective, myelo-
suppressive 6-thioguanine nucleotides (6-TGN). Due to the developing 
knowledge of thiopurine metabolism, 6-thioguanine (6-TG) was introduced in 
IBD therapy in 2001, because this thiopurine is closely related to the active 6-
TGN metabolites4,5. The first results with 6-TG in AZA or 6MP intolerant IBD 
patients were promising, with good short term efficacy and safety6-12. 
In 2003, Dubinsky reported a high frequency (16%) of nodular regenerative 
hyperplasia (NRH), found in the liver biopsies of 111 IBD patients treated with 
6-TG13. Recently, Seiderer described NRH in eight of 45 (18%) 6-TG treated 
IBD patients14. Magnetic resonance imaging (MRI) was presented as an 
alternative diagnostic test, but its sensitivity (77%) and specificity (72%) were 
relatively low. Otherwise, MRI revealed NRH in some patients with normal liver 
histology. Still, liver biopsy seems most sensitive for the detection of NRH, but 
specific impregnation techniques like silver-reticulin or trichrome are required, 
as hematoxylin-eosin alone does not reveal all cases13.  
Since 2001, we started 6-TG treatment in AZA and 6-MP intolerant IBD 
patients in the Maasland Hospital Sittard, Netherlands according to a study 
protocol. Short term results were favourable with good efficacy and low 
toxicity7. No hepatotoxicity was found by regular laboratory analysis and 
ultrasonography. After the reports about NRH we decided to take biopsies in 
our 6-TG treated IBD patients to investigate hepatotoxicity. 
Methods and patients 
All IBD patients in the Maasland Hospital Sittard, Netherlands, treated with 
6-TG for at least 24 months, were informed about the risk of NRH and were 
asked to undergo an undirected, ultrasonography monitored, percutaneous 
liver biopsy. Histopathologic criteria for NRH were micronodularity without 
cirrhosis; hyperplastic hepatocytes in the centre of the nodules are surrounded 
by atrophic appearing compressed hepatocytes; hepatocytes lay in two cells 
thick plates; compressed sinusoidal space; fibrosis in the portal areas without 
septae. Red blood cell (RBC) 6-TGN metabolite levels, blood cell counts and 
liver function tests were measured as well. The protocol was approved by the 
Medical Ethical Committee. All included patients gave written informed 
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consent. After the report about patients with NRH negative liver histology, but 
NRH positive MRI we asked our patients to undergo a MRI as well14. The MRI 
was performed according to Seiderer’s protocol14. In summary, the patients 
were scanned before and after infusion of two intravenous contrast agents, 
gadolinium (0.2 mg/kg) and liver specific super paramagnetic ferrumoxide 
(1.4 ml ferocarbutran - Resovist®). 
Results 
Fourteen patients had used 6-TG for at least 24 months. These patients have 
all been described in two previous reports about a 6-TG treated IBD cohort7,12. 
Thirteen patients were included, one refused (Table 10.1). Mean age was 41 
years (SD 10.0, range 25-53). Eight patients had Crohn´s disease, five had 
ulcerative colitis. Man/female ratio was 3/10. All patients were in remission at 
inclusion. All patients had started 6-TG therapy because of intolerability for 
AZA and/or 6-MP. One patient (F) previously had a mild hepatitis due to 6-MP, 
which was recovered before starting 6-TG. Mean 6-TG therapy duration was 36 
months (SD 6.0, range 27-45). Mean daily 6-TG dose was 18.8 mg (SD 3.7, 
range 6.6-20) and 0.28 mg/kg bodyweight (SD 0.08). Mean 6-TGN levels were 
705 pmol/8x108 RBC (SD 332) at the moment of liver biopsy. All patients had 
normal liver function tests and blood cell counts. With hematoxylin-eosin and 
silver-reticulin impregnation techniques no NRH was found by two independent 
pathologists. Two patients had mild steatosis hepatis without fibrosis, assigned 
to obesity. 
 
Table 10.1 Patient characteristics. 
Patient 
 
Sex 
 
Age 
(years) 
Weight
(kg) 
IBD type 
 
6-TG use 
(months) 
6-TG daily 
dose (mg) 
6-TG dose 
(mg/kg) 
6-TGN
level 
Liver histology 
 
MRI 
 
A f 52  54 UC 41  20 0.37  1092 no NRH no NRH 
B f 38  55 CD c 44  20 0.36  106 no NRH no NRH 
C f 28  55 CD i + c 45  20 0.36  669 no NRH no NRH 
D f 30  64 CD i + c 38  20 0.31  890 mild steatosis mild steatosis 
E f 44  100 UC 38  20  0.2  336 no NRH refused 
F m 53  83 UC 38  20 0.24  1072 no NRH refused 
G f 53  60 CD i + c 41  20 0.33  986 mild steatosis mild steatosis 
H m 36  74 UC 30  20 0.27  392 no NRH no NRH 
I m 35  91 UC 30  20 0.22  225 no NRH no NRH 
J f 52  77 CD i + c 30  20 0.26  798 no NRH no NRH 
K f 25  60 CD i + pa 30  20 0.33  972 no NRH no NRH 
L f 41  54 CD c 27  18 0.33  802 no NRH no NRH 
M f 48  60 CD i 36    6.6 0.11  828 no NRH no NRH 
mean  41  68  36  18.8 0.28  705   
F, female; m, male; UC, ulcerative colitis; CD, Crohn’s disease; i, ileitis terminalis; c, colitis; pa, perianal disease; 6-TG, 
6-thioguanine; 6-TGN, 6-thioguanine nucleotide metabolites (in pmol/8x108 RBC); NRH, nodular regenerative hyperplasia of the 
liver; MRI, magnetic resonance imaging. 
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Eleven of the thirteen biopsied patients underwent the MRI protocol, two 
refused (one because of claustrophobia). No signs of NRH, portal hypertension 
or splenomegaly were found. In both patients with mild steatosis hepatis, MRI 
confirmed these findings. Patient F, with hepatitis due to 6-MP treatment, had 
no signs of drug induced hepatitis in his liver histology. Unfortunately, he 
refused MRI. 
Discussion  
What are possible explanations for the fact that no NRH was found by liver 
biopsy and MRI in these longterm treated IBD patients, in contrary to the much 
shorter treated patients of Dubinsky (median 12 months, range 1-26) and 
Seiderer (median 16 months, range 2-27)? At first, 6-TG doses used by 
Dubinsky were relatively high (above 40 mg/day, estimated on the presented 
data), resulting in approximately two times higher 6-TGN levels: median 
1230 pmol/8x108 RC (range 502-2310)13. Seiderer even used daily 6-TG doses 
up to 80 mg, but unfortunately no 6-TGN levels were reported14. Therefore it 
seems possible that 6-TG induced NRH is a dose or metabolite level-
dependent phenomenon. In our series the patients used relatively low doses 
(mean 18.8 mg daily, not exceeding 20 mg), with good efficacy, as previously 
reported7,12. No dose-finding studies have been performed for 6-TG in IBD, but 
using higher doses than 20 mg (approximately 0.2-0.3 mg/kg bodyweight) 
seems unnecessary.  
Secondly, NRH is not specifically correlated with 6-TG, but also with IBD itself 
and with several immunosuppressives like cyclosporin, corticosteroids and 
-importantly- with AZA and 6-MP15-19. All patients described by Dubinsky and 
Seiderer used AZA or 6-MP for a relatively long period, before 6-TG was 
started (median 12 months, range 0.5-96 and median 11 months, range 0.5-60, 
respectively). No liver histology before start of 6-TG therapy was reported by 
them and therefore already existing liver damage by AZA or 6-MP before start 
of 6-TG can not be excluded. All our patients had used AZA or 6-MP as well, 
but only for some weeks, because of adverse events (nausea, pancreatitis and 
hepatitis). The only patient with hepatitis in our series did not show any signs of 
NRH or drug induced liver damage in his liver histology. 
A striking point, which is often not mentioned in the discussion about the role of 
6-TG in the development of NRH, is that AZA and 6-MP are prodrugs, 
metabolised to the same 6-TGN metabolites as 6-TG. And again, in studies 
about these prodrugs lower 6-TGN levels are measured, compared to 6-TG 
treatment20,3,8. This may explain the less frequent prevalence of NRH in AZA or 
6-MP treated patients compared to the 6-TG treated patients. 
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At last, NRH is found by coincidence in autopsy studies in 2.5-5%, suggesting 
its presence in an asymptomatic background population21. 
 
On the other hand, some remarks about our study can be made. At first, the 
patient number is quite low. When taking the 16-18% prevalence in former 
studies on NRH into account, two patients were expected to have NRH in our 
group. Finding no NRH does not automatically mean that 6-TG is totally safe in 
low doses. Otherwise, in these patients with very longterm 6-TG treatment one 
would expect to find at least some minor histopathological changes in the liver.  
Secondly, a male predominance in developing hepatotoxicity or NRH in 
thiopurine treatment has been suggested13,22. Our patient group included only 
three men, which could underestimate NRH prevalence in this series 
theoretically.  
Although our findings regard a small number of patients, we find them 
important to report, because they may explain a part of the pathogenesis of 
NRH in 6-TG treated IBD patients: a 6-TG dose or metabolite level-dependent 
effect. No reports have been published yet about such a long therapy interval, 
intensive follow up and screening for NRH in 6-TG treated IBD patients. 
Conclusions 
There is much concern about the use of 6-TG in IBD due to the findings of 
NRH. This small observational study shows no hepatotoxicity by laboratory 
analysis, liver histology and MRI in longterm, low dose 6-TG treated IBD 
patients. A possible metabolite level-dependent effect is suggested. So far, the 
effects of longterm IBD treatment with AZA or 6-MP on NRH development are 
little studied, while all three thiopurines mentioned result in 6-TGN metabolites, 
which are held responsible for NRH. Therefore, studies about NRH in 6-MP or 
AZA treated patients seem important, but are still lacking. In expectation of 
these studies, we believe that 6-TG can be used, but only in selected patients, 
intolerant for all other immunosuppressives, in a low dose and under close 
surveillance of 6-TGN metabolite levels and hepatotoxity. This is in accordance 
with a recent advise given by an European 6-TG Working Party23. 
176 
 No hepatotoxicity in longterm 6-thioguanine therapy 
References 
1. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in 
the management of inflammatory bowel disease: short- and long-term toxicity. Ann 
Intern Med 1989;111:641-9. 
2. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory 
ulcerative colitis. Am J Gastroenterol 1990;85:717-22. 
3. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman 
EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine 
therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13. 
4. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, 
Vasiliauskas EA. An open-label pilot study using thioguanine as a therapeutic 
alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. 
Inflamm Bowel Dis 2001;7:181-9. 
5.  Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. 
Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug 
monitoring and clinical recommendations. Dig Liver Dis 2005;37:282-97. 
6.  Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (Or how pharmacogenomics 
can make old drugs brand new). Inflamm Bowel Dis 2001;7:190-1. 
7.  Derijks LJ, De Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, 
Mulder CJ. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-
intolerant inflammatory bowel disease patients: a short-term safety assessment. 
Eur J Gastroenterol Hepatol 2003;15:63-7. 
8.  Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: 
a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or 
azathioprine. Am J Gastroenterol 2003;98:1058-63. 
9.  Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot 
G, Metman EH, Cortot A, Colombel JF; Getaid. Tioguanine in patients with Crohn's 
disease intolerant or resistant to azathioprine/ mercaptopurine. Aliment Pharmacol 
Ther 2003;18:401-8. 
10.  Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange 
EF. Remission maintenance by tioguanine in chronic active Crohn's disease. 
Aliment Pharmacol Ther 2003;17:1459-64. 
11.  Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, 
Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF. 6-Thioguanine-
efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 
2003;17:503-8. 
12.  de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den 
Hartog G, Hooymans PM, Mäkelburg AB, Westerveld BD, Naber AH, Mulder CJ, 
de Jong DJ. On tolerability and safety of a maintenance treatment with 
6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J 
Gastroenterol 2005;11:5540-4. 
13. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin 
P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine can cause 
serious liver injury in inflammatory bowel disease patients. Gastroenterology 
2003;125:298-303. 
14.  Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna 
P, Stritesky J, Schoenberg SO, Schima W, Göke B, Ochsenkühn T. A multicenter 
assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J 
Hepatol 2005;43:303-9. 
177 
Chapter 10 
15.  Stromeyer FW, Ishak KG. Nodular transformation (nodular regenerative 
hyperplasia) of the liver. A clinicopathologic study of 30 cases. Human Pathology 
1981;12:60-71. 
16.  Naber AHJ, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: in 
important cause of portal hypertension in non-cirrhotic patients. J Hepatology 
1991;12:94-99 
17.  Zarday Z, Veith FJ. Irreversible liver damage after azathioprine. JAMA 
1972;222:690-1. 
18.  Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J. Veno-occlusive 
disease, nodular regenerative hyperplasia and hepatocellular carcinoma after 
azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol 
Hepatol 2001;13:287-90.  
19.  Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol M, Coutarel 
P, Loison P, Jian R, Marteau P. Azathioprine induced nodular regenerative 
hyperplasia in IBD patients. Gastroenterol Clin Biol 2005;29:600-3. 
20.  Tremaine WJ, Editorial: 6-TG for IBD: simple, but safe? Am J Gastroenterol 
2003;98: 950-2. 
21.  Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the 
liver: a report of 64 cases among 2500 autopsies and a new classification of 
benign hepatocellular nodules. Hepatology 1990;11:787-97. 
22.  Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC and Soloway RD. 
Azathioprine and hepatic venocclusive disease in renal transplant patients. 
Gastroenterology 1986;90:446-54. 
23.  de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, 
Ochsenkühn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger 
KR, Seiderer J, Vogelsang H, Mulder CJ; Dutch 6-TG working group. 
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a 
European 6-TG working party. Digestion 2006;73:25-31. 
 
178 
  
 
 
Section F 
 
  
 
 
 
 
General discussion, conclusions and 
clinical advice, summary 
 
 
 
 
 
 
 
 
  
179 
 
  
180 
  
 
 
Chapter 11 
 
 
 
 
 
 
General discussion 
 
 
 
 
 
 
 
181 
 
Chapter 11 
182 
 General discussion 
General discussion 
Inflammatory bowel diseases (IBD) include Crohn’s disease (CD), ulcerative 
colitis (UC) and indeterminate colitis. Until now, it is still not clear why and how 
someone gets IBD. Many contributing factors have been revealed: genetic, 
environmental, nutritional, smoking and medication1. However, the trigger 
which starts IBD is still not known. Due to an unknown agent or process, a pro-
inflammatory cascade is set up, leading to bowel inflammation differing from 
mild local mucositis to deep penetrating or even perforating ulcerations. 
Crohn’s disease can manifest from mouth to anus, while ulcerative colitis is 
limited to the colon. Several extra-intestinal organs can be involved: eyes, liver, 
joints and skin. These great inter-individual differences in disease phenotype 
make IBD difficult to study in clinical research, but also fascinating.  
Because of the lacking identification of a causative agent, it has been very 
difficult to develop a targeting treatment for IBD. Recently, biologicals such as 
infliximab, adalimumab and certolizumab have been developed. These 
antibodies against a specific cytokine in the inflammatory cascade, tumor 
necrosis factor alfa (TNFα), show good short term efficacy and safety2,3. 
However, they are expensive and their long term safety profiles are not known 
yet. Therefore traditional medications like mesalamines, corticosteroids and 
thiopurines (azathioprine and 6-mercaptopurine) are still very important in daily 
practice. 
In thiopurine therapy new strategies, such as therapeutic drug monitoring 
(TDM) and genotyping or measurement of activity of crucial enzymes, were 
developed in last decades to improve efficacy and safety, as discussed in the 
review about thiopurines in Chapter 1. TDM includes measurement of 
thiopurine metabolite levels with the purpose of improving safety and efficacy of 
thiopurine therapy. From 1996 on, several reports have suggested a correlation 
between metabolite levels and efficacy and/or toxicity of thiopurine therapy4-8. 
In all studies no correlation is found between thiopurine dose and metabolite 
levels or disease activity. This contrasts with the fact that until now most 
gastroenterologists dose thiopurine therapy on patient bodyweight: 2-3 mg/kg 
for azathioprine (AZA) and 1.0-1.5 mg/kg for 6-mercaptopurine (6-MP)9. This 
thesis presents several aspects of TDM in thiopurine therapy of IBD patients 
and explores the clinical usefulness of TDM in daily practice. 
Thiopurine metabolism 
Pharmacokinetics 
Thiopurine metabolite levels have large inter-individual variations, due to 
enzyme polymorphisms4-8. Thiopurine S-methyltransferase (TPMT) is the most 
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important enzyme influencing the balance between immunosuppressive 
6-thioguanine nucleotides (6-TGN) levels and hepatotoxic 6-mercaptopurine 
ribonucleotides (6-MMPR), in favour of the latter metabolites (Figure 
11.1)4,13-15. This enzyme has a trimodal genetic variation, determining its 
activity. In Chapter 2, 3 and 5 of this thesis this finding is confirmed10-12. 6-TGN 
metabolites have a 7 fold range and 6-MMPR metabolites a 16 fold range. In a 
prospective study described in Chapter 2, a half life of 6-TGN and 6-MMPR 
metabolites of five days is demonstrated: metabolite concentrations reach a 
steady state after 25-30 days10. This means that metabolite concentrations are 
stable during the day, suggesting that it makes no difference at what time of the 
day TDM is performed after ingestion of a thiopurine during steady state 
maintenance therapy. In case of 6-thioguanine therapy this is also shown by 
measuring 6-TGN curves during the day in Chapter 716. The relatively long half 
life of thiopurine metabolites may also be the reason why thiopurines are only 
effective after several weeks of treatment: it takes one month to have steady 
state metabolite levels. With an intravenous loading dose, higher 6-TGN levels 
are found after one week of thiopurine therapy, but steady state doses are 
reached at the same moment as in patients with only oral thiopurine 
treatment17. Hence, thiopurines are not suitable for acute therapy of IBD (in 
contrast to corticosteroids).  
Pharmacodynamics 
Until recently thiopurines were believed to be effective due to the incorporation 
of 6-TGN metabolites into DNA of leucocytes. These metabolites inhibit cell 
proliferation due to a structural similarity to the endogenous purine-base 
guanine as demonstrated in Figure 11.3 of Chapter 1. More recently, new 
details in the mechanism of action of thiopurines have been discovered. AZA 
and its metabolites were found to be responsible for T cell apoptosis by 
modulation of Rac1 activation upon CD28 costimulation18. Rac1, a small 
GTPase that plays a role in inhibiting T cell apoptosis, is a target for 
6-thioguanine triphosphate (6-thio-GTP), a metabolite of thiopurines, which is 
one of the measured nucleotides of the 6-TGN level (see Figure 11.1). 6-Thio-
GTP binds to Rac1 in stead of GTP, thereby suppressing the activation of Rac1 
target genes like mitogen activated protein kinase MEK, NF-κB and bcl-xL, 
leading to apoptosis. CD28 is a transmembrane protein which plays a role in 
the anti-apoptotic signaling pathway as well. T-cell apoptosis by 6-thio-GTP is 
increased upon co-stimulation of Rac1 by CD28. It was demonstrated that 
especially specific T memory lymphocytes (CD45RO), which are the main 
effector cells in IBD, become apoptotic. These recent findings suggest a new 
molecular mechanism of action of AZA. In future, 6-thio-GTP derivatives with 
more affinity for Rac1 may be designed, leading to stronger and more specific 
immunosuppressive effects. 
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In 2004, a correlation between 6-TGN metabolite levels and decreased 
interferon gamma (IFNγ) production was found in azathioprine treated Crohn’s 
disease patients19. IFNγ is a mediator of intestinal inflammation, which has an 
inhibitory effect on interleukine-10 (IL-10), which is a down-regulator of 
inflammation.  
Additionally, 6-MMPR metabolites may have some myelosuppressive effects 
as well, as demonstrated in the fifth case presented in Chapter 311,20. This case 
has been described more extensively in a recently published case-report, 
showing that extremely high 6-MMPR metabolite levels (57000 pmol/8x108 
RBC) may cause pancytopenia21. 
 
 
 
 
Figure 11.1 Proposed thiopurine metabolism. 
  AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-TUA, 6-thiouric acid; 6-MMP, 
6-methylmercaptopurine; 6-TIMP, 6-thioinosine-5’-monophosphate; 6-MMPR level, 
6-methylmercaptopurine ribonucleotides; 6-TITP, 6-thioinosine triphosphate; 
6-TIDP, 6-thioinosine diphosphate; 6-TG, 6-thioguanine; 6-TGN level, 6-thioguanine 
nucleotides; 6-MTG, 6-methyl thioguanine; HPRT, hypoxanthine phosphoribosyl-
transferase; XO, xanthine oxidase; ITPA, inosine triphosphate pyrophospho-
hydrolase; MPK, monophosphokinase; DPK, diphosphokinase; TPMT, thiopurine 
S-methyltransferase; IMPDH, inosine monophosphate dehydrogenase; GMPS, 
guanosine monophosphatase synthetase. 
 
6-MTIMP, 6-MTIDP and 6MTITP together form the 6-methylmercaptopurine 
ribonucleotides (6-MMPR). 6-TGMP, 6-TGDP and 6-TGTP together form the 
6-thioguanine nucleotides (6-TGN). In therapeutic drug monitoring, 6-MMPR levels 
consist of the sum of 6-MMP, 6-MTIMP, 6-MTIDP and 6-MTITP levels, while 6-TGN 
levels consist of the sum of 6-TGMP, 6-TGDP, 6-TGTP (if AZA or 6-MP is 
administered) and 6-TG levels (if 6-TG is administered as such). 
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Therapeutic and toxic ranges of thiopurine metabolites 
a) Azathioprine and 6-mercaptopurine therapy 
Therapeutic and toxic ranges of thiopurine metabolite concentrations have 
been described in the past: therapeutic 6-TGN metabolites should be between 
235 and 500 pmol/8x108 red blood cells (RBC)4-8. In case of 6-TGN levels 
above 500 pmol/8x108 RBC the risk for leukocytopenia is increased5-9. 
6-MMPR levels higher than 5700 pmol/8x108 RBC are correlated with 
hepatotoxicity4-5. Pancreatitis is not associated with metabolite levels and 
seems an idiosyncratic reaction1,5,10,22. 6-MMPR/6-TGN ratio should be below 
1123. In case of a ratio above 11, the balance between toxic 6-MMPR and 
therapeutic 6-TGN levels is unfavourable. Dose increment will lead to relatively 
more 6-MMPR metabolites in this situation, increasing the risk for 
hepatotoxicity. In case of a 6-MMPR/6-TGN ratio above 11 and ineffective 
thiopurine therapy, other immunomodulating therapy should be considered23. 
Only recently, it has been shown that thiopurine dose decrease in combination 
with allopurinol 100 mg would improve 6-MMPR/6-TGN ratio24. Some remarks 
should be made about the studies proposing these therapeutic and toxic 
thresholds: the first studies were performed in paediatric populations, often with 
small patient numbers, were descriptive and sometimes retrospective. Other 
studies, some of which were performed in adults, found contradictory 
results25-29. A recent meta-analysis of six studies on TDM of thiopurines 
confirmed this therapeutic 6-TGN threshold of 235 pmol/8x108 RBC30. The 
therapeutic and toxic thresholds have also been studied in this thesis. In 
Chapter 2 the therapeutic 6-TGN threshold is confirmed: 83% of the patients 
with initially active IBD and remission after eight weeks of 6-MP treatment had 
6-TGN levels above the proposed therapeutic threshold level of 
235 pmol/8x108 RBC. Inversely, 75% of the patients without clinical 
improvement of IBD activity after eight weeks of 6-MP treatment had 6-TGN 
levels below 235 pmol/8x108 RBC. The toxic 6-TGN threshold was also 
confirmed: all four patients who developed leukopenia had 6-TGN levels above 
500 pmol/8x108 RBC10. Moreover, these patients had 6-TGN levels higher than 
300 pmol/8x108 RBC after one week of 6-MP therapy. This could be a useful 
predictive factor when starting thiopurine therapy. In this study, 6-MMPR levels 
above the toxic threshold of 5700 pmol/8x108 RBC did not correlate with 
hepatotoxicity. A prospective study, presented in Chapter 5, comparing 6-TGN 
levels between IBD patients with exacerbations versus remissions, found that 
the relation between disease activity and 6-TGN levels seems to be less 
clear12. Although the proposed 6-TGN threshold level of 235 pmol/8x108 RBC 
is confirmed in an adult IBD population in several analyses in our study, it has a 
low sensitivity (71%) and specificity (73%), positive and negative predictive 
values (67 and 73%) and accuracy (69%). This is in accordance with earlier 
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mentioned studies showing no clear correlation between disease activity and 6-
TGN levels25-29. 
Although Chapter 5 describes a poor correlation between 6-TGN levels and 
disease activity, a significant difference in reaching the therapeutic 6-TGN 
threshold is found: 59% of remissions and 37% exacerbations had sufficient 
6-TGN levels above 235 pmol/8x108 RBC, with an OR of 3.7 for having an 
exacerbation in case of 6-TGN levels below 235 pmol/8x108 RBC12. Similar 
results were found in the earlier mentioned meta-analysis: 62% of the patients 
with 6-TGN levels above 230-260 pmol/8x108 RBC were in remission versus 
36% remissions in case of 6-TGN levels lower than 230 pmol/8x108 RBC with 
an OR of 3.3 for having 6-TGN levels higher than 230-260 pmol/8x108 RBC in 
case of clinical remission30. Chapter 5 is in fact the fifth study, demonstrating a 
threshold of 230-260 pmol/8x108 RBC, however with a relatively low sensitivity 
and specificity. Another important result of this chapter is the high prevalence 
of non-compliance which is revealed by TDM. Therefore, the conclusion of the 
chapter is that TDM may be useful in a clinical setting, in case of thiopurine 
refractory IBD, mostly to reveal non-compliance and secondly to identify 
underdosing and unfavourable metabolite profiles, although with low sensitivity 
and specificity. Chapter 3 demonstrates in some individual cases, 
demonstrating the potential usefulness of TDM in daily practice11. 
One of the critical remarks on the mentioned meta-analysis should be the 
exclusion of several studies, including our study mentioned in Chapter 2, 
although all inclusion criteria are met (data on 6-TGN levels, patients treated 
with AZA or 6-MP, disease activity measured, published before November 
2004, written in English)10,30. Nevertheless, our study would have strengthened 
the conclusion of this meta-analysis, as would have the results presented in 
Chapter 5. 
Recently, a prospective study on 6-TGN metabolites in AZA treated IBD 
patients found no difference in reaching clinical remission between patients 
dosed and followed in a conventional way (AZA dose 2.5 mg/kg and follow up 
by blood counts and liver function test) compared to patients with dose 
adjustments by TDM31. Only, the patient number of this study seems to be too 
small (N=57). We calculated in a power analysis that at least 74 patients would 
be needed tot find a significant difference in 6-TGN metabolite concentrations 
between exacerbations and remissions, as shown in Chapter 512. 
Nevertheless, the discussion about the value of TDM in optimising efficacy and 
safety of thiopurine therapy is not closed yet, with several studies pro and 
contra TDM. In fact, a prospective study on TDM versus conservative follow up 
(blood cell counts, liver test and amylase or lipase testing) of thiopurine therapy 
should be performed. This study should be prospective, randomised, 
examining efficacy, failures of treatment and toxicity at several time points, with 
dose adjustments based on TDM. However, such an interventional study 
187 
Chapter 11 
should include more than 250 patients in both groups to find significant results, 
based on the known prevalence of leukopenia (2-5%), hepatotoxicity (10-15%) 
and other adverse events. This study would also take years and would 
probably demand a (multi)national approach. 
b) 6-Thioguanine therapy 
For 6-thioguanine (6-TG) therapy no therapeutic threshold levels have been 
defined yet, although the original pilot-study in only ten patients suggested a 
threshold therapeutic 6-TGN level of 1400 pmol/8x108 RBC32. No clear 
association between 6-TGN levels and disease activity has been found in other 
reports33,34. Strikingly, 6-TGN levels are four to seven-fold higher than with AZA 
or 6-MP therapy in all reports and leukopenia seems to be related with higher 
6-TGN levels as well30,33. The results presented in Chapters 7-9 of this thesis 
are similar16,35,36. One explanation might be the fact that no 6-MMPR 
metabolites are formed in case of 6-TG therapy, as 6-MMPR metabolites may 
have some myelosuppressive effect as well11,19,20. Thus, the myelosuppressive 
effect of 6-TGN metabolites starts at higher concentrations in case of a lack of 
6-MMPR metabolites. Accordingly, Chapter 7 shows no correlation between 
6-TGN levels and 6-TG dose or between 6-TGN levels and disease activity16. A 
five-fold range of 6-TGN levels is found. In Chapter 8 a correlation between 
6-TG dose and 6-TGN levels is suggested in a short term study of 8 weeks16. 
Mean 6-TGN levels are 937 pmol/8x108 RBC in case of 20 mg 6-TG daily and 
1621 pmol/8x108 RBC in case of 40 mg daily. The risk of hepatotoxicity of 6-TG 
therapy seems to increase when 6-TGN concentrations are higher than 1000 
pmol/8x108 RBC: nodular regenerative hyperplasia (NRH) of the liver is 
demonstrated in reports describing patients with mean 6-TGN levels above this 
threshold37. Chapter 10 suggests that lower 6-TGN levels may decrease the 
risk of developing NRH during 6-TG therapy38. It is the first long term study 
examining hepatotoxicity during 6-TG treatment. The toxicity of 6-TG is 
discussed in the last part of this chapter. 
Important enzymes in thiopurine therapy 
The most important enzyme in thiopurine metabolism seems to be TPMT. 
TPMT has a trimodal variation in genetics. Ninety percent of Caucasians have 
a wildtype TPMTH/H genotype with high activity, 10% have one mutant allele 
with decreased activity (TPMTH/L) and 0.3% of patients have homozygous 
mutant TPMTL/L, with no activity. Wildtype TPMT alleles are *1 and *1S, mutant 
alleles are *2, *3A, *3B, *3C, *3D, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, 
*15, *16, *17, *18, responsible for TPMT deficiency39,40. TPMT deficiency is 
correlated with higher 6-TGN concentrations and leukopenia. In the study of 
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Chapter 2 the prevalence of TPMTH/H,TPMTH/L and TPMTL/L genotypes was 
80%, 16% and 4% respectively, but patient numbers were relatively small (25 
patients of 30 included patients were genotyped)10. Importantly, patients with 
one or two mutant TPMT alleles had a twelve times higher risk of developing 
leukopenia, which stresses the usefulness of TPMT genotyping before starting 
thiopurine therapy. In fact it was a poor chance to find one patient with 
homozygous deficient TPMT in this relatively small group of patients. In 
Chapter 5 TPMT activity measurements in 100 patients show normal to high 
activity in 98% and low activity in only 2%: relatively few patients with deficient 
TPMT activity were found12. The included patients had used a thiopurine for at 
least three months, thus excluding patients with early toxicity, such as 
leukopenia, which is theoretically caused by high 6-TGN levels in case of 
deficient TPMT activity. In fact there was some selection bias in this study, 
because of possible deletion of TPMT deficient patients. TPMT activity was 
inversely correlated with 6-TGN levels (r= -0.318, p= 0.01) and the two patients 
with low TPMT activity had high 6-TGN levels and relatively low 6-MMPR 
levels, as expected.  
TPMT genotyping is useful when performed before starting thiopurine 
therapy41-48. Genotyping may help to reveal patients with low or no activity 
(10% and 0.3% respectively), which is also shown in Chapters 2 and 310,11. In 
case of low TPMT activity dose reduction should be performed from the start of 
thiopurine therapy or alternative immunomodulating therapy should be 
chosen46-50. TPMT genotyping or determining TPMT activity in a retrospective 
way seems not useful, as all patients with early toxicity have already 
discontinued thiopurine therapy then. This is also shown in Chapter 5: only two 
patients (2%) have low TPMT activity (instead of expected 10%), with high 
6-TGN levels as expected, but without any signs of myelotoxicity12. However, it 
should be mentioned that leukopenia is not exclusively caused by mutant 
TPMT alleles: in only 27% of leukopenic patients treated with a thiopurine, 
TPMT deficiency is found, as shown in two studies48,49. A relation between 
extremely high 6-MMPR levels and and leukopenia has been demonstrated in 
case 5 in Chapter 311. No other mechanism is known yet. 
Inosine triphosphate pyrophosphohydrolase (ITPase) has recently been 
discovered as another important enzyme in the thiopurine pathway. Decreased 
ITPase activity is correlated with flu-like symptoms, rash, leucopenia and 
pancreatitis due to accumulation of 6-TITP42,51. ITPase has no influence on 
6-TGN or 6-MMPR levels. In the research performed for this thesis, ITPase 
was only measured in the study described in Chapter 5 (results not published). 
In a steady state thiopurine treated cohort of IBD patients no clinical relevance 
was found for determining the activity of this enzyme. As expected no 
correlation with 6-TGN or 6-MMPR was found. 
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All other enzymes noted in Figure 11.1 are theoretically important, but clinical 
relevancy is unclear yet and therefore these enzymes were not studied in this 
thesis. However, XO inhibition by allopurinol leads to severe myelotoxicity. 
Therefore thiopurine dose should be decreased with 25-33% when used in 
combination with allopurinol52. In two recent studies from the same group the 
usefulness of allopurinol in case of non-responders to AZA or 6-MP therapy 
with unfavourably high 6-MMPR and low 6-TGN levels has been 
demonstrated24,53. After thiopurine dose reduction to 25-50% of original dose 
and introduction of 100 mg allopurinol 6-TGN levels increased from 199 to 400 
pmol/8x108 RBC and 6-MMPR levels decreased from 10605 to 2001 
pmol/8x108 RBC, with improving disease scores24. Due to an unknown 
mechanism the unfavourable 6-MMPR/6-TGN ratio is improved by introducing 
allopurinol in these patients.  
In theory, extremely high XO activity may lead to undetectable 6-MMPR and 
6-TGN metabolite levels. This can theoretically serve as an alternative 
explanation for undetectable metabolite levels, such as described in Chapter 4 
and 5, instead of non-compliance. Recently a case report has been published 
demonstrating this theoretical concept54. In a thiopurine treated patient zero 
metabolite levels were measured even when medication was taken under 
supervision. After introduction of allopurinol high 6-TGN and 6-MMPR levels 
were measured (1163 and 10015 pmol/8x108 RBC respectively, after two 
weeks of treatment). 
Non-compliance and TDM 
Inter-individual differences in metabolism could be a reason for performing 
TDM.  Another reason may be the detection of non-compliance. It is well known 
that a relatively high prevalence of non-compliance is found in chronic diseases 
in general, especially in asymptomatic conditions55. It has been demonstrated 
in IBD patients, that non-adherence can exceed 60% in treatment with 
sulphasalazine, mesalazine and azathioprine56-62. Nevertheless, when an 
individual IBD patient is presenting with an exacerbation during thiopurine 
treatment, very often an alternative immuno-modulator is chosen instead of 
excluding non-compliance or under-dosing. In Chapter 4 a non-compliance rate 
of 40% is described in a cohort of steady state azathioprine treated IBD 
patients in remission, in an outpatient clinic setting63. Patient numbers were 
however small (N=15). Chapter 5 shows a non-compliance rate of 12% in 
exacerbations and 19% in remissions (16% overall) in a larger study of 100 
AZA or 6-MP treated adult IBD patients12. This means that almost one out of 
eight patients with an exacerbation of IBD during thiopurine therapy is not 
compliant! Both studies demonstrate one of the main indications for performing 
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TDM in thiopurine treated IBD patients: non-compliance appears to be very 
common and TDM is the only way to reveal this. Non-compliance has only 
been reported incidentally in earlier reports about TDM, but it is not clear 
whether patients with zero metabolite levels were in- or excluded for analysis in 
these reports4-6,25,26. Otherwise, one could discuss if very low or even 
unmeasurable metabolite levels are always caused by non-compliance. In 
theory, malabsorption due to severe inflammation of the gut, or still unknown 
abnormalities in enzyme activity (such as very high XO activity, as discussed 
earlier) could be alternative explanations54. However, in these cases TDM 
seems useful as well as it reveals low metabolite levels. 
Interactions and TDM 
As demonstrated in Figure 11.1 many enzymes play a role in thiopurine 
metabolism. In theory, enzymes can be inhibited or stimulated by several 
causes such as (metabolites of) drugs. TPMT seems the most important 
enzyme in thiopurine metabolism because it interferes in several steps of the 
metabolic pathway. Therefore this enzyme is best studied. In vitro studies have 
demonstrated that 5-aminosalicylic acid (5-ASA) compounds (i.e. mesalazine, 
balsalazide, olsalazine and sulphasalazine) are potent TPMT inhibitors64-66. 
In vivo, 6-TGN concentrations are significantly higher when thiopurines are 
combined with 5-ASA. Consequently, a higher frequency of leukopenia is 
observed in patients using this combination64-67. The observed higher 6-TGN 
levels can not solely be explained by TPMT inhibition. Other, yet unknown 
interaction mechanisms may exist68. 
In Chapter 6 the third in vivo study on effects of 5-ASA on thiopurine 
metabolite levels is described69. A significant 20% decrease of 6-TGN levels 
from 262 pmol/8x108 RBC (CI95% 212-312) at baseline to 209 pmol/8x108 
RBC (CI95% 170-247) has been noted when 5-ASA has been discontinued for 
four weeks. The effect on clinical outcomes has not been studied yet, neither 
in this study. Unexpectedly, no significant change of TPMT activity was found 
during or without the combination of thiopurine therapy and 5-ASA. 
Nevertheless, this is in accordance with previous studies67,68. Possibly the 
analytical procedure of TPMT activity measurement itself is the explanation 
herefore: during preparation of the erythrocyte lysates all metabolites are 
washed out. It is unknown whether 5-ASA metabolites are washed out as well 
or whether 5-ASA metabolites irreversibly inhibit TPMT. If these metabolites 
are removed during TPMT analysis this might lead to normalisation of 
inhibition of TPMT activity. Alternatively, other and even still unknown 
enzymes of the thiopurine metabolism could be influenced by 5-ASA as well. 
191 
Chapter 11 
Other frequently prescribed TPMT inhibitors include acetylsalicylic acid, 
angiotensin I converting enzyme inhibitors and diuretics (eg. furosemide, 
bendroflumethiazide and trichlorthiazide)70,71. These have not been extensively 
studied and were not examined in this thesis. 
Allopurinol potently inhibits XO. When combining, a thiopurine dose-reduction 
to 25-50% of standard daily dosages is recommended24,52,53. Mycophenolate 
inhibits IMPD, theoretically reducing the conversion of 6-TIMP to 6-TXMP and 
consequently 6-TGN72. These two enzymes were not studied in this thesis. 
New therapeutic options in IBD due to the knowledge of 
thiopurine metabolism: 6-thioguanine 
Thiopurines are well-known medications, existing for more than four decades. 
Originally, 6-MP was used in maintenance treatment of acute lymphoblastic 
leukaemia in children73. AZA was one of the first medications applied in 
immunosuppressive prophylaxis of acute rejection in organ transplantation74. 
Thirty years ago, the indication of thiopurine treatment was extended to other 
immune disorders and inflammatory bowel diseases.  However, until 1990 
there was ample debate about efficacy of AZA and 6-MP treatment in IBD 
patients. Only few centres used this medication then75. The interest in 
thiopurine treatment in IBD began to grow around 1990 after publications 
about successful treatment of approximately 500 patients with ulcerative colitis 
by Present and Adler respectively76,77. Nowadays, thiopurines are widely used 
in IBD therapy.  
Since 2000 a third thiopurine, 6-thioguanine (6-TG), has become of interest in 
IBD treatment, due to the increasing knowledge about thiopurine metabolism. It 
had already been used in therapy of childhood lymphoblastic leukaemia for 
several decades73,78. When studying the metabolism of thiopurines, as 
illustrated in Figure 11.1, it is understandable why 6-TG is a potential candidate 
in IBD therapy, especially in case of AZA or 6-MP intolerance. 6-TG is closer to 
the effective 6-TGN metabolites than AZA or 6-MP. By treating with 6-TG, 
several enzymatic pathways are excluded, decreasing the amount of many 
-potentially toxic- metabolites and diminishing the effect of mutant alleles or 
co-medication on enzyme activity. The first report on short term 6-TG therapy 
in paediatric IBD patients was very promising32. The second report on his 
subject was the study presented in Chapter 8, also demonstrating good short 
term tolerability and safety in 81% of AZA and/or 6-MP intolerant IBD patients, 
without any myelo- or hepatotoxicity35. This study shows that 6-TG may be 
considered as a safe alternative in case of intolerancy for other 
myelomodulators. 
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A second, longer term study on tolerability of 6-TG in AZA and/or 6-MP 
intolerant IBD patients is presented in Chapter 936. In this retrospective, 
multicentre study, 6-TGN metabolite levels, laboratory and disease activity 
parameters and ultrasonography of the liver are described. Mean 6-TG dose 
was 24.6 mg daily, which is lower than other studies (at least 40 mg and even 
up to 80 mg daily)37,79. Tolerability was 79% for one year of 6-TG treatment in 
95 patients. Reasons for discontinuation (N=20) were GI-complaints (31%), 
malaise (15%), hepatotoxicity (15%), myelodepression (4%), pancreatitis (4%), 
allergic reactions (4%) and others (27%). Haematological events occurred in 
three patients, one discontinued treatment. In the 6-TG tolerant group 9% 
(7/75) had elevated liver tests, but two patients had these on beforehand and 
one had symptomatic choledocholithiasis. An abdominal ultrasound was 
performed in 54% of patients: one patient had splenomegaly, no other signs of 
portal hypertension were found. Liver histology was not examined. This study 
shows that the majority of AZA or 6-MP intolerant IBD patients (79%) is able to 
tolerate maintenance treatment with 6-TG (dosages between 0.3 to 0.4 
mg/kg/day). 6-TG may be considered as an escape maintenance 
immunosuppressant in this group of patients, that is difficult to treat.  
One of the limitations of 6-TG is that no adequate dose finding studies have 
been performed until now. The short term study in Chapter 8 shows that a 
6-TG dose of 20 mg daily is equally effective compared to 40 mg daily35. 
Strikingly, 20 mg 6-TG gives rise to very high 6-TGN levels of 937 pmol/8x108 
RBC, which is four to seven-fold higher than on AZA 100 mg and 6-MP 50 
mg10,80. On 40 mg 6-TG, 6-TGN levels are even higher: 1621 pmol/8x108 
RBC11. Surprisingly, no myelotoxicity has been found despite these high 6-TGN 
levels. This has already been discussed earlier in this chapter. So far, TDM 
seems not very useful in case of 6-TG therapy, as no therapeutic or toxic 
threshold levels have been described yet. Prospective studies on this subject 
might be lacking in the future, because of the recently reported toxicity of 6-TG. 
It seems, however, that 6-TGN levels below 800 pmol/8x108 RBC are effective 
and that hepatotoxicity is related with levels higher than 1000 pmol/8x108 RBC, 
as described in Chapters 8, 9 and 1035,36,38. 
 
In recent years, reports have been published about nodular regenerative 
hyperplasia (NRH) of the liver, veno-occlusive disease and non-cirrhotic portal 
hypertension during 6-TG therapy in IBD patients. In 2003, ultrasonography 
guided liver histology showed NRH in up to 16% of 6-TG treated IBD patients, 
even without biochemical signs of hepatotoxicity37. Later, a report on a special 
magnetic resonance imaging (MRI) technique with two contrast agents 
(gadolinium and ferrocarbutran) showed that some patients with normal liver 
histology, had signs of NRH on MRI79. This latter study demonstrated the 
complementary findings of both diagnostics in the search for NRH. In fact, NRH 
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or veno-occlusive disease in combination with 6-TG is not new, as it has been 
described in 6-TG treated children with leukaemia81,82. 
 
In Chapter 10 the results of the search for hepatotoxicity and mainly NRH are 
described in an IBD cohort from a general district hospital, using 6-TG for a 
long term38. Thirteen of fourteen patients using 6-TG for at least 24 months 
volunteered to undergo blood analysis for liver chemistry, ultrasonography 
guided liver biopsy and MRI. Mean 6-TG therapy duration was 36 months, 
mean daily 6-TG dose was 18.8 mg (0.28 mg/kg) and mean 6-TGN levels were 
705 pmol/8x108 RBC. No signs of hepatotoxicity or portal hypertension were 
found by biochemical analysis and ultrasonography of the liver and spleen. 
Liver histology and MRI showed no NRH. This study is the first to describe 
such long term 6-TG treated IBD patients, examined according to a uniform 
protocol.  6-TG dose and metabolite levels were lower compared to previous 
NRH reports: 6-TG dose of 20 mg (0.2-0.3 mg/kg) with 6-TGN levels of 705 
pmol/8x108 RBC versus 6-TG dose of 40-80 mg and 6-TGN levels of 1230 
pmol/8x108 RBC in previous reports37,38,79. This suggests a yet unknown 
metabolite level or dose dependent effect on the development of NRH. 
Some remarks should be made about NRH. NRH is found in combination with 
many diseases and medications, as described in case reports or patient 
series83-88. It has been related to IBD itself and several immunosuppressives, 
including AZA, 6-MP and corticosteroids89. Also, it has been described in 2.5% 
of a general population in a post-mortem study90. In the study presented in 
Chapter 10, only short term AZA or 6-MP treatment has been given before 
initiation of 6-TG therapy, because of intolerance38. The two main reports about 
NRH reported longer lasting AZA or 6-MP treatment prior to the switch to 6-TG 
therapy: median twelve months (range 0.5-96) and median eleven months 
(range 0.5-60) respectively37,79. Hence, the discussion about the effects of long 
term 6-TG treatment and the influence of other confounding factors like IBD 
itself or previously/concurrently used medications seems not yet closed 
therefore. Nevertheless, we believe that 6-TG can still be useful in IBD 
treatment, but in selected patients, intolerant for other immunosuppressives, at 
low dose and under close surveillance of metabolite levels and hepatotoxity. 
Prior to initiation, all patients should be informed extensively about the risks of 
6-TG. In future, a larger group of long term 6-TG treated IBD patients should be 
examined to explore the correlation between 6-TG dose, metabolites and NRH. 
In addition, it seems necessary to perform liver histology and/or MRI in a large 
group of long term AZA or 6-MP treated IBD patients to examine whether NRH 
is found regularly in these patients as well.  
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 Conclusions and clinical advice 
This thesis describes several aspects of therapeutic drug monitoring (TDM) of 
thiopurine therapy in IBD patients. It shows that the knowledge about thiopurine 
metabolism gives rise to new concepts such as TDM, genotyping and 
phenotyping of crucial enzymes and even the rebirth of 6-thioguanine (6-TG), 
an old thiopurine. Thereby the clinical usefulness of thiopurines has been 
enlarged. After reading this manuscript one could ask when to perform TDM. 
Several aspects of TDM will be mentioned shortly, referring to the associated 
chapters  in  this manuscript for more detailed information. 
 
1. Thiopurines, such as azathioprine (AZA) and 6-mercaptopurine (6-MP) are 
metabolised in several steps as described in Figure 12.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.1 Proposed thiopurine metabolism.  AZA, azathioprine; 6-MP, 6-mercaptopurine; 
6-MMP, 6-methylmercaptopurine; 6-TUA, 6-thiouric acid; 6-MTIMP, 
6-methylthioinosine monophosphate; 6-MTIDP, 6-methylthioinosine diphosphate; 
6-MTITP, 6-methylthioinosine triphosphate; 6-TIMP, 6-thioinosine monophosphate; 
6-TIDP, 6-thioinosine diphosphate; 6-TITP, 6-thioinosine triphosphate; 6-TXMP, 
6-thioxanthosine monophosphate; 6-TGMP, 6-thioguanine monophosphate; 6-TGDP, 
6-thioguanine diphosphate; 6-TGTP, 6-thioguanine triphosphate; 6-MTGMP, 
6-methylthioguanine monophosphate; 6-TG, 6-thioguanine; 6-MTG, 
6-methylthioguanine; XO, xanthine oxidase; TPMT, thiopurine S-methyltransferase; 
HPRT, hypoxanthine phosphoribosyl transferase; IMPD, inosine monophosphate 
dehydrogenase; GMPS, guanosine monophosphate synthetase; MPK, 
monophosphate kinase; DPK, diphosphate kinase; ITPA, inosine triphosphate 
pyrophosphatase.  
 In therapeutic drug monitoring, the 6-MMPR level consists of the sum of 6-MMP, 
6-MTIMP, 6-MTIDP and 6-MTITP levels, while the 6-TGN level consists of the sum of 
6-TGMP, 6-TGDP, 6-TGTP (if AZA or 6-MP is administered) and 6-TG levels (if 6-TG 
is administered as such).  
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2.  Two groups of metabolites are formed: 
- 6-TGN metabolites, which are immunosuppressive. In case of 
AZA/6-MP therapy, therapeutic 6-TGN levels should be between 235 
and 500 pmol/8x108 RBC. 
When 6-TGN levels are higher than 500 pmol/8x108 RBC the risk of 
leukopenia or even pancytopenia is increased (Chapter 2). 
When 6-TGN levels are higher than 300 pmol/8x108 RBC after one 
week of therapy, TPMT deficiency is strongly suspected. Hence 
thiopurine dose should be decreased to prevent myelotoxicity (Chapter 
2). 
 
- 6-MMPR metabolites, which are correlated with hepatotoxicity in case 
of levels higher than 5700 pmol/8x108 RBC. 
 
3.  Thiopurine metabolites have a half life of five days (Chapter 2). This means 
that metabolite concentrations will reach a steady state level after 25 days -
one month. Also, when patients discontinue ingestion of thiopurines, 
metabolite levels can be measured during 25 days (five times half life). 
Metabolite levels are very stable therefore, as shown in 6-TG treated 
patients (Chapter 7). When steady state is reached, blood samples can be 
taken at any time of the day after ingestion of thiopurines for TDM. When 
thiopurine dose is adjusted, new TDM is only useful after at least one 
month. 
 
4. Mean therapeutic 6-TGN metabolite levels are not significantly different 
between patients with exacerbations and remissions in the study presented 
in Chapter 5, but this is in contrast with a recent meta-analysis. 
Nevertheless, a lower cut-off therapeutic 6-TGN level of 235 pmol/8x108 
RBC has been identified by several studies (Chapter 5). 
 
5. In cohort studies, thiopurine metabolite levels do not correlate with 
thiopurine dose. In contrast, intra-individually there is a correlation: when 
drug dose is increased in an individual patient, 6-TGN and 6-MMPR 
metabolite levels will increase as well (Chapter 3). The genetic 
polymorphism of the TPMT enzyme seems an important reason for these 
inter-individual differences. 
 
6. TDM is the only objective method to reveal non-compliance, especially in 
case of thiopurine refractory disease (Chapter 4 and 5). 
 
206 
 Conclusions and clinical advice 
7. TDM may give insight in adverse events, such as the cause of leukopenia 
or hepatotoxicity (Chapter 2 and 3). Pancreatitis, an adverse event of 
thiopurine therapy occurring in 1.5-10% of IBD patients (mostly Crohn’s 
disease), seems to be an idiosyncratic reaction, which means that 
thiopurine metabolite concentrations and drug dose are not correlated 
(Chapter 2).  
 
8. TDM may give insight in interactions of medications with thiopurine 
metabolism (Chapter 6). 
 
9. TPMT genotyping before initiation may predict the chance on leukopenia: 
in case of at least one mutant allele the relative risk is twelve times higher 
(Chapter 2). 
 
10. Importantly, TDM does not replace or exclude frequent checking of blood 
cell counts and liver tests! 
 
 
 
The following recommendations can be made based on the results of Chapter 
2, 3 and 5 (see also Table 12.1): 
 
TDM in case of azathioprine of 6-mercaptopurine therapy: 
 
When starting AZA or 6-MP therapy: 
 • after one week: to prevent early toxicity: 6-TGN should not exceed 
300 pmol/8x108 RBC.  
 • after at least four weeks: to detect suboptimal dosing: 6-TGN lower 
than 235 pmol/8x108 RBC. 
 • late toxicity: 6-TGN should not be higher than 500 pmol/8x108 RBC 
(not in this manuscript).  
 
Indications for TDM in established AZA or 6-MP therapy: 
 • in case of an exacerbation: -to exclude non-compliance 
   -to exclude under-dosing or 
    unfavourable metabolite profiles  
 • in case of a remission:  -to consider dose reduction. 
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Table 12.1  Possible utilization of metabolite measurement in IBD patients treated with 
azathioprine or 6-mercaptopurine. 
Explanation 6-TGN level 
(pmol/8x108 RBC) 
6-MMPR level 
(pmol/8x108 RBC) 
therapeutic target achieved 235-500   <5700 
non-compliance <<235 <<5700 
under-dosing   <235   <5700 
potential myelotoxicity (absent TPMT activity) >>500 <<5700 
possible myelotoxicity (low TPMT activity)   >500   <5700 
possible myelotoxicity, when measured 
 after one week of therapy 
  >300  
possible hepatotoxicity (high TPMT activity) <235-500   >5700 
potential myelotoxicity (very high TPMT activity) <<235 >>5700 
6-TGN, 6-thioguanine nucleotides; 6-MMPR, 6-methylmercaptopurine ribonucleotides; pmol, 
picomoles; RBC, red blood cells; TPMT, thiopurine S-methyltransferase. 
 
TDM in case of 6-thioguanine therapy: 
- 6-Thioguanine (6-TG) is an effective alternative in case of intolerance for 
other immunomodulators, but should only be used for this indication 
(Chapter 7-9). The findings of nodular regenerative hyperplasia of the liver 
are very important, although a possible metabolite level dependent effect 
has been shown (Chapter 10). The possible dangers of 6-TG use should 
be discussed with the patient and strict monitoring of blood counts, liver 
tests, ultrasonography and regular liver biopsy should be performed as 
published in a recommended guideline mentioned in Chapter 10. 
 
- In case of 6-TG use, no 6-MMPR levels can be measured as to be 
expected from thiopurine metabolism. 6-TGN levels reach a steady state 
level after four weeks of 6-TG treatment, in accordance with AZA or 6-MP 
therapy. 6-TGN levels can be four to seven times higher than in the case of 
AZA or 6-MP use. No clear therapeutic or toxic 6-TGN levels have been 
described yet. It seems however, that 6-TGN levels below 800 pmol/8x108 
RBC are effective and that hepatotoxicity is related with levels higher than 
1000 pmol/8x108 RBC, as described in Chapters 8, 9 and 10. 
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Limitations of TDM of thiopurine therapy 
- No significant difference between mean 6-TGN levels of patients with 
active IBD and remission (Chapter 5). 
- No clear upper limit defined for 6-TGN levels (not studied in this 
manuscript). 
- No relation between metabolite levels and pancreatitis. 
- Leucopenia is not always related to high 6-TGN levels. 
- No clear therapeutic and toxic 6-TGN levels defined in case of 6-TG 
therapy. 
- Metabolite level measurements are very labour-intensive and therefore 
quite expensive (approximately 55 euro’s in the Netherlands per set of 
6-TGN/6-MMPR levels). 
- Still, not many hospitals can measure thiopurine metabolites. 
 
What should you do when considering TDM during thiopurine 
therapy? 
 
1. Take blood in two lithium heparinised containers of 10 ml (sprayed, no 
heparinised granules). 
2. Send these cooled containers to a nearby (toxicology) laboratory, which 
can perform thiopurine metabolite measurements, eg. the Laboratory of 
Toxicology in the Department of Clinical Pharmacy, Maasland Hospital, PO 
Box  5500, 6130 MB, Sittard, the Netherlands. 
3. In case of questions call the Laboratory of Toxicology in the Department of 
Clinical Pharmacy in Sittard, the Netherlands, for information, tel.+31-46-
4597391. 
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Summary 
Chapter 1 starts with a short introduction about inflammatory bowel diseases 
(IBD). IBD consist of Crohn’s disease, ulcerative colitis and indetermined 
colitis. The cause of these diseases seems multifactorial. IBD are characterised 
by an overactive, pro-inflammatory immune system in-, or even outside the 
bowel. One group of immunomodulatory medications used in IBD therapy are 
thiopurines, such as azathioprine (AZA), 6-mercaptopurine (6-MP) and 
6-thioguanine (6-TG). 
In the second part of this chapter a review is presented about thiopurine 
pharmacology, pharmacogenetics, interactions and new strategies for 
optimization of pharmacotherapy, including therapeutic drug monitoring (TDM) 
and genotyping of thiopurine S-methyltransferase (TPMT), an important 
enzyme in thiopurine metabolism. Thiopurines are metabolised to therapeutic 
6-thioguanine nucleotides (6-TGN) and hepatotoxic 6-methylmercaptopurine 
ribonucleotides (6-MMPR), which both can be measured in red blood cells 
(RBC). 
In the third part the outline of this thesis is described: the clinical usefulness of 
TDM of thiopurine therapy in IBD. Theoretically, measuring metabolite levels of 
thiopurines could improve individual efficacy and safety of this therapy. The 
possible clinical usefulness of TDM in thiopurine therapy is demonstrated in 
several clinical trials. 
 
Chapter 2 describes in detail the method of metabolite measurements and 
TPMT genotyping in a prospective study in 30 IBD patients, who have started 
with 6-MP treatment. TDM is performed at t= 0, 1, 2, 4 and 8 weeks after 
starting 50 mg 6-MP daily. Large inter-individual differences in metabolite 
concentrations were demonstrated. No correlation was found between 
metabolite levels and 6-MP dose. Steady state 6-TGN and 6-MMPR metabolite 
levels were found after four weeks, thus the half life of these metabolites is 
approximately five days. One patient had homozygous mutant TPMT alleles, 
four patients had heterozygous TPMT mutants. A correlation between TPMT 
genotype and 6-TGN level was found. One mutation of a TPMT allele 
increased the risk of leukopenia twelve times. All patients with leukopenia had 
6-TGN levels of at least 300 pmol/8x108 RBC after one week of 6-MP therapy. 
No correlation was found between metabolite levels and hepatotoxicity (one 
patient) or pancreatitis (three patients). Interestingly, 83% of the patients with 
initially active IBD and remission after eight weeks of 6-MP treatment had 
6-TGN levels above the proposed therapeutic threshold level of 
235 pmol/8x108 RBC. Inversely, 75% of the patients without clinical 
improvement of IBD activity after eight weeks of 6-MP treatment had 6-TGN 
levels below 235 pmol/8x108 RBC. This is in accordance with previous 
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literature on this subject. 
This study clearly indicates the usefulness of TPMT genotyping and especially 
TDM of thiopurine therapy in this population. TPMT genotyping before start of 
thiopurine treatment may prevent early myelotoxicity due to thiopurine 
treatment in a selection of patients. TDM may facilitate the clinician to improve 
6-MP efficacy by demonstrating suboptimal dosing and predicting the risk of 
leukopenia. Based on this study following recommendations can be made: 
TDM after one week (to prevent early toxicity: 6-TGN should not exceed 
300 pmol/8x108 RBC) and after four weeks (to detect suboptimal dosing: 
6-TGN are lower than 235 pmol/8x108 RBC then).  
 
Five thiopurine treated IBD patients from daily clinical practice are described in 
Chapter 3. The first case demonstrated non-compliance, as is often seen in 
chronic patients in general. TDM is the only method to detect this phenomenon. 
The second case showed that high 6-MMPR levels may give rise to a toxic 
hepatitis. This patient with wildtype TPMTH/H genotype had a preferential 
metabolism of 6-MP to 6-MMPR, resulting in a failure to achieve adequate 
clinical benefit (which is associated with 6-TGN levels), but leading to hepatitis 
due to high 6-MMPR metabolite concentrations. This case subscribes earlier 
findings that TDM can reveal a subgroup of patients resistant to 6-MP 
treatment, in danger of hepatotoxicity when 6-MP dose is increased. Case 2 is 
also an example of treatment with 6-TG, a product near the end of the 
metabolic pathway of thiopurines, which can be used as an alternative 
immunosuppressive therapy in case of AZA or 6-MP intolerance, as described 
in Chapters 7-9.  
In case 3 relatively high 6-TGN and low 6-MMPR levels were measured. 
Sufficient 6-TGN levels were reached at 50% of the initial dose. This patient is 
an example of an intermediate metaboliser (heterozygous TPMTL/H). This case 
also illustrates the inter-individual differences in TPMT activity and corresponds 
with earlier findings in which clinical response only correlates with 6-TGN levels 
and not with any other variable such as drug dose.  
The fourth case represents the one out of 300 patients with no functional TPMT 
activity (TPMTL/L), showing extremely high 6-TGN levels within just one week of 
6-MP treatment. This patient had a homozygous variant allele (TPMT *3A/*3A).  
Case 5 is extraordinarily interesting, presenting reversible pancytopenia due to 
extremely high 6-MMPR levels. This is the first case showing this phenomenon 
and points out the relation between myelotoxicity and other 6-MP metabolites 
than just 6-TGN alone.  
This chapter illustrates in a descriptive way some clinical situations, in which it 
is worthwhile to employ TDM during initiation of thiopurine treatment. TDM 
improves efficacy of treatment and diminishes risks of serious complications 
such as myelodepression and hepatitis. TDM can also be used to reveal bad 
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compliance or undertreatment in steady state treated patients and might help 
clinicians to overcome their fear for overdosing. TPMT-genotyping before 
starting thiopurine treatment may be complementary to TDM. TPMT genotype 
predicts the chance of early neutropenia, while TDM can be used to adjust 
6-TGN and 6-MMPR levels.  
 
 
Chapter 4 describes a prospective pharmacokinetic study in IBD patients with 
steady state AZA treatment. The original intention of this study was to examine 
the metabolite levels in a small cohort of AZA treated IBD patients, after 
previous publications about the 6-TGN metabolite threshold. TDM was 
performed at t= 0, 1, 4 and 8 weeks in fifteen IBD patients with established 
AZA therapy. Primary outcomes were 6-TGN and 6-MMPR metabolite levels, 
secondary were the correlation between metabolite levels, drug dose, disease 
activity and laboratory parameters and compliance. Eleven patients completed 
the eight week study interval (one intolerant and three non-compliant patients 
dropped out). Mean baseline 6-TGN levels were relatively low: 158 pmol/8x108 
RBC and increased during the study interval, but not significantly. Overall, non-
compliance was found in six of fifteen cases (40%), TDM revealed non-
compliance in four of these six patients, two patients did not show up for blood 
withdrawal. This result is in accordance with literature on non-compliance in 
other chronic diseases, such as diabetes mellitus. 
 
In Chapter 5 a prospective study is reported about a relevant clinical question: 
is TDM useful in case of an exacerbation of IBD during thiopurine therapy? In 
daily practice a switch to different therapy, for example to a biological 
immunomodulator (infliximab, adalimumab or certolizumab), is considered in 
this situation. In case of an exacerbation the question should be however, 
whether the patient has been compliant and whether the thiopurine dose was 
adequate in the individual patient. 
This study was performed to examine the possible difference of thiopurine 
metabolite levels between exacerbations versus remissions and to redefine a 
therapeutic threshold 6-TGN level in adult IBD patients. Forty-one adult IBD 
patients with an exacerbation of IBD were compared with 59 patients with IBD 
in remission during thiopurine therapy (AZA or 6-MP). Thiopurine metabolite 
levels and TPMT phenotype were measured. Disease activity was scored by 
CAI (UC) and CDAI (CD). Primary outcomes were 6-TGN and 6-MMPR 
metabolite levels, secondary were TPMT activity, laboratory parameters and 
correlations between metabolite levels, disease activity and laboratory 
parameters. 
At first, a high prevalence of non-compliance was found. Zero 6-TGN levels 
were measured in 12% of the patients with an exacerbation versus zero or very 
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low levels in 19% of the patients in remission (16% in all included patients). It is 
well known that non-compliance is seen in up to 60% of treatment of chronic 
diseases in general. Nevertheless, this is often underestimated in daily clinical 
practice, especially in IBD patients. The only way to exclude non-compliance 
as the cause of an exacerbation is by measuring metabolite levels.  This seems 
one of the most important arguments to perform TDM in case of thiopurine 
refractory disease, presenting in daily clinical practice.  
Secondly, no significant differences in 6-TGN or 6-MMPR metabolite levels 
were found between patients with exacerbations and remissions. Beside, no 
correlation between thiopurine dose (in mg or mg per kilograms bodyweight) 
and metabolite levels was found. 
Calculations for three different situations were made: in all included patients 
(N= 100), in all exacerbations versus compliant patients in remission (N=89), 
and in all compliant patients (N= 84). In all calculations a cut-off therapeutic 
6-TGN level was found between 235-250 pmol/8x108 RBC. Optimal values of 
sensitivity, specificity and positive predictive value were found in the sub-
analysis without non-compliant remittent patients (71, 73 and 67%, AUC 0.70 
respectively), but were relatively low. Only in this sub-group 6-TGN levels 
showed a difference between exacerbations and remissions (237 versus 320 
pmol/8x108 RBC, p= 0.0007) and a correlation was found between 6-TGN and 
disease activity (r= -0.24, CI95% -0.42- -0.029). The OR for having an 
exacerbation in case of 6-TGN levels below the proposed threshold of 
235 pmol/8x108 RBC was 4.7 (CI95% 1.9-11.5). 
In the first analysis (all included patients), active disease was found in 52% of 
patients below, versus 30% above this threshold (OR 2.5, CI95% 1.11-5.75, 
p=0.04), although no significant difference in mean 6-TGN levels was found.  
At last, a quartile analysis, as originally described by Dubinsky, showed a very 
similar cut-off 6-TGN level between 233-236 pmol/8x108 RBC and significantly 
more remissions above this threshold.  
This is the fifth study demonstrating a threshold 6-TGN within the interval of 
230-260 pmol/8x108 RBC, with significant differences in the prevalence of 
remission above and below this cut-off, confirming its value, but also with a 
relatively low sensitivity and specificity. In conclusion, TDM may be useful in a 
clinical setting, in case of thiopurine refractory IBD, mostly to reveal non-
compliance and secondly to find underdosing or unfavourable metabolite 
profiles, however, with low sensitivity, specificity and predictive values. 
 
Chapter 6 demonstrates the effect of mesalamine use on thiopurine metabolite 
levels in IBD patients. In vitro studies had indicated a potentiating effect of 
mesalamines on 6-TGN levels by inhibition of TPMT activity. In this 
pharmacokinetic study in 17 patients, TDM was performed during a steady 
6-MP therapy in combination with a steady mesalamine dose (t=0), as well as 
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four weeks after mesalamine discontinuation (t=4 weeks) and four weeks after 
reintroduction (t=8 weeks). A significant decrease of 6-TGN levels was 
measured after four weeks of discontinuation compared to baseline (from 262 
to 209 pmol/8x108 RBC), significantly increasing to 270 pmol/8x108 RBC after 
reintroduction. In contrary to in vitro experiments, in vivo TPMT activity did not 
change significantly during the study. Maybe the method of measurement of 
TPMT activity plays a role in this contrasting result. The mechanism of the 
measured synergistic effect of mesalamine on 6-TGN levels remains unclear 
therefore. 
 
In 2001 6-Thioguanine (6-TG) was introduced as an alternative for AZA or 6MP 
intolerant IBD patients. By using 6-TG, the effective 6-TGN metabolites are 
formed more directly, without the formation of several potentially toxic 
metabolites. Chapter 7 describes a short term prospective pharmacokinetic 
study in 6-TG treated IBD patients. TDM was performed at t= 0, 1, 2, 4 and 8 
weeks in 28 AZA/6MP intolerant IBD patients. Eight week and 24 hour 6-TGN 
curves were measured. High steady state 6-TGN levels (mean 856 pmol/8x108 
RBC, CI95% 715-997) were found, when compared to AZA or 6-MP treatment, 
with a large, five-fold inter-patient variability. No correlation with drug dose was 
found. 6-TGN levels reached steady state after four weeks, suggesting a half 
life of five days. Twenty-four hour curves in steady state patients showed 
constant levels, as expected with this half life of 6-TGN metabolites. No 
correlation between 6-TGN levels and myelo- or hepatotoxicity, or pancreatitis 
was found (one patient had temporarily elevated lipase values without 
symptoms). Sixteen patients had active disease at baseline: five out of eleven 
CD patients (45%) and three out of five UC (60%) achieved remission. 
However, no correlation between disease activity and 6-TGN levels was found. 
 
In Chapter 8 an open, prospective, multicentre, short term safety study on 6-TG 
treatment in AZA or 6-MP intolerant IBD patients is presented. The occurrence 
of adverse events, 6-TGN metabolite levels and laboratory parameters were 
obtained in 32 AZA/6MP intolerant IBD patients at baseline, 1, 2, 4 and 8 
weeks after initiation of 6-TG therapy. Primary outcomes were 6-TG tolerance 
and adverse events, secondary outcomes were 6-TGN levels and laboratory 
parameters. 6-TG was tolerated in 26 patients (81%) during the first eight 
weeks. In two patients side effects were probable (gastro-intestinal symptoms) 
and in one patient obvious (fever and erythema nodosum). No clinically 
relevant myelo- or hepatotoxicity occurred. Steady state 6-TGN levels were 
1621 pmol/8x108 RBC on 40 mg daily and 937 pmol/8x108 RBC on 20 mg, 
showing a significant difference. In conclusion, 6-TG safety seems promising in 
AZA/6-MP intolerant IBD patients in this short term study. A relatively low 6-TG 
dose was used in contrary to previously reported studies, and measured 
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6-TGN levels were lower as well. Efficacy of 6-TG was not examined in this 
study. 
 
Chapter 9 describes the tolerability and safety of 6-TG in 95 IBD patients, 
intolerant for AZA or 6-MP, during at least one year of 6-TG treatment. In this 
retrospective, multicentre study primary outcomes were tolerance and safety of 
6-TG, secondary were clinical and laboratory parameters, metabolite levels and 
ultrasonography of the liver. Mean 6-TG dose was 24.6 mg (0.34 mg/kg/day), 
which is lower than other studies. Twenty out of 95 (21%) patients discontinued 
6-TG within one year. Altogether they had 26 adverse events, such as gastro-
intestinal complaints (31%), malaise (15%), hepatotoxicity (15%), 
myelodepression (4%), pancreatitis (4%), allergic reactions (4%) and others 
(27%). Haematological events occurred in three patients, one discontinued 
treatment. In the 6-TG tolerant group 9% (7/75) were classified as having 
hepatotoxicity, but two patients had mildly disturbed liver tests before initiation 
of 6-TG and one had symptomatic choledocholithiasis. An abdominal 
ultrasound was performed in 54% of patients: one patient had splenomegaly, 
no other signs of portal hypertension were found. No liver histology was 
examined in this study.  
This study shows that the majority of AZA or 6-MP intolerant IBD patients 
(79%) is able to tolerate maintenance treatment with 6-TG. 6-TG may (still) be 
considered as an escape maintenance immunosuppressant in this difficult 
group of patients.  
 
In 2003, some reports showed nodular regenerative hyperplasia (NRH) in liver 
biopsies in up to 16% of 6-TG treated IBD patients, even without biochemical 
signs of hepatotoxicity. Later, a report on a special magnetic resonance 
imaging (MRI) technique showed that some patients with normal liver histology, 
had signs of NRH on their MRI, demonstrating the complementary findings of 
both methods in the search for NRH. In Chapter 10 the results of liver histology 
and MRI in long term 6-TG treated IBD patients are presented. 
All IBD patients of the Sittard IBD cohort, using 6-TG for at least 24 months, 
were asked to undergo a liver biopsy and MRI with two intravenous contrast 
agents (gadolinium and ferrocarbutran). Thirteen of fourteen patients 
participated. Mean 6-TG therapy duration was 36 months, mean daily 6-TG 
dose was 18.8 mg (0.28 mg/kg) and mean 6-TGN levels were 705 pmol/8x108 
RBC. No signs of hepatotoxicity or portal hypertension were found by 
biochemical analysis and ultrasonography of the liver and spleen. Liver 
histology and MRI showed no NRH.  
This study is the first to describe a long term follow-up of 6-TG treated IBD 
patients. 6-TG dose and 6-TGN levels were lower compared with previous 
NRH reports, suggesting dose or metabolite level-dependent effects (6-TG 
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dose of 20 mg or 0.28 mg/kg versus 40 - 80 mg and 6-TGN levels of 705 
pmol/8x108 RBC versus 1230 pmol/8x108 RBC, respectively). 
No NRH has been found in our IBD patients with longterm, low dosed 6-TG 
with low 6-TGN metabolite levels. Hence, 6-TG still seems useful, in selected 
patients intolerant for other immunosuppressives, when it is low dosed and 
close surveillance is kept of metabolite levels and hepatotoxity. Also, patients 
should be informed extensively about the risks of 6-TG prior to initiation. 
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Samenvatting 
Hoofdstuk 1 begint met een korte introductie over inflammatoire darmziekten 
(IBD). Onder IBD worden de ziekte van Crohn (CD), colitis ulcerosa (UC) en 
indetermined colitis verstaan. De oorzaak van deze ziekten lijkt multifactorieel 
te zijn. IBD kenmerken zich door een overactief, pro-inflammatoir 
immuunsysteem in en buiten de darm. Er worden verschillende immuun-
modulerende medicijnen gebruikt in de behandeling van IBD, zoals bijvoor-
beeld de thiopurines, bestaande uit azathioprine (AZA), 6-mercaptopurine 
(6-MP) en 6-thioguanine (6-TG). 
In het tweede gedeelte van dit hoofdstuk wordt een overzicht gegeven over de 
farmacologie, farmacogenetica en interacties van thiopurines en nieuwe 
strategieën voor optimalisatie van de behandeling met thiopurines bij IBD 
patiënten, zoals het meten van metaboliet concentraties, ook wel therapeutic 
drug monitoring (TDM) genaamd en genotypering van thiopurine 
S-methyltransferase (TPMT), een belangrijk enzym in het metabolisme van 
thiopurines. Thiopurines worden gemetaboliseerd tot twee groepen 
metabolieten: therapeutische 6-thioguanine nucleotiden (6-TGN) en 
hepatotoxische 6-methylmercaptopurine ribonucleotiden (6-MMPR), welke 
allebei gemeten kunnen worden in rode bloedcellen (RBC). 
In het derde deel van dit hoofdstuk wordt de opzet van dit proefschrift 
beschreven: patiëntgebonden onderzoek naar de klinische bruikbaarheid van 
TDM in de behandeling van IBD met thiopurines. 
 
Hoofdstuk 2 beschrijft in detail de bepaling van metabolieten van thiopurines en 
TPMT genotypering middels een prospectieve studie bij 30 IBD patiënten, 
tijdens start van de behandeling met 6-MP. TDM werd uitgevoerd op t= 0, 1, 2, 
4 en 8 weken na de start van 50 mg 6-MP per dag. Grote inter-individuele 
verschillen in concentraties van thiopurine metabolieten werden gevonden. Er 
was geen correlatie tussen 6-MP dosis en metaboliet spiegels. Stabiele 
concentraties van 6-TGN en 6-MMPR werden gevonden na vier weken, 
waaruit een halfwaardetijd van ongeveer vijf dagen kan worden berekend. Eén 
patiënt was homozygoot voor mutante TPMT allelen, vier hadden één mutant 
allel. Er werd een correlatie tussen TPMT genotype en 6-TGN spiegel 
gevonden. Eén mutant TPMT allel verhoogde het risico op leukopenie twaalf 
keer. Alle patiënten met een leukopenie hadden een week na het starten van 
6-MP 6-TGN spiegels van minimaal 300 pmol/8x108 RBC. Er werd geen 
correlatie gevonden tussen metaboliet concentraties en hepatotoxiciteit (een 
patiënt) en pancreatitis (drie patiënten). Opvallend was het feit dat 83% van de 
patiënten met vooraf actieve IBD en remissie na acht weken behandeling, een 
6-TGN spiegel had boven de in de literatuur voorgestelde therapeutische 
drempel van 235 pmol/8x108 RBC. Omgekeerd, had 75% van de patiënten 
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zonder klinische verbetering van de ziekte-activiteit na acht weken behandeling 
met 6-MP 6-TGN spiegels onder deze drempel. Deze resultaten komen 
overeen met eerdere publicaties. 
Deze studie toont duidelijk het klinische nut van TPMT genotypering en vooral 
TDM van de behandeling met 6-MP. TPMT genotypering voor de start van 
6-MP kan vroege myelodepressie voorkomen door het aantonen van mutante 
TPMT allelen. TDM kan de clinicus helpen om de effectiviteit van 6-MP te 
verbeteren door onderdosering aan te tonen en het risico op leukopenie te 
voorspellen. Gebaseerd op deze studie kan het volgende advies gegeven 
worden: TDM na één week behandeling (om vroege myelotoxiciteit te 
voorkomen: 6-TGN moeten lager dan 300 pmol/8x108 RBC zijn) en na vier 
weken (om suboptimale dosering op te sporen: 6-TGN zouden dan hoger 
moeten zijn dan 235 pmol/8x108 RBC). 
 
In Hoofdstuk 3 worden vijf IBD patiënten uit de dagelijkse praktijk beschreven, 
die worden behandeld met een thiopurine. In de eerste casus wordt door TDM 
non-compliance onthuld. Non-compliance komt veel voor bij chronische ziekten 
in het algemeen en TDM is de enige methode om dit objectief aan te tonen. De 
tweede casus laat zien dat hoge 6-MMPR concentraties aanleiding kunnen 
geven tot toxische hepatitis. Deze patiënt met een wildtype TPMTH/H genotype 
had een preferentieel metabolisme van 6-MP naar 6-MMPR, leidend tot 
onvoldoende effectiviteit van de behandeling door te lage 6-TGN concentraties, 
maar wel tot hepatitis door hoge 6-MMPR concentraties. Deze casus bevestigt 
eerdere bevindingen dat TDM een subgroep van patiënten kan onderscheiden, 
die weerstandig is aan de behandeling met 6-MP, met een verhoogd risico op 
hepatotoxiciteit als de dosis 6-MP wordt verhoogd. De tweede casus is 
daarnaast een voorbeeld van de behandeling met 6-TG, een medicament dat 
zich dichter bij de effectieve metabolieten in het thiopurine metabolisme 
bevindt. Het kan worden gebruikt als een alternatief immuunsuppressivum in 
geval van intolerantie voor AZA of 6-MP, zoals ook beschreven wordt in 
Hoofdstuk 7-9. 
In Casus 3 werden relatief hoge 6-TGN en lage 6-MMPR concentraties 
gemeten. Sufficiënte 6-TGN spiegels werden bereikt met 50% van de initiële 
dosis. Deze patiënt is een voorbeeld van een intermediaire metaboliseerder 
(heterozygoot TPMTL/H). Deze casus illustreert ook de inter-individuele 
verschillen in TPMT activiteit, corresponderend met de eerder gerapporteerde 
bevindingen dat de klinische respons op de behandeling met een thiopurine 
alleen correleert met 6-TGN concentraties en niet met de thiopurine dosis.  
De vierde casus is een voorbeeld van de één op 300 patiënten zonder 
functioneel TPMT (TPMTL/L), met extreem hoge 6-TGN spiegels binnen een 
week na start van de behandeling met 6-MP. Deze patiënt heeft een 
homozygoot variant TPMT *3A/*3A. 
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Casus 5 is buitengewoon interessant, omdat het een reversibele pancytopenie 
door extreem hoge 6-MMPR concentraties toont. Dit is de eerste casus die dit 
fenomeen beschrijft. Het demonstreert dat niet alleen 6-TGN metabolieten 
myelotoxiciteit kunnen veroorzaken tijdens behandeling met een thiopurine.  
Dit hoofdstuk beschrijft enkele alledaagse klinische situaties tijdens de 
beginfase van de behandeling met een thiopurine, waarin het nuttig is om TDM 
toe te passen. TDM verbetert de effectiviteit van de behandeling en vermindert 
de kans op ernstige complicaties, zoals myelodepressie en hepatitis. TDM kan 
daarnaast ook gebruikt worden om non-compliance of onderdosering aan te 
tonen in patiënten met een onderhoudsbehandeling en kan theoretisch clinici 
helpen om hun angst voor overdosering te overwinnen. TPMT-genotypering 
voor de start van de behandeling met een thiopurine kan een complementaire 
rol vervullen naast TDM. Het TPMT genotype voorspelt de kans op een vroege 
neutropenie, terwijl TDM toegepast kan worden om de 6-TGN en 6-MMPR 
concentraties te beïnvloeden. 
 
Hoofdstuk 4 beschrijft een prospectieve, farmacokinetische studie bij IBD 
patiënten met een onderhoudsbehandeling met AZA. De oorspronkelijke 
bedoeling van deze studie was om de metaboliet concentraties van AZA te 
bestuderen van een kleine groep IBD patiënten, naar aanleiding van recente 
publicaties over de therapeutische drempel van de 6-TGN spiegel. TDM werd 
uitgevoerd op t= 0, 1, 4 en 8 weken bij vijftien IBD patiënten met AZA 
onderhoudsbehandeling. De primaire uitkomstmaten waren de 6-TGN en 
6-MMPR spiegels, secundaire waren de correlatie tussen metaboliet 
concentraties, AZA dosis, ziekte-activiteit en laboratorium parameters en 
compliantie. Elf patiënten vervolledigden de acht weken durende 
onderzoeksperiode (één intolerante en drie niet-compliante patiënten vielen 
uit). De gemiddelde baseline 6-TGN concentratie was relatief laag: 158 
pmol/8x108 RBC en steeg gedurende het studie-interval, maar niet significant. 
In totaal werd non-compliance aangetoond in zes van de vijftien patiënten 
(40%), TDM onthulde er hiervan vier en twee patiënten kwamen niet opdagen 
voor afspraken om bloed te laten prikken. Dit resultaat komt overeen met de 
literatuur over non-compliance in andere chronische ziekten, zoals diabetes 
mellitus. 
 
In Hoofdstuk 5 wordt een prospectieve studie gepresenteerd over een 
relevante klinische vraag: is TDM bruikbaar in geval van een exacerbatie van 
IBD tijdens de behandeling met een thiopurine? In de dagelijkse praktijk wordt 
in dit geval omschakeling naar een ander medicament overwogen, zoals 
bijvoorbeeld een ‘biological’ (infliximab, adalimumab of certolizumab). Eigenlijk 
zou de eerste vraag in geval van een exacerbatie echter moeten zijn of de 
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patiënt wel compliant is geweest en of de thiopurine dosis wel correct was voor 
deze individuele patiënt. 
Er werd een studie opgezet om te bestuderen of er een verschil was tussen 
hoogte van de metaboliet concentraties bij patiënten met een exacerbatie 
versus remissie en om een nieuwe drempelwaarde voor de therapeutische 
6-TGN spiegel te formuleren voor volwassen IBD patiënten. 
Eenenveertig IBD patiënten met een exacerbatie werden vergeleken met 59 
patiënten in remissie tijdens de behandeling met een thiopurine (AZA of 6-MP). 
Thiopurine metaboliet concentraties en TPMT activiteit werden gemeten. De 
ziekte-activiteit werd gemeten met een CAI (UC) en CDAI (CD). Primaire 
uitkomstmaten waren 6-TGN en 6-MMPR metaboliet spiegels, secundaire 
waren TPMT activiteit, laboratorium parameters en correlaties tussen 
metaboliet spiegels, ziekte-activiteit en laboratorium parameters.  
Ten eerste werd een hoge prevalentie van non-compliance gevonden: bij 16% 
van alle geïncludeerde patiënten. Bij 12% van de patiënten met een 
exacerbatie werden 6-TGN spiegels van nul gemeten. Bij 19% van de 
patiënten in remissie werden 6-TGN spiegels van nul of zeer lage spiegels 
gevonden. Het is bekend dat bij tot wel 60% van de behandeling van 
chronische ziekten in het algemeen non-compliance voorkomt. Niettemin wordt 
non-compliance toch nog altijd onderschat in de dagelijkse praktijk, met name 
bij IBD patiënten. De enige manier om het aan te tonen als oorzaak van een 
exacerbatie is door metaboliet concentraties te meten. Een van de 
belangrijkste redenen om TDM uit te voeren in de dagelijkse praktijk lijkt 
derhalve in geval van een thiopurine refractaire IBD. 
Ten tweede werden er geen significante verschillen gevonden in 6-TGN of 
6-MMPR spiegels tussen patiënten met een exacerbatie en remissie. 
Daarnaast werd geen correlatie gevonden tussen thiopurine dosis (in mg of mg 
per kilogram lichaamsgewicht) en metaboliet spiegels. 
Er werden berekeningen voor drie afzonderlijke klinische situaties uitgevoerd: 
voor alle geïncludeerde patiënten (N=100), voor alle exacerbaties versus 
compliante patiënten in remissie (N=89) en voor alle compliante patiënten 
(N=84). In alle situaties werd een therapeutische 6-TGN drempelwaarde van 
235-250 pmol/8x108 RBC gevonden. Optimale sensitiviteit, specificiteit en 
positief predictieve waarde voor exacerbatie werden gevonden in de groep 
zonder niet-compliante patiënten met een remissie: 71, 73 en 67% (AUC 0.70), 
maar waren relatief laag. Alleen in deze subgroep bleken de 6-TGN spiegels 
significant verschillend tussen exacerbaties en remissies (237 versus 320 
pmol/8x108 RBC, p= 0.0007) en was er een correlatie tussen 6-TGN en ziekte-
activiteit (r=-0.24, CI95% -0.42- -0.029). De OR om in geval van een 
exacerbatie een 6-TGN spiegel onder de drempel van 235 pmol/8x108 RBC te 
hebben was 4.7 (CI95% 1.9-11.5). 
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In de eerste analyse (alle geïncludeerde patiënten) werd actieve ziekte 
gevonden bij 52% van de patiënten met een 6-TGN spiegel onder, versus 30% 
boven de drempelwaarde (OR 2.5, CI95% 1.11-5.75, p=0.04), hoewel er geen 
significant verschil werd aangetoond in 6-TGN concentraties. 
Ten laatste toonde een quartiel analyse, zoals oorspronkelijk beschreven door 
Dubinsky, om de 6-TGN drempelwaarde van 235 pmol/8x108 RBC te 
berekenen, een sterk overeenkomende therapeutische 6-TGN drempelwaarde 
van 233-236 pmol/8x108 RBC, met significant meer remissies boven deze 
drempel. 
Dit is de vijfde studie die een therapeutische 6-TGN drempelwaarde binnen het 
interval van 230-260 pmol/8x108 RBC toont, met significante verschillen in 
remissies onder en boven deze drempel, wat de waarde van deze drempel lijkt 
te bevestigen, maar met een relatief lage sensitiviteit en specificiteit. 
Concluderend kan worden gesteld dat TDM nuttig is in de dagelijkse praktijk, in 
geval van een exacerbatie, om vooral non-compliance aan te tonen en ten 
tweede om onderdosering of ongunstige metabolietprofielen te vinden, maar 
met een lage sensitiviteit, specificiteit en predictieve waarden. 
 
Hoofdstuk 6 demonstreert het effect van mesalazine op de concentraties van 
thiopurine metabolieten bij IBD patiënten. In vitro onderzoeken toonden al een 
potentiërend effect van mesalazines op 6-TGN concentraties door remming 
van de TPMT activiteit. In de huidige farmacokinetische studie, die uitgevoerd 
werd bij 17 patiënten, werden 6-TGN en 6-MMPR gemeten tijdens een stabiele 
onderhoudsbehandeling met 6-MP in combinatie met een stabiele dosis 
mesalazine (t=0), vier weken na het stoppen van mesalazine (t=4 w) en vier 
weken na herstart hiervan (t=8 w). Er werd een significante afname van de 
6-TGN spiegels gemeten vier weken na stoppen van mesalazine, vergeleken 
met t=0 (van 262 tot 209 pmol/8x108 RBC), significant toenemend na herstart 
hiervan tot 270 pmol/8x108 RBC. In tegenstelling tot eerdere in vitro 
onderzoeken veranderde de TPMT activiteit niet tijdens de studie. Mogelijk 
speelt de meetmethode van TPMT hierin een rol. Het mechanisme achter het 
synergistisch effect van mesalazine op 6-TGN concentratie blijft nog steeds 
onduidelijk. 
 
In 2001 werd 6-thioguanine (6-TG) geïntroduceerd als alternatief 
immuunsuppressivum voor AZA of 6-MP intolerante IBD patiënten. Door 6-TG 
te gebruiken worden de effectieve 6-TGN metabolieten directer gevormd, 
zonder dat er verschillende potentieel toxische metabolieten ontstaan. In 
Hoofdstuk 7 wordt een kortdurende prospectieve, farmacokinetische studie 
beschreven bij IBD patiënten die met 6-TG werden behandeld. TDM werd 
uitgevoerd op t=0, 1, 2, 4 en 8 weken bij 28 AZA/6-MP intolerante IBD 
patiënten. Er werden 6-TGN curves getekend voor de acht weekse periode, 
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maar ook enkele 24-uurs curves. Er werden hoge steady state 6-TGN spiegels 
(gemiddeld 856 pmol/8x108 RBC, CI95% 715-997) gevonden, vergeleken met 
metingen bij eerdere onderzoeken met AZA of 6-MP, met daarnaast een grote, 
vijfvoudige inter-individuele spreiding. Er werd geen correlatie tussen 6-TG 
dosis en 6-TGN spiegels gevonden. 6-TGN concentraties bereikten een steady 
state na vier weken, hetgeen een farmacokinetische halfwaardetijd van vijf 
dagen suggereert. Vierentwintig uur-curves in steady state toonden constante 
6-TGN spiegels, zoals verwacht bij de beschreven halfwaardetijd. Er werd 
geen correlatie gevonden tussen 6-TGN spiegels en myelo- of hepatotoxiciteit, 
of pancreatitis (één patiënt had tijdelijk asymptomatisch verhoogde 
lipasewaarden). Zestien patiënten hadden actieve ziekte bij start van de studie; 
vijf van de elf Crohn-patiënten (45%) en drie van de vijf colitis ulcerosa 
patiënten (60%) waren in remissie na acht weken. Toch werd er geen correlatie 
gevonden tussen 6-TGN concentraties en ziekte-activiteit. 
 
In Hoofdstuk 8 wordt een open, prospectieve, multicenter, korte termijnsstudie 
beschreven naar de veiligheid van de behandeling met 6-TG bij AZA of 6-MP 
intolerante IBD patiënten. Het voorkomen van bijwerkingen, laboratorium-
parameters en 6-TGN concentraties werden geregistreerd bij 32 IBD patiënten 
bij start (t=0) en na 1, 2, 4 en 8 weken behandeling met 6-TG. Primaire 
uitkomstmaten waren tolerantie voor 6-TG en bijwerkingen, secundaire waren 
6-TGN spiegels en laboratoriumparameters. 6-TG werd goed verdragen door 
26 patiënten (81%) gedurende het studie-interval van acht weken. Bij twee 
patiënten werden bijwerkingen als waarschijnlijk (gastro-intestinale 
symptomen) en bij één als duidelijk (koorts en erythema nodosum) 
geclassificeerd. Er werd geen relevante myelo- of hepatotoxiciteit vastgesteld. 
Steady state 6-TGN concentraties waren significant verschillend voor de 
behandeling met 40 mg en 20 mg 6-TG: 1621 pmol/8x108 RBC en 
937 pmol/8x108 RBC respectievelijk. Concluderend lijkt de veiligheid van 6-TG 
veelbelovend op de korte termijn bij IBD patiënten die intolerant zijn voor AZA 
of 6-MP. Een relatief lage dosis 6-TG werd gebruikt vergeleken met eerdere 
studies en de gevonden 6-TGN concentraties waren ook lager. De effectiviteit 
van 6-TG werd niet onderzocht in deze studie. 
 
Hoofdstuk 9 beschrijft de tolerantie en veiligheid van 6-TG bij 95 IBD patiënten, 
intolerant voor AZA of 6-MP, gedurende minimaal één jaar behandeling met 
6-TG. In deze retrospectieve, multicenter studie waren de primaire 
uitkomstmaten tolerantie en veiligheid van 6-TG, secundaire waren klinische en 
laboratorium parameters, metaboliet concentraties en echografie van de lever. 
De gemiddelde 6-TG dosis was 24.6 mg (0.31 mg/kg lichaamsgewicht), wat 
lager is dan in andere studies. Twintig van de 95 patiënten (21%) staakten de 
behandeling met 6-TG binnen een jaar. Zij hadden samen 26 bijwerkingen of 
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laboratoriumafwijkingen, waarvan gastro-intestinale bezwaren (31%), malaise 
(15%), hepatotoxiciteit (15%), myelodepressie (4%, naast deze ene patiënt 
waren er nog twee andere patiënten die de behandeling niet hoefden te 
staken), pancreatitis (4%), allergische reacties (4%) en andere oorzaken 
(27%). Van de 75 6-TG tolerante patiënten hadden zeven patiënten tekenen 
van hepatotoxiciteit, waarvan er twee al mild gestoorde levertesten hadden 
voor start van 6-TG en één bewezen choledocholithiasis had. Abdominale 
echografie werd verricht bij 54% van de patiënten: één patiënt had 
splenomegalie, geen andere tekenen van portale hypertensie werden 
gevonden. Lever histologie werd niet onderzocht in deze studie. 
Deze studie toont dat het grootste deel van de AZA of 6-MP intolerante IBD 
patiënten (79%) een onderhoudsbehandeling gedurende minimaal één jaar 
met 6-TG (dosis 0.3-0.4 mg/kg/dag) goed verdraagt. 6-TG kan daarom (nog 
altijd) overwogen worden als alternatief immunosuppressivum in deze moeilijk 
te behandelen IBD patiënten. 
 
In 2003 beschreven enkele publicaties het voorkomen van nodulaire 
regeneratieve hyperplasie (NRH) van de lever bij in totaal 16% van de met 
6-TG behandelde IBD patiënten, gediagnosticeerd door een leverbiopt. Niet bij 
alle patiënten waren er biochemische aanwijzingen voor hepatotoxiciteit. Later 
verscheen er een rapport over een speciale magnetische resonantie imaging 
(MRI) techniek, waarbij patiënten met normale lever histologie toch 
aanwijzingen voor NRH hadden bij MRI. Dit demonstreerde de 
complementariteit van beide onderzoeksmethoden in de zoektocht naar NRH. 
In hoofdstuk 10 worden de resultaten van lever histologie en MRI bij IBD 
patiënten die langdurig met 6-TG werden behandeld beschreven. Alle IBD 
patiënten uit het Sittardse IBD cohort, die minimaal 24 maanden met 6-TG 
werden behandeld, werden gevraagd om een leverbiopt en MRI met twee 
contrastmiddelen (gadolinium en ferrocarbutran) te ondergaan. Dertien van de 
veertien patiënten namen deel aan het onderzoek. De gemiddelde duur van de 
behandeling met 6-TG was 36 maanden, de gemiddelde dagelijkse dosis was 
18.8 mg (0.28 mg/kg) en de gemiddelde 6-TGN spiegels waren 
705 pmol/8x108 RBC. Er waren geen tekenen van hepatotoxiciteit of portale 
hypertensie bij biochemische analyse en echografie van de lever en milt. Lever 
histologie en MRI toonden geen argumenten voor NRH. 
Dit is de eerste studie die IBD patiënten, behandeld met 6-TG, gedurende een 
lange termijn heeft gevolgd. De 6-TG dosis en 6-TGN concentraties waren 
lager vergeleken met eerdere publicaties over NRH, wat een mogelijk dosis- of 
metabolietconcentratie-afhankelijk effect suggereert (6-TG dosis 20 mg of 
0.28 mg/kg versus 40-80 mg en 6-TGN spiegels van 705 pmol/8x108 RBC 
versus 1230 pmol/8x108 RBC, respectievelijk). 
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Er werd dus geen NRH gevonden bij patiënten, die langdurig een lage dosis 
6-TG kregen en waarbij lage 6-TGN spiegels werden gemeten. Daarom lijkt 
6-TG toch nog bruikbaar in een geselecteerde groep IBD patiënten die 
intolerant is voor andere immuunsuppressiva, wanneer 6-TG laag gedoseerd 
wordt en de metaboliet spiegels en hepatotoxiciteit regelmatig gecontroleerd 
worden. Daarnaast dienen patiënten vanzelfsprekend goed geïnformeerd te 
worden over de risico’s van 6-TG vóór start van de behandeling hiermee. 
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Lennard Gilissen werd geboren op 10 mei 1975 in Weert. Na het behalen van 
het VWO-examen op de Philips van Horne Scholengemeenschap te Weert in 
1993, begon hij aan de Katholieke Universiteit te Leuven, België met de 
opleiding tot Arts. Op 28 juni 2000 behaalde hij het artsenexamen met 
onderscheiding. Vanaf oktober 2000 startte hij als arts-assistent in opleiding tot 
internist op de afdeling Interne Geneeskunde en Gastroenterologie van het 
Maaslandziekenhuis te Sittard, met als opleiders dr. B.J. Looij en prof. dr. 
H.F.P. Hillen. Tijdens deze opleiding kwam zijn voorliefde voor 
Gastroenterologie, die al tijdens co-schappen in Roeselare en Leuven was 
ontstaan, weer bovendrijven. Hij participeerde vanaf medio 2001 op initiatief 
van dr. L.G.J.B. Engels in een onderzoek naar bloedspiegels van 
afbraakprodukten van thiopurines bij patiënten met inflammatoire darmziekten, 
in samenwerking met de afdeling Klinische Farmacie in het Maasland-
ziekenhuis. Dit onderzoek vormde uiteindelijk de basis voor dit proefschrift.  
Vanaf februari 2004 werd de opleiding Interne Geneeskunde voortgezet in het 
Academisch Ziekenhuis Maastricht (azM), met als opleider prof. dr. K.M.L. 
Leunissen. Na 4 jaar vooropleiding Interne Geneeskunde begon hij op 
1 oktober 2004 met de opleiding Maag-, darm- en leverziekten (MDL) in het 
azM, met als opleiders prof. dr. R.W. Stockbrügger en later prof. dr. A.A.M. 
Masclee. Op 1 oktober 2007 volgde zijn registratie als MDL-arts en sindsdien is 
hij werkzaam in het Catharina ziekenhuis te Eindhoven. Hij is in 2004 getrouwd 
met Edith Rietra en is vader van Eline (juli 2005) en Luc (september 2007). 
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Dankwoord 
Het is klaar! Een gevoel van opluchting, tevredenheid en onwerkelijkheid vult 
mijn lichaam. Als ik vooraf had geweten hoeveel uren vrije tijd in dit proefschrift 
zouden gaan zitten, was ik er misschien niet aan begonnen. Maar de basis van 
dit onderzoek was altijd plezier. Plezier in het onderzoeken van een nieuw 
concept, om onze patiënten beter te kunnen behandelen. Plezier in het 
schrijven van protocollen en van artikelen over de resultaten. En na een tiental 
publicaties kom je tot de conclusie dat het met een mooi kaftje eromheen wel 
eens een promotie zou kunnen opleveren. Het klinkt eenvoudig, maar 
grotendeels is het wel zo gegaan…  
Toch werd mijn gevoel de laatste jaren heen en weer geslingerd tussen 
enerzijds nieuwsgierigheid en interesse om onderzoek te doen en anderzijds 
onrust, omdat er wel interessante resultaten waren, maar onvoldoende tijd om 
ze te beschrijven. Dit onderzoek vond namelijk parallel aan mijn opleiding tot 
MDL-arts plaats, dus naast alle dagelijkse werkzaamheden, onderwijs-
momenten en referaten. Met name in het begin van de opleiding was er 
daarom weinig tijd en energie over om in de vrije avonduren nog gegevens te 
verwerken of een artikel te schrijven.  
Maar nu dit boekje er ligt, kijk ik natuurlijk met veel voldoening terug op de 
afgelopen jaren. Ik ben trots dat het me gelukt is om naast mijn specialisatie 
een perifeer onderzoek om te buigen naar een promotie-onderzoek. 
Dit was natuurlijk onmogelijk geweest als er niet de juiste mensen op het juiste 
tijdstip mijn pad kruisten en als mijn vertrouwde omgeving mij niet zo warm 
ondersteund had. Ik doe een poging om iedereen die betrokken is geweest te 
bedanken. Mijn excuses als ik iemands bijdrage over het hoofd gezien heb. 
 
De belangrijkste persoon die ik wil bedanken is natuurlijk dr. L. Engels. 
Leopold, ik noem je wel eens gekscherend mijn ‘tweede vader’, maar als ik 
bedenk hoe jij me in de wondere wereld van de gastro-enterologie hebt 
ingewijd en welke deuren er door jouw toedoen voor mij zijn opengegaan, kan 
ik geen andere benaming bedenken. Je hebt me bij mijn nekvel gegrepen toen 
ik direct na mijn arts-examen in Leuven, nog Vlaams pratend en groen achter 
de oren, bij jullie in Sittard in opleiding kwam. Een eerste opzet voor een 
onderzoek lag al klaar en je zocht iemand die een paar jaar zou blijven, terwijl 
ik hard bezig was om als ‘broekie’ te overleven op jullie afdeling. Slechts 
enkele maanden later stond ik al de eerste resultaten op de Voorjaars-
vergadering te presenteren en dat smaakte naar meer! Nu ben ik, na Luc 
Derijks de tweede telg uit het Maasland, die op dit onderwerp gaat 
promoveren. En ik ben denk ik niet de laatste! 
Daarnaast heb ik van jou de kneepjes van het MDL-vak geleerd. Op de 
afdeling leerde ik het klinisch redeneren en communiceren met patiënten. 
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 Daarnaast heb je bij mij IBD als zwakke plek veranderd in een zwak hebben 
voor IBD. Mijn eerste endoscopische ervaringen deed ik op onder jouw 
vleugels. Je had steeds een haast grenzeloos vertrouwen in me. Je hebt me 
dan ook al snel bij prof. dr. Stockbrügger aanbevolen om in opleiding tot MDL-
arts te komen. Mijn dank hiervoor is groot! 
Naast deze serieuze zaken, heb ik ook verschillende bourgondische 
herinneringen aan je. Ik denk even aan de multipele Notfälle bei dem Franz in 
St. Christoph, aan het IBD congres in Leuven, voorafgegaan door een stevig 
aantal Stella’s en een flesje St. Joseph van een uitgelezen jaartal dat ik me niet 
meer kan herinneren, aan het cultureel uitstapje naar de Ständige Vertretung in 
Oost-Berlijn. Overal waar je komt weet je wel een gezellig cafeetje, goed 
restaurant of jazz-club te vinden, ongelofelijk! Ik heb bewondering voor jouw 
bourgondische levensstijl! 
De leukste ervaring bewaar ik echter tot het laatst: we hebben samen 
regelmatig in een Oostenrijkse lounge muziek gemaakt, waarbij het vaak leek 
alsof we al jaren samenspeelden: jij op de vleugel (met de zonnebril van Rens) 
en ik op de sax, terwijl we nog nooit een noot geoefend hadden. Of alle 
hotelgasten onze interpretaties van Autumn leaves, Blue bossa, My funny 
Valentine en Tequila (met Bert-Jan op zijn knieën met de vier-snarige gitaar!) 
even veel gewaardeerd hebben als wijzelf weet ik niet, maar het waren 
onvergetelijke momenten. Een ding hoop ik wel nog: dat je een keer All blues 
met mijn jazz-combo meespeelt, als we weer eens in de buurt optreden! 
 
Prof. dr. R. Stockbrügger, beste Reinhold. Ik werd vanaf het begin met open 
armen ontvangen op je afdeling. Ook na jouw emeritaat zijn onze contacten 
steeds hartelijk, maar ook productief gebleven. Ik heb enorme bewondering 
voor je wetenschappelijk inzicht, je gedrevenheid en je snelheid bij het 
corrigeren van manuscripten. Je bent een Europeaan pur sang, daar kunnen 
veel Nederlanders nog een voorbeeld aan nemen. Hoewel het onderwerp van 
mijn onderzoek aanvankelijk misschien niet in jouw domein thuis hoorde, 
hebben jouw interesse, enthousiasme en neutrale visie een belangrijke rol 
gespeeld in het totstandkomen van een wetenschappelijk verantwoorde thesis. 
 
Dr. P. Hooymans, beste Piet. Wat een unieke samenwerking tussen de kliniek 
en farmacie heb jij samen met Leopold opgezet! Twee verschillende werelden 
binnen een huis zijn weer samengesmolten tot één; daar kunnen veel 
ziekenhuizen nog wat van opsteken. Ik heb je leren kennen als een zeer 
correcte en deskundige man. Je plaatst je zelden op de voorgrond, maar bent 
wel degelijk onmisbaar geweest door het faciliteren van dit onderzoek. 
Daarnaast speel je verdienstelijk sambabal (of niet Luc?)! 
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Dr. L. Derijks, beste Luc. Wie had nou bij onze eerste ontmoeting in 2000 
gedacht, dat we allebei zouden gaan promoveren? Jouw gedrevenheid en 
schrijf-tempo waren nauwelijks bij te benen, daar ben ik in de begin-fase vaak 
jaloers op geweest. Door jouw drive raakten ook andere ziekenhuizen 
geïnteresseerd in ons onderwerp, wat weer nieuwe onderzoeken genereerde. 
Maar veel belangrijker nog vind ik de persoonlijke vriendschap die we hebben 
overgehouden aan onze vruchtbare samenwerking. Ons wederzijds 
paranimfschap onderstreept dit nog eens. Ik hoop dat we samen met Judith en 
Edith nog veel gezellige avonden mogen beleven.  
 
Dr. E. Keulen, beste Eric. Het is al even geleden, maar onze opleidingstijd in 
Sittard blijft in mijn herinnering als het gezelligste deel van mijn specialisatie. 
We kunnen zowel privé als op de werkvloer altijd prima met elkaar overweg. Ik 
hoop dat onze contacten als “concurrenten” in de regio Eindhoven goed blijven. 
Ik ben blij dat je een van mijn paranimfen wilt zijn! 
 
Geachte leden van de beoordelingscommissie, prof. dr. R.P. Koopmans, prof. 
dr. J.M.J.P. van der Linden, prof. dr. A.A.M. Masclee, dr. M.G.V.M. Russel en 
prof. dr. S. Vermeire. Ik wil u danken voor de kritische beoordeling van mijn 
manuscript. 
 
Prof. dr. C. Mulder. Chris, na mijn presentatie tijdens de Voorjaarsvergadering 
in 2001 kwam jij met het idee om onderzoek naar 6-thioguanine te doen bij IBD 
patiënten. Zoals ik inmiddels van je gewend ben, werd het onderzoek in een 
razend tempo opgezet. Je hebt een enorm enthousiasme, ongekende energie 
en 1001 ideeën. Ik heb grote waardering voor je inzet voor de MDL-wereld in 
Nederland en daarbuiten. Bedankt, dat je in de commissie zitting hebt willen 
nemen. 
 
Dr. N. de Boer. Nanne, ongelofelijk wat je in een paar jaar hebt gepresteerd! Zo 
help je mee bij een IBD onderzoek tijdens het afstuderen in Maastricht en zo 
ben je zelf al gepromoveerd in Amsterdam! Je hebt in een heel korte tijd een 
groot aantal artikelen gepubliceerd. Het was voor mij een enorme stimulans om 
zelf ook te blijven schrijven. Onze boekjes bijten elkaar uiteindelijk niet en zijn 
een bewijs van de veelzijdigheid van ons onderwerp. Ik ben blij dat ik met je 
heb mogen samenwerken. Veel succes bij je opleiding tot MDL-arts. 
 
Dr. R. Bos. Rens, jij hebt natuurlijk naast Leopold en alle andere Sittardse 
internisten een belangrijke rol gespeeld in mijn opleiding in het Maasland 
ziekenhuis. Daarnaast ben je een van de hofleveranciers geweest van 
patiënten voor ons onderzoek, waarvoor hartelijke dank! 
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 Drs. P. Bus. Paul, bedankt voor je betrokkenheid bij het onderzoek en je 
enthousiasme. Ik hoop dat je ook in de toekomst patiënten blijft includeren in 
onze onderzoeken. 
 
Dr. J. Bierau, drs. J. Bakker en dr. A. van Gennip (†). Beste Jörgen en Jaap, 
thiopurinofielen in het azM. Toevalligerwijze bleek dat we dezelfde voorliefde 
en interesse in thiopurines hebben. Bedankt voor jullie bijdrage aan de laatste 
twee onderzoeken. Ik hoop dat de samenwerking op dezelfde wijze voortgezet 
wordt. 
 
Drs. D. Wong. Dennis, ik wil je bedanken voor je inzet, die het laatste 
onderzoek heeft doen slagen. Ik kan me voorstellen dat het niet gemakkelijk 
moet zijn geweest om in de voetsporen te treden van Luc, maar inmiddels heb 
je je draai volledig gevonden in de materie. Nog een paar originele 
onderzoeken en dan komt jouw promotie er ook aan. Succes!! 
 
Dr. A. Voogd. Beste Adri, ik ben je veel dank verschuldigd voor de statistische 
ondersteuning van Hoofdstuk 5! Je nam steeds de tijd om mij, als statistisch 
onbenul, rustig uitleg te geven en om de zoveelste berekening te maken. 
 
Dr. De Jong. Beste Dirk, jij hebt op het juiste moment de juiste input vanuit 
Arnhem/Nijmegen in ons onderzoek gegeven. Inmiddels ben je zelf 
gepromoveerd en een van de IBD-specialisten in Nederland. Bedankt voor 
onze samenwerking. 
 
Alle laboranten die bij het onderzoek betrokken zijn geweest. Ik wil met name 
de laboranten van het Toxicologisch Laboratorium in het Maaslandziekenhuis 
Sittard bedanken: Jean Cilissen, Jean-Pierre Bollen, Miet Fiddelaers, Milevis 
Reitsma - Emanuel en Marielle Maas, maar ook Esther Vogels van het 
laboratorium Gastro-enterologie (o.l.v. prof. SJ van Deventer) in het AMC en 
Marc Breuer van het laboratorium voor Erfelijke Metabole Ziekten in het azM, 
Maastricht. Jullie hebben allemaal je uiterste best gedaan om betrouwbare 
resultaten te presenteren, waarvoor mijn dank. 
 
Alle patiënten die hebben meegedaan aan het onderzoek. Zonder jullie 
bereidwilligheid was dit proefschrift nooit tot stand gekomen. Ik heb vooral diep 
respect voor de mensen die een leverbiopt hebben ondergaan! 
 
Prof. dr. D. Hommes en prof. dr. S. van Deventer, beste Daan en Sander. We 
hebben dan wel niet direct samen zaken gedaan, maar via Luc, die als spin in 
het web tussen de verschillende centra fungeerde, heb ik toch de gelegenheid 
gekregen om met zulke gerenommeerde IBD-specialisten als jullie te mogen 
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publiceren. Daarnaast wil ik jullie bedanken voor de inzet van het laboratorium 
in het AMC. 
 
Ik wil alle MDL-artsen en internisten van het Rijnstate ziekenhuis in Arnhem, 
Universitair ziekenhuis St. Radboud in Nijmegen, Isala kliniek in Zwolle en het 
VU medisch centrum in Amsterdam, die patiënten hebben geïncludeerd 
hartelijk danken. Een speciaal woord van dank voor Mariëlle Romberg-Camps, 
vanwege de enthoesiaste inclusie tijdens de laatste studie. Succes met het 
afronden van je eigen proefschrift! 
 
De maatschap Interne Geneeskunde van het Maaslandziekenhuis in Sittard. Ik 
wil jullie bedanken voor het vertrouwen dat er in mij gesteld werd om direct 
vanuit de schoolbanken in Leuven in opleiding te mogen komen. Ik heb een erg 
fijne en leerzame tijd gehad. Met name de ski-weekenden zal ik natuurlijk nooit 
meer vergeten. Veel succes in het nieuwe ziekenhuis!  
 
De maatschap Interne Geneeskunde en Maag-, darm- en leverziekten van het 
Catharina ziekenhuis in Eindhoven. Ik ben nog steeds vereerd en trots, dat ik al 
een jaar voor afronding van mijn MDL-opleiding door jullie benaderd werd om 
toe te treden tot jullie maatschap. Ik hoop dat onze samenwerking net zo 
prettig en vruchtbaar blijft als die tot nu toe is geweest. 
 
Dr. J. van Spreeuwel, dr. A. Stronkhorst en dr. E. Schoon. Beste Jan, Arnold 
en Erik, mijn directe collega’s. Zo kijk je enorm op tegen drie gepromoveerde 
bazen in een hoog aangeschreven ziekenhuis en zo mag je in het rijtje 
aanschuiven, ongelofelijk. Ik hoop dat ik de verwachtingen waar kan maken en 
een waardige uitbreiding ben van de MDL-afdeling. 
 
Alle collega assistenten Maag-, darm- en leverziekten in het azM. Jullie hebben 
me snel thuis laten voelen op de afdeling toen ik in 2004 begon (Frank, Jan, 
Marielle, Silvia en Ulrike) en altijd geprobeerd de sfeer er goed in te houden 
(Susan, Annick, Rogier, Bas, Alexander, Sita, Michiel en Wout). Ik wil jullie 
bedanken voor de fijne tijd in het azM en de collegialiteit. Ik ben blij dat ik 
dankzij jullie op de valreep nog kennis heb kunnen maken met Tripel Carmeliet 
in café Thembi, proost!! 
 
Alle (voormalige) stafleden MDL in het azM. Ik wil jullie bedanken voor de 
opleiding die ik heb mogen volgen. Ik heb enorm respect voor de wijze waarop 
jullie ondanks jarenlange onderbezetting toch het hoofd boven water hebben 
gehouden en een volwaardige opleiding hebben kunnen verzorgen.  
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 Alle secretaresses van de polikliniek en afdeling Maag-, darm- en leverziekten 
in het Maaslandziekenhuis Sittard, Laurentius ziekenhuis Roermond, 
Academisch ziekenhuis Maastricht en Catharina ziekenhuis Eindhoven. Ik wil 
jullie hartelijk danken voor jullie ondersteuning bij het onderzoek en het 
verzamelen van medische dossiers. Met name Ingrid Mols, voormalige 
secretaresse van dr. Engels, wil ik bedanken. 
 
Tiny Wouters. Beste Tiny, zonder jouw zorgvuldige blik en je tips zou dit boekje 
bestaan uit schots en scheve tabellen, verschillende lettertypes en diverse 
afkortingen. Bedankt voor al je uren (vrije) tijd die je in dit werk hebt willen 
steken. 
 
Peter Gorter. Beste Peter, als peetoom/petekind hebben we door de jaren 
heen een onregelmatig, maar altijd hartelijk contact gehad. Ik ben erg blij dat je 
met jouw ervaring in de wereld van vormgeving een belangrijke steen aan dit 
boekje hebt willen bijdragen. De vraag blijft of thiopurines ook helpen bij 
‘ulcerative saxophonitis’; de eerste studie moet nog uitgevoerd worden. 
 
Zoals inmiddels wel duidelijk is, speelt muziek een belangrijke rol in mijn leven. 
Het vanaf jongsaf aan optreden heeft me zelfvertrouwen en een open kijk op 
de wereld gegeven, wat me dagelijks van pas komt. Ik wil dan ook alle 
muzikanten bedanken die me de afgelopen jaren geholpen hebben om de 
gedachten even van werk en onderzoek af te leiden. Met name de jongens van 
Guarantee, JazzMinded! en Harry & de Gebroeëke Zwiegelkes wil ik bedanken 
voor alle mooie optredens die ik heb mogen meemaken en nog hoop te gaan 
geven. Het zal schipperen worden tussen het gezinsleven en werk (en 
diensten) door, maar ik blijf spelen tot ik er bij neerval! Daarnaast bedank ik 
ook het bestuur en de leden van de Kerkelijke Harmonie St. Joseph 1880 voor 
het ondersteunen van mijn muzikale vorming en de warme contacten die er 
altijd zijn gebleven. 
 
De Poodtjes en de Eckjes: twee doktersfamilies in wording. Bij jullie 
bourgondische en mediterrane levensstijl voelen Edith en ik ons steeds weer 
thuis. De deur staat altijd open en het glas wijn is al ingeschonken. We hopen 
nog vele mooie reizen naar de zon en/of sneeuw te mogen maken met jullie!  
 
Martine, met je interesse en hartelijkheid laat je altijd weer de zon bij ons thuis 
schijnen, als een heuse huisvriendin. Nog even en dan zit jouw ‘karwei’ er ook 
op en kan je aan het echte werk gaan beginnen: kinderarts worden. Zet hem 
op! 
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 Dankwoord 
Het wordt tijd om mijn wortels in het zonnetje te zetten. Lieve pa en ma, jullie 
hebben me nooit gedwongen, maar altijd gesteund om de wegen in te slaan 
die ik wilde kiezen. Ik ben dankbaar dat jullie (weer) in goede gezondheid zijn 
en hoop dat jullie nog lang van het leven, elkaar en ons gezin mogen blijven 
genieten. 
Allan, van buiten lijken we niet direct op elkaar (‘je bent mijn broer, man!’), 
maar in ons binnenste loopt er een synchroon ritme: muziek maken, verbeteren 
en er over praten blijft een enorme passie van ons allebei. Het wordt tijd dat we 
weer eens samen op het podium staan, niet? 
Oma Lies, ik ben een enorme bewonderaar van u. U bent een krachtige vrouw 
die ondanks verschillende tegenslagen in het leven toch steeds een positieve 
kijk heeft gehouden. Uw 90-jaar jonge levensvisie is er een die ik in mijn 
dagelijkse leven goed kan gebruiken: geef elkaar de ruimte, geniet van de dag 
en de mooie dingen die de natuur ons geeft. Wanneer gaan we weer eens eten 
bij De Cuyp? 
  
Jan en Tiny. Fijnere schoonouders had ik niet kunnen wensen. Jullie zijn een 
perfecte combinatie van vooruitstrevendheid en behoudenheid, houden van 
bourgondisch leven, blijven niet stil zitten en zijn warm en geïnteresseerd. Mijn 
slogan blijft dan ook: je ouders kun je niet kiezen, je schoonouders wel! Vanaf 
nu hoop ik zelf weer het onkruid in onze tuin bij te kunnen houden. 
Marc, Guido, Marielle, Louise, Olivier en tante Toos. Jullie zijn echt familie van 
mij geworden. Ik voel me bij jullie altijd op mijn gemak als we lekker eten, 
discussiëren, ravotten en spelen. Zo’n fijn familieleven is belangrijker dan een 
promotie. 
 
Edith, mijn liefje, de grootste drijfveer achter dit proefschrift. Jij hebt een zwarte 
dag in april omgetoverd in een zonovergoten avond. Ik ben zo dankbaar dat ik 
jou ben tegengekomen! Je bent vlot, spontaan, elegant en sportief. Je weet als 
geen ander wat mooi, maar soms ook moeilijk is aan het werk met patiënten. Ik 
ben blij dat we de stap gezet hebben om jouw eigen praktijk te starten en heel 
trots hoe jij deze organiseert, in combinatie met het moederschap! Zonder jou 
was dit boekje nooit tot stand gekomen. 
 
Eline en Luc. Papa is blij dat dit werk erop zit voordat jullie groot genoeg zijn 
om te beseffen dat ik de afgelopen periode iedere avond voor de computer zat. 
Jullie aanwezigheid en komst hebben mij de energie gegeven om de eindsprint 
in te zetten.  
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